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ABSTRACT 
 
Objectives: The prevalence of cardiovascular diseases including heart failure (HF), 
atrial fibrillation (AF) and peripheral vascular disease (PVD) rises sharply among 
those aged 85 years and over, who now constitute the most rapidly increasing age 
group worldwide. Majority of this disease burden remains undiagnosed. Most 
previous community-based studies of left ventricular (LV) dysfunction and HF 
included only small numbers in this age group. We conducted a community-based 
study of 85+ year olds using domiciliary echocardiography, electrocardiography and 
ankle brachial index (ABI) assessments to estimate the prevalence of LV dysfunction, 
AF and PVD. We cross-referenced our findings to pre-existing HF, AF and PVD 
diagnoses present in general practice (GP) medical records to estimate the proportion 
of undiagnosed cardiovascular pathology. We also assessed to diagnostic performance 
of NT-proBNP to detect underlying LV dysfunction. 
 
Design: Cross-sectional analysis of data from Newcastle 85+ Cohort Study. 
 
Setting: Primary care, North-East England. 
 
Participants: 427 men and women (60.9% women) aged 85+ years and above, from 
Newcastle 85+ Study.     
 
Measurements: Assessment was conducted in home setting. 2-D and Doppler 
echocardiography was performed, with LV systolic and diastolic function graded 
according to American Society of Echocardiography guidelines.  A dyspnoea 
questionnaire was used to assign New York Heart Association (NYHA) functional 
severity class. ABI measurement and other measures to assess arterial stiffness 
including pulse wave velocity and pulse wave analysis were carried out by portable 
sphygmoCor and vicorder devices. Bloods samples were taken for NT-proBNP levels. 
Previous diagnoses of HF, AF and PVD were abstracted from the GP medical records.  
Results:  Normal LV function (ejection fraction greater than 55% and normal/mildly 
impaired diastolic function) was found in just 37.2% of participants. 48.4% had LV 
systolic dysfunction and 14.4% had isolated diastolic dysfunction. 66.1% people with 
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underlying LV systolic or diastolic dysfunction, had symptoms of breathlessness 
(NYHA II or above). Overall 37.4% of participants had undiagnosed symptomatic 
significant LV dysfunction (29.5% systolic, 7.9% isolated diastolic).  23.8% of 
participants with pre existing diagnosis of HF, had no echocardiographic evidence of 
underling systolic or diastolic dysfunction. Markers of arterial stiffness were not 
significantly associated with LV dysfunction. Diagnostic performance of NT-proBNP 
to detect underlying symptomatic or asymptomatic dysfunction was not robust. 
Prevalence of peripheral vascular disease was 22.1%. 19.0% of participants who had 
no formal GP diagnosis of PVD had definite PVD on the basis of ABI assessment. 
Prevalence of atrial fibrillation was 25.5% in the entire cohort. Nearly half (53.2%) of 
these patients had had no existing GP diagnosis of AF. 87.2% participants with AF 
were CHA2DS2-VASc score 3 or above. Only 15.6% participants with AF were 
taking warfarin. In remaining 84.4% participants with AF, who were not on warfarin, 
only 42.4% participants were taking antiplatelet medications. 
 
 Conclusions:  Systolic and diastolic LV dysfunction was much commoner in 85+ 
year olds than most previous studies have suggested, affecting around half of a 
community-dwelling sample; the majority of cases were symptomatic. Despite a 
national initiative to improve heart failure management within primary care in 
England, over 80% of very old people with symptomatic significant LV dysfunction 
remained undetected. Prevalence of AF and PVD is also much common in that rapidly 
expanding fraction of population, majority of which remains undiagnosed. There is 
need to establish effective ways to detect this cardiovascular disease burden in very 
old population. 
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Introduction and Literature Review 
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Chapter 1: Ageing 
The world is experiencing a continuing change in the ageing structure of its population, 
which has never been witnessed in the history of mankind. In almost every country, the 
proportion of older people is growing faster than any other age group. This overall shift 
in population structure towards older ages is termed as “ageing of population”. 
Population ageing has many socioeconomic and health implications for societies. 
 
1.1 Measuring Population Ageing 
The aging of the population can be described by various indices. The total head count of 
elderly people is one way of looking at it. The number of older persons has tripled over 
the last 50 years and is projected to triple again over the next 50 years. According to the 
figures released by United Nations in 2007, there were just over 200 million persons 
aged 60 or over throughout the world in 1950, which has increased about three times to 
606 million. Over the first half of the current century, the global population 60 or over 
is projected to expand by more than three times to reach nearly 2 billion in 2050. [1] 
The percentage of people of retirement ages (usually 65 years) is often used to describe 
population ageing and if this exceeds 8-10% a society is considered relatively old. By 
this standard, the percentage of elderly people in the United Kingdom stood at 15% in 
2006, compared with only 6.1% in 1921 and a projected increase to 23% by the year 
2034. [2] 
The young-old balance is shifting throughout the world. Another useful indicator to 
describe this change in young-old balance is the aging index, defined as the number of 
people aged 65 and over per 100 youths under age 15. The ageing index is projected to 
triple over the next half century. The ratio of people aged 60 or over to children younger 
than 15 has increased from 24 per hundred in 1950 to 33 per hundred in 2000. It is 
estimated that by the year 2050, there will be 101 people 60 years or older for every one 
hundred children (less than 15 years) in the world. [1] The UK is facing a similar 
demographic shift. In December 2009 the Office for National Statistics reported that the 
proportion of the UK population younger than 16 had dropped from 25% in 1971 to 
19% in 2008. At the same time, the proportion aged 65 and over had risen to 16% 
compared to 13% in 1971. This trend is projected to continue. By 2031, 22% of the 
population will be aged 65 and over compared to 18% aged 16 or younger. [3] 
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1.2 Growing Number of the “85+ Year Olds” 
The most striking feature of this population ageing is the progressive ageing of the older 
population itself. The “85+ years old” fraction of the population is the fastest growing 
fraction. At the global level, the 85+ fraction of population is expected to increase 155% 
between 2005 and 2030, compared to 104% increase in population 65 and above. 
(Figure 1.1) According to the United Nations the world population of 80 and above will 
reach almost 379 million by year 2050, having been less than 14 million in 1950 (Figure 
1.2). In Europe the number of “85+ individuals” is expected to rise by 181% by 2050. 
[1] The 85+ year old age group is the fastest growing fraction of the population in the 
UK. Their numbers have doubled from just over 600,000 in 1983 to 1.3 million in 2008. 
This trend is projected to continue and by 2033 the number of people aged 85 and over 
will reach 3.2 million. [4] 
 
1.3 Demographic Determinants Of Population Ageing  
Underlying global population ageing is a process known as the “demographic 
transition” in which mortality and then fertility declines from higher to lower levels. 
Decreasing fertility along with lengthening life expectancy has changed the age 
structure of the population in most regions of the world by increasing the median age of 
the population and altering the young old balance. The role of international migration in 
changing age distributions has been far less important than the decline in fertility and 
mortality. [5] There are two main demographic factors causing these demographic 
changes: 
 
1.3.1 Low / Declining Fertility Rate 
Fertility decline is a global phenomenon but is happening at a faster pace in some 
countries than others, and is the largest contributor to population ageing in the world 
today. One of the most common measures of fertility is the ‘total fertility rate (TFR)’ – 
the average number of children that would be born to each woman if current age- 
specific fertility rates stayed constant across her childbearing years. We have seen a 
global fertility (TFR) decline from 5.02 per woman in 1950 to 2.55 per woman in 2005 
and the TFR is expected to fall to almost 2.0 per woman in 2050 (Figure 1.3). [1]  
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Figure 1.1: Projected increased in global population between 2005 and 2030  
(Adapted from Paula J Dobriansky, Why Population Aging Matters: A Global Perspective. 
National Institute on Aging, ; 2007) [6] 
 
 
 
 
 
Figure 1.2: Estimated growth of “80+ years old” between 2005 and 2030  
(Adapted from United Nations Department of Economic and Social Affairs Population Division. 
World Population Ageing: 1950-2050) [1] 
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Figure 1.3 : Decline in global total fertility rate between 1950-2050  
(Adapted from United Nations Department of Economic and Social Affairs Population Division.  
World Population Ageing: 1950-2050) [1] 
 
 
 
 
 
Figure 1.4: Trends in total fertility rate in England and Wales  
(Source: E Wrigley & A Schofield The Population History of England 1981.Office of National 
Statistics) 
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Women in the UK like other countries are having fewer children than in previous 
generations. In 1871 the average woman was having 5.5 children but by 1971 this had 
gradually fallen to 2.1 children and presently it is below 2.0. (Figure 1.4) [7, 8] 
 
1.3.2 Rising Longevity 
Life expectancy is the average number of years that a person can expect to live if they 
experience the current mortality rate of the population at each age. Along with the 
decline in fertility, the increase in life expectancy as a consequence of declining 
mortality, especially at older ages, has played an important role in population ageing. In 
developed countries, where fertility is low for relatively longer periods, population 
ageing is primarily determined by improved survival at old ages. [9] 
According to a United Nation’s recent report (2007) life expectancy is increasing 
globally, although there is a marked variation between developed and developing 
countries. Overall, globally life expectancy at birth has risen by almost 20 years form 
46.6 years in 1950-55 to 66 years in 2000-05 and is expected to increase by another 10 
years to 76 years by 2050. This trend is slightly less marked in developed countries than 
developing countries. In the UK average life expectancy at birth increased from 69.2 
years in 1950-55  (66.7 years male, 71.8 years female) to 79.4 years in 2005 (77.2 years 
male, 81.6 years female). The gain in life expectancy is projected be more marked in 
older ages, as we have seen an significant and accelerated improvement in the mortality 
in this group over last 25 years (Figure 1.5). This was probably the reason that official 
population projections underestimated the size of the elderly population, especially 
those in the oldest age groups.[10] The increase in the life expectancy at the age of 80 
by 2050 is projected as 22% at global level, compared to 18% and 19% at the age 60 
years and 65 years respectively. This relative gain in the life expectancy of the “oldest 
old” is projected to be more marked in the developed regions according to the United 
Nations. [1] In the more developed regions, average life expectancy at age 80 is 
projected to increase by 27% by 2050 as compared with 19% at age 60 and 9% at birth. 
Whereas, an average life expectancy at age 80 in the less developed regions is expected 
to increase by 28% as compared with 22% at age 60 and 17%at birth (figure 1.6).  
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UN estimate 1980
UN estimate 1990
UN estimate 2000
Figure 1.5: Life expectancy from 1840 to the present.  
Dotted red lines show UN projection in females life expectancy, which clearly were underestimated the 
rise in life expectancy especially at older age. 
(Adapted from Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science. 
2002[10] 
 
 
Figure 1.6: Highest gains in life expectancy are seen in the “oldest old” cohort.  
(MDR = more developed regions and LDR = less developed region as per UN classification)  
(Adapted from United Nations Department of Economic and Social Affairs Population Division. 
World Population Ageing: 1950-2050) [1] 
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1.4 Implication of Population Ageing  
Population aging has a number of socioeconomic and health implications for a society. 
On the one hand, it shows “a great triumph of civilization” over disease and injury, 
which have constrained human life expectancy for thousands of years. [11] On the 
other, it presents various challenges to public institutions that must adapt to a changing 
age structure. 
As populations age, the prevalence of disability, and burden of chronic illnesses 
including cardiovascular disease, cerebrovascular disease, malignancies and 
Alzheimer’s disease increase significantly.  Some experts raise concerns that mankind 
may become a “global nursing home”. [12]The Health Survey for England (HSE) 
comprises a series of annual cross sectional surveys and is part of an overall programme 
of surveys commissioned by the Department of Health and designed to provide regular 
information on various aspects of the nation's health. Each of these surveys consists of a 
questionnaire and various anthropometric measurements and is an important source for 
monitoring population trends in disability over time. Figure 1.7 shows disability 
prevalence rates per 1000 adults by 5-year age intervals for adults aged 16 and over in 
the health surveys conducted in 1985, 1995, 1996 and 2001. All four surveys show a 
similar pattern of increasing disability with advancing age and a marked rise in the 
“oldest old” group. [13] The prevalence of non-communicable diseases including 
cardiovascular disease (CVD) also increases with age (Figure 1.8). [14] Cardiovascular 
diseases (CVD) are the leading cause of death and morbidity worldwide in all 
population and specifically in the “oldest old”. Nearly 40% of all cardiovascular deaths 
were reported in the oldest old in the US in year 2005 (Figure 1.9). [15] In the US 
almost 8.6 million deaths were due to CVD in year 2005 and nearly 3.3 million deaths 
happened in the oldest old age group, which were four times higher than deaths due to 
malignancies in this age group. CVD is also the leading cause of death in England. In 
2004 it claimed over 190,000 deaths (>92,500 IHD and >40,000 stroke deaths) in 
England and Wales, and 89% of these deaths occurred in people aged 65 and over. [14]  
In old age although the mortality from coronary heart disease has decreased since the 
1970s, the prevalence, incidence and mortality from chronic heart failure has increased 
(Figure 1.10). [16, 17] In the ageing population, chronic heart failure (CHF) is an 
increasing public health problem with significant financial implication for healthcare 
system due to its association with frequent hospitalizations and the need for long-term  
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Figure 1.7: Trends in the prevalence of disability by age.   
(Adapted from Health Survey for England (HSE) annual report 2001. Department of Health. 
[13] 
 
 
 
Figure 1.8: Prevalence of cardiovascular diseases by age.   
(Source:Heart Disease and Stroke Statistics--2010 Update: A Report from the American Heart 
Association.) [15] 
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treatment. [16, 18, 19] Trends of population ageing and increasing burden of disease 
and disability with age probably explain why healthcare utilization also increases with 
age. In 2001-02 people of age 65 and over utilized £32 billion, almost 40% of the total 
health and community health expenditure (HCHE) in England. Total per capita 
healthcare spending also increased significantly with age. Per capita spending was 
highest in the “oldest old”. The average per capita spending was £646 which rose to 
more than five times for people aged 85 and over (Figure 1.11). [20]  
 
Life expectancy is continuously increasing with maximum gains in the “oldest old” 
fraction of the population despite higher prevalence of disease and disability. Health and 
cardiovascular phenotyping of the 85+ years old, which probably play an important role 
in the growing life expectancy in this cohort, is not very much studied in detail. The role 
of age associated stiffness of the arteries and its interplay with cardiac function and 
development of heart failure is discussed later in the chapter.
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Figure 1.9: Mortality due to cardiovascular diseases by age.   
(Heart Disease and Stroke Statistics--2010 Update: A Report from the American Heart 
Association.[15] 
 
 
 
Figure 1.10: Prevalence of heart failure by age.   
(Heart Disease and Stroke Statistics--2010 Update: A Report from the American Heart 
Association. [15] 
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Figure 1.11: Hospital and community health service expenditure by age.   
(Office for National Statistics. Hospital and community health service expenditure: by age of 
recipient, 2001/02: Social Trends 34. 2004) [20] 
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Chapter 2: Heart Failure and 85+ Year Olds 
 
2.1 Brief Historical Background 
The concept of heart failure (HF) is very old and has evolved throughout history. Some 
of the first descriptions of heart failure scenarios were recorded by ancient Egyptians, 
Greeks and Romans in 1500 BC. “Hydropsy” or “Dropsy” is a term that was used to 
describe this condition up through the middle ages. It is synonymous for oedema, a 
generalized swelling due to the accumulation of excess water.  The ancient Egyptian 
physicians used to treat heart failure by “emptying the system” by bloodletting.[21] 
Even in the 19
th
 century and early 20
th
 century Southey’s tubes were used to drain the 
fluid from oedematous peripheries. It was an introduction of organomercurial diuretics 
in 1920 and thiazide diuretics in 1958 that helped to treat fluid overload better by 
diuresis and ended the era of bloodletting to treat fluid overload. Discovery of X-rays by 
Rontgen and introduction of cardiac ultrasound in 1950’s by Hellmuth Hertz improved 
the understanding and investigations of the condition.[22] Modern day 
echocardiography, cardiac catheterization and nuclear medicine have since improved 
the diagnosis of the patients with heart failure. 
There are many definitions of heart failure but one of the most widely quoted 
definitions in literature was proposed by Eugene Braunwald  as “ a pathophysiological 
state in which the heart is unable to pump blood at a rate commensurate with the 
requirements of the metabolising tissues or can do so only from an elevated filling 
pressures”[23] 
One of the difficulties in defining and diagnosing heart failure is the non-organ specific 
nature of most features of the condition, and there may be only a few features in the 
early stage of the disease. This has led modern day physicians to define heart failure as 
a clinical syndrome characterised by typical features, clinical signs and objective 
evidence of heart dysfunction. The Task Force on Heart Failure of the European Society 
of Cardiology has recently published guidelines (2008) on the diagnosis and treatment 
of heart failure, which require the presence of symptoms (breathlessness at rest or on 
exercise, fatigue, tiredness, ankle swelling), signs (tachycardia, tachypnoea, pulmonary 
rales, pleural effusion, raised jugular venous pressure, peripheral oedema, 
hepatomegaly) and an objective evidence of cardiac dysfunction (cardiomegaly, third 
heart sound, cardiac murmurs, abnormality on the echocardiogram, raised natriuretic 
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peptide concentration) [24]. Reversibility of signs and symptoms to appropriate therapy 
are also desirable but not essential. The echocardiogram is considered the gold standard 
investigation for the diagnosis of left ventricular dysfunction, the principal anatomical 
correlate of the clinical syndrome of heart failure.  
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2.2 Heart Failure with Reduced and with Preserved Ejection Fraction 
Heart failure is often caused by ‘pump failure’ in which the left ventricle fails to pump 
enough blood into the circulation. This pumping ability of the heart is referred as 
‘systolic function’. Systolic function of the left ventricle is assessed by an 
echocardiography and is measured in terms of left ventricular ejection fraction (LVEF). 
LVEF is defined as the proportion of blood that is pumped into the circulation during 
systole, received by left ventricle during diastole. The term “systolic heart failure “is 
used when heart failure develops in the setting of left ventricular systolic dysfunction 
i.e. reduced LVEF. It is also termed as heart failure with reduced ejection fraction 
(HFREF). 
Heart failure can also develop in the settings of normal or near normal ejection fraction. 
In this setting failure of the heart to relax during the diastolic phase of the cardiac cycle 
(diastolic dysfunction) is considered as the principal underlying cause for this clinical 
presentation of heart failure which is therefore termed  “diastolic heart failure”. This 
term was first used by Kessler in 1988.[25] Some other terms have been used in the 
literature to describe this clinical entity such as heart failure with normal ejection 
fraction (HFNEF) or heart failure with preserved systolic function (HFPSF). There is no 
consensus on the cut off values of LVEF for preserved systolic function. In a recent 
large population based US study in Olmsted County, LVEF 50% or above was used to 
describe preserved systolic function.[18]  
Many recent population based echocardiographic studies from both US and UK have 
shown high prevalence of asymptomatic LV systolic and diastolic dysfunction, termed 
as ‘preclinical systolic or diastolic heart failure’. Although this condition is not 
equivalent to heart failure, due to lack of symptoms, it has shown to be an important 
predictor of heart failure and other cardiovascular events. In the Olmsted County study 
preclinical systolic dysfunction was associated with increase in all cause mortality when 
compared with normal LVEF (HR, 8.31; 95%CI, 3.0 – 23.1). Preclinical diastolic 
dysfunction was also associated with increase in all cause mortality when compared to 
normal diastolic function (HR10.2; 95%CI, 3.9 – 31.0).   [26-29]  In the Cardiovascular 
Health Study the relative risk of heart failure in participants with abnormal baseline 
preclinical LV systolic or diastolic dysfunction was 2.84 (CI 1.63
 
to 4.93); in those with 
prevalent coronary disease it was 2.11
 
(CI 1.34 to 3.32).[30] 
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2.3 Epidemiology 
Heart failure has been described as a growing and major public health problem in 
developed countries with ageing populations by many writers.[31, 32]  
 
2.3.1 Prevalence 
Prevalence of heart failure is increasing with estimated 15 million patients with heart 
failure in Europe and almost 5.7 million patients in USA. [24, 33] In UK prevalence of 
heart failure has been reported as 1-2% in MONICA study.[34] The “Heart of England” 
screening study assessed the prevalence of heart failure, in the West Midlands, England 
between 1995 and 1999. Prevalence of heart failure was reported as 3.0% in males and 
1.7% in females.[35] Improved survival after acute myocardial infarction, better 
prevention of coronary artery disease and increasing longevity in the west is thought to 
be behind overall increase in the prevalence of heart failure. [32] Major evidence on the 
prevalence of heart failure in the population comes from the large population based 
cohort studies carried out in United States and Europe. Figure 2.1 summarises the 
reported prevalence of heart failure and mean age of the participants in these studies. 
Differences in reported prevalence across different studies is probably due to the mean 
age of the cohort, number of elderly people in the sample but most importantly the 
difference in the case definition employed. Heart failure is predominantly a disease of 
the elderly, with its prevalence increasing progressively with age. There is a sharp rise 
in prevalence especially after age of 75 years. Large cohort studies carried out in USA 
and Europe have established that fact. Figure 2.2 summarises the rise of prevalence in 
elderly cohort. In the Olmsted County study the prevalence of heart failure was 2.7%, 
increasing from 0.7% in people between aged 45 – 54 years old to 8.4% for 75 years 
and older.[18]  In the Helsinki study where mean age of participants was 80 years, the 
prevalence of heart failure has been reported as 8.9%. [36]Much has been studied and 
learnt about the epidemiology of diastolic heart failure especially in last 2 decades. 
More than half of the diagnosed heart failure patients have been reported to have 
diastolic heart failure in recent cross-sectional population based echocardiographic 
studies. [37] In the Helsinki ageing study 72% of the heart failure patients had preserved 
systolic function.Figure 2.3 summarises the proportion of heart failure with preserved 
systolic function in major heart failure studies. Variation in the prevalence among 
various studies might reflect the difference in the definition used for “preserved” heart 
failure, methods used to assess LV function and mean age of the cohort. 
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 Figure 2.1: Prevalence of Heart Failure in major echocardiographic based 
studies. [16, 18, 36, 38-43]  
(Height of the bars represents prevalence in % & mean age of participants in 
these studies is given at bottom of the table) 
 
 
 
 
Figure 2.2: Prevalence of Heart Failure increases with age  [16, 18, 38, 39, 41] 
(Blue bars represent overall % prevalence of heart failure and red bars 
represent % prevalence in participants of 75 years or above age. Mean age of 
the cohort is given at the bottom of the figure) 
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Figure 2.3: Proportion of heart failure with preserved systolic function in major 
population based echocardiographic studies. [16, 18, 36, 38-43]  
(Height of the bars represents prevalence in % & mean age of participants in 
theses studies is given at bottom of the table) 
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2.3.2 Incidence 
Relatively less information is available about the incidence of heart failure. Again 
difference in methodologies between studies makes comparison difficult.  
In the Framingham heart study (US) the annual incidence of heart failure was 0.2% in 
women and 0.3% in men aged 50-59 years, rising to 2.2% in women and 2.7% in men 
aged 80-89 years. [44] 
In Rotterdam (Netherlands) the incidence of heart failure increased from 0.25% per 
annum (age 55-64 years) to 4.4% per annum in aged 85 years and above. [17] 
In the Hillingdon heart failure study (UK) the annual incidence of heart failure 
increased from 0.1% in women and 0.2% in men aged 55-64 years old to 1.0% in 
women and 1.7% in men aged 85 years and over. [45] 
As noted, the overall incidence of heart failure was higher in men than women. 
There is less data available in the literature about the incidence of diastolic heart failure. 
In the Olmsted county study 216 new cases of heart failure were reported in the year 
1991. Of these 63% of patients had preserved systolic function. Patients with preserved 
systolic function were female (69% vs 41%) and older (78 vs 74 years). [18] 
 
2.3.3 Aetiology and risk factors 
There are many conditions that can cause heart failure including coronary artery disease 
(CAD), hypertension and valvular heart disease but, coronary artery disease is the most 
common initiating cause in almost 70% of the patients with heart failure.[24].  
Table 2.1 lists the major causes of heart failure. It is difficult to be certain of a primary 
aetiological factor when multiple conditions co-exist. 
 
 
Table 2.1: Aetiology of heart failure 
 Coronary artery disease 
 Hypertension 
 Valvular heart disease 
 Cardiomyopathies 
 Tachyarrhythmias  
 Non cardiac causes like anaemia, thyrotoxicosis, pulmonary 
hypertension etc 
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In the Framingham heart study (US) almost 53% of heart failure patients were reported 
to have ischemic aetiology. [44] In the Bromley heart failure study (UK) 52% of heart 
failure patients had an ischemic cause, which was established by using myocardial 
perfusion scan and coronary angiography for establishing the diagnosis.[46] 
Risk factors for the development of HF have been examined by various studies, [17] 
which include hypertension, diabetes mellitus, advancing age, obesity, renal failure and 
COPD.  
The Framingham heart study data suggests that hypertension was a very common risk 
factor in the HF patients. [44]  Hypertension, diabetes, coronary artery disease, 
advancing age and obesity are common risk factors for both systolic and diastolic heart 
failure. However, in diastolic heart failure hypertension and in systolic heart failure 
coronary artery disease were more common risk factors.[47] 
 
2.3.4 Prognosis 
The survival after the diagnosis of HF, although improving with the advent of new 
medications, remains poor across the globe. Heart failure mortality rates are in excess of 
many common cancers (breast, colon and prostate). 
Long-term prospective data from 44 years follow-up from the Framingham heart study 
(US) and 20 years follow-up of its off-spring cohort suggest high mortality from heart 
failure with 80 % of men and 70% of women under the age of 65 years diagnosed with 
heart failure dying from it within 8 years. In men after the diagnosis of heart failure 
mortality rates at one-years, five-year and ten-year were 43%, 75% and 89% 
respectively. In women the corresponding mortality rates at one, five and ten years were 
46%, 62% and 79%. [33] 
The Olmsted County study reported 1 year mortality from heart failure in men as 21% 
and 17% in women, and 5 year mortality was 50% in men and 46% in women. [17] This 
slightly better survival in The Olmsted county study might be due to the fact that 
patients were not hospitalized, implying that their symptoms were less severe. 
In the Hillingdon heart failure study (UK) median follow-up time was 16 months 
(range, 6-26 months) and total 220 incident cases of heart failure (118 men, 102 
women) were identified. During follow-up period 90 people died with overall 6, 12 and 
18 months mortality of 30%, 38% and 43% respectively.[48]  
In Rotterdam study median follow-up time was 7.1 years and total 725 incident cases of 
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heart failure (335 men, 390 women) were identified. Survival at one year of diagnosis of 
heart failure was 63%, 51% at two years and 35% at five years, with no significant 
difference between men and women (p=0.15).  [49] 
Mortality associated with systolic heart failure in population based studies in general 
has been higher than associated with diastolic heart failure. In recently published meta-
analysis mortality among patients with diastolic heart failure was half that observed in 
those with systolic heart failure. In this meta-analysis 17 studies were included with 
24501 patients (68% males, mean age 67 years) with heart failure. 38% patient 
(n=9299) died over a mean follow-up period of 47 months. LV systolic function was 
assessed by echocardiography in 16 studies. Definition of HF-PSF varied in the studies 
from LVEF 40-55%. Overall, 2468 patients died among the 7688 patients with HF-PEF 
compared with 6831 deaths among the 16 813 patients with HF-REF. Patients with HF-
PEF had an OR for all-cause death of 0.51 (95% CI: 0.48, 0.55) compared with those 
with HFR-EF. [50] 
Many determinants of prognosis in heart failure have been identified and were 
highlighted a in recent publication of Task Force for the Diagnosis and Treatment of 
Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.[24] 
Major powerful predictors of poor prognosis include: advancing age, NHYA class III-
IV, low LVEF, Hyponatraemia, markedly elevated plasma BNP and low peak VO2.  
  
2.3.5 Healthcare burden 
The cost of chronic health care in developed countries is rising significantly. Recently 
published data has suggested 4 times increase in total healthcare spending in US since 
1989. In US total cost for HF in 2009 was $37.2 billion.[33] In European countries >2% 
of total healthcare spending is related to HF management and 70% of this cost is related 
to inpatient admissions.[24] In the UK heart failure management is estimated to cost 
NHS £625 million every year and over 60% of this cost is related to hospital inpatient 
care.[51] 
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2.4 Major Echocardiography Based Heart Failure Studies 
 
2.4.1 The Olmsted County Study 
Redfield et al carried out a cross sectional study of 2042 randomly selected residents of 
Olmsted County, Minnesota (US), aged 45 or older from 1997 to 2000.[29] 
Echocardiography was carried out in hospital.  Systolic function of left ventricle was 
assessed by eyeball method, m-mode and biplane method. Diastolic function was 
assessed by using mitral valve inflow doppler velocities and tissue doppler velocities of 
mitral valve annulus. LVEF was available by eyeball method for 99% (n=2036) 
participants, by biplane method for 79.2% (n=1617) and by m-mode method for 78.0% 
(n=1593) participants. Diastolic function was classifiable as normal or abnormal (mild, 
moderate, severe) in 1779 (87.1%) participants. Diagnosis of heart failure was 
confirmed from hospital medical records using Framingham Criteria for the clinical 
diagnosis of congestive heart failure. [52] Mean (SD) age of the participants was 62.8 
years (10.6) with only 290 participants aged 75 or above. The prevalence of heart failure 
was reported as 2.6% (95%CI, 1.9% - 3.3%). 44% of these people had HFPSF. The 
overall prevalence of LVSD (LVEF <50%) was 6.0% (95%CI, 5.0% - 7.1%), and this 
was higher in males than females (p<0.001).  20.8% (95% CI, 19.0%-22.7%) had mild, 
6.6% (95% CI, 5.5% - 7.8%) had moderate, and 0.7% (95% CI, 0.3% - 1.1%) had 
severe diastolic dysfunction with 5.6% (95% CI, 4.5% - 6.7%) having moderate or 
severe diastolic dysfunction with normal LVEF. Prevalence of preclinical systolic 
dysfunction (LVEF <50%) was 4.9% (95%CI, 5.6% - 8.0%) and preclinical diastolic 
dysfunction (moderate-severe) was 16.5% (95%CI, 12.6% - 20.9%). Half of the 
participants with an LVEF <40% or with moderate to severe diastolic dysfunction did 
not had a validated diagnosis of heart failure.  
 
2.4.2 The Cardiovascular Health Study 
This major multi-center study recruited community –dwelling participants (n=5201, 
43% males, 57% females) aged 65 or above from four US states (Forsyth County, North 
Carolina; Sacramento County, California; Allegheny County, Pennsylvania; and 
Washington County, Maryland).[53] Mean (SD) age of the participants was 73.3 (5.8) 
years for males and 72.4 (5.4) years for females.   Echocardiography was carried out in 
hospital based centre.  Systolic function of left ventricle was assessed by eyeball 
method and m-mode method. Diastolic function was assessed by using mitral valve 
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inflow doppler velocities. Heart failure was defined as self-report at baseline and later 
confirmed by medical records or heart failure medication. LVEF by m-mode method 
was unavailable in 1/3
rd
 of the participants. Doppler mitral inflow measurements were 
available in 97% of cohort. The prevalence of heart failure was reported as 8.8 %, 
55.0% of these normal LV systolic function (LVEF>55% on eyeball assessment).[54] 
Among women, 67% of participants with heart failure had normal systolic function 
versus 42% in men (p <0.001).[54] 
 
2.4.3 The Helsinki Ageing Study 
Kupari et al studied 501 randomly selected participants from Helsinki (Finland), aged 
75 years or above (only 136 participants were 85 years or above). These participants 
underwent clinical examination by a cardiologist, chest X-ray (CXR) and 2D 
echocardiography. Heart failure was diagnosed in the presence of three out of four 
following criteria: (i) history of breathlessness, (ii) signs of HF (third heart sound, raised 
neck veins or palpable hepatomegaly) on physical examination (iii) presence of 
pulmonary venous congestion on CXR and cardiomegaly on CXR (cardio-thoracic ratio 
>0.55). LV systolic dysfunction was defined as fractional shortening (FS) < 0.25 (on m-
mode measurements). HF-PSF was defined as fractional shortening > 0.25 and 
diagnosis of HF. Investigators reported prevalence of HF as 8.2%, 72% of these people 
had normal LV systolic function (FS >0.25). Prevalence of HF was slightly more 
(10.2%) in 85+ years old. Diastolic function was assessed by measuring mitral inflow 
velocities by doppler, but was not used to define diastolic heart failure. [55] 
Regional wall motion of LV was not assessed before LV systolic function assessment, 
which could potentially lead to inaccurate measurement of LVEF or fraction shortening 
by m-mode assessment method.   
 
2.4.4 The Rotterdam Study: 
Mosterd et al recruited 5540 participants resident in Rotterdam (Netherlands) aged 55 
years or above (mean age 65 years, only 29 participants 85+ years). Participants were 
interviewed at home and subsequently examined for signs and symptoms of heart 
failure at the research centre. In 2823 participants echocardiography was performed. LV 
systolic function was measured by m-mode method. In 19.7% of the participants m-
mode measurements were inadequate due to poor echo windows (raised BMI or 
COPD). Heart failure was diagnosed by a physician in the presence of signs and 
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symptoms of HF. LV systolic dysfunction was defined as fractional shortening < 0.25. 
The overall prevalence of heart failure was 3.9% (95%CI, 3.0±4.7) and did not differ 
between males and females. LV systolic dysfunction (fraction shortening < 0.25) was 
5.5% (95%CI, 4.1±7.0). 71% of the peoples with HF had normal LV systolic function. 
[16] 
 
2.4.5 The ECHOES Study: 
The Echocardiographic Heart of England Screening Study (ECHOES) was carried out 
in 16 general practices of the West Midlands region of England between 1995 and 1999. 
[35]  Out of 6162 participants of the study, 3850 participants were randomly selected 
for the cardiac substudy. Mean (SD) age of the participants was 61 (10) years. Only 66 
participants were 85 years or above. Participants were assessed by history and 
examination, electrocardiography, and echocardiography, which were carried out in a 
research centre. Heart failure was diagnosed by a specialist panel in accordance with the 
European Society of Cardiology (ESC) criteria.[56] LV systolic dysfunction was 
defined as LVEF < 40%. Heart failure was seen in 2.3% of the participants (95%CI, 
1.9-2.8). Prevalence of heart failure was increased to 21.1% (10/66) in people aged 85 
years or above. The overall prevalence of LVSD (LVEF <40%) was 1.8% (95%CI, 1.4 
– 2.3), which rose to 3.6% in those aged 75 years or above. 43% of the people with 
LVSD had no symptoms of breathlessness (NYHA I). 45.6% of participants with heart 
failure had LVEF > 50%. [35] 
 
2.4.6 The WHO MONICA Projects: 
The MONICA (Multinational MONItoring of trends and determinants in 
CArdiovascular disease) Project was established by WHO in the early 1980s in many 
Centres around the world to monitor trends in cardiovascular diseases, and to relate 
these to risk factor changes in the population over a ten year period. The Glasgow 
MONICA study and the Augsburg MONICA study are two important cross-sectional 
echocardiographic surveys that looked at the prevalence of LV systolic and diastolic 
dysfunction in general population. [34, 57] 
The Glasgow MONICA study was carried out in 1997, in Glasgow (UK). It was a cross-
sectional study of randomly selected 1640 participants aged 25-74 years. Participants 
completed a detailed questionnaire detailing current medication, history and symptoms 
of breathlessness. ECG and echocardiogram was performed in a research centre. LV 
25 
 
systolic function was assessed by biplane Simpson’s method, which was measureable in 
89.5% (n=1467) of participants. Definite LV systolic dysfunction was defined as LVEF 
≤ 30%. Definite LVSD was present in 2.9% of the participants (males 4.0%, females 
2.0%). Overall 113 (7.7%) participants had LVEF 35% or lower and 77% among those 
had no symptom of breathlessness. Diastolic function of LV was not assessed in this 
study. [34] 
The Augsburg MONICA study was carried out in 2001, in Augsburg (Germany) to 
determine the prevalence of diastolic function abnormalities in the population. It was a 
cross-sectional study of randomly selected 1678 participants; aged 25-75 years (mean 
age, 51±14). LV systolic function was assessed by m-mode method and LV diastolic 
function was assessed by measuring mitral inflow doppler velocities including E/A ratio 
and IVRT (isovolumetric relaxation time). LV systolic dysfunction was defined as 
LVEF <45%. In this study validated symptoms score for the heart failure was not 
available. Echocardiography was available in 85.5% (n=1418) of the cohort. People 
with LVEF <45% (n=19, 2.3%) were excluded from the diastolic function analysis as 
those were not considered to have isolated diastolic abnormalities. Diastolic 
abnormalities were defined as proposed by the European Study Group on Diastolic 
Heart Failure. [58] According to the study group, diastolic abnormalities was considered 
to be present when E/A<50years  was < 1.0, or E/A>50years was <0.5, or IVRT<30years was 
>92 ms, or IVRT30-50years was >100 ms or IVRT>50years was 105 ms in the presence of  
Preserved LVEF (LVEF ≥45%). Diastolic dysfunction was defined as 
echocardiographically derived diastolic abnormalities in the presence of diuretic therapy 
and/or left atrial enlargement (LA diameter > 45mm).  Based on the cut-points, they 
identified 141 individuals with diastolic abnormalities (89 with prolonged IVRT, 68 
with decreased E/A ratio and 8 people showed both prolonged IVRT and decreased E/A 
ratio). The overall prevalence of diastolic abnormalities was 11.1% (13.8% in males and 
8.6% in females) and diastolic dysfunction was 3.1% (3.9% in males and 2.3% in 
females). Despite using age adjusted cut-points for diastolic abnormalities, the 
probability of diastolic abnormalities increased with age. In males it increased from 9 to 
21% (p<0.03) and in females it increased from 5 to 14% with age ranges from 25 to 75 
years. [57] 
 
2.4.7 The Danish Study: 
In 2001 Neilsen et al carried out a cross sectional study to estimate the prevalence of 
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heart failure and LV systolic dysfunction in the general population. They randomly 
selected a cohort aged 50 years and above (n=2158) registered with three general 
practices in Copenhagen. GP records and hospital notes were reviewed for any cardiac 
history. A medical questionnaire was sent to all eligible participants asking about 
shortness of breath, angina, any previous treatment or hospitalisation for heart trouble. 
On the basis of screening information participants were classified into one of three 
groups: Definite heat disease (Ischaemic heart disease, atrial fibrillation, and 
hypertension or valvular heart disease), suspected heart disease (pacemaker, 
cardiomegaly on CXR, paroxysmal supraventricular tachycardia or pulmonary 
embolism) and no apparent heart disease.  People with signs and symptoms of heart 
failure were classified by a primary care physician using the modified version of the 
Boston index (score ≥ 5 points). [59]  LV systolic function was measure by using m-
mode method. LV systolic dysfunction was defined as a fractional shortening <26.0 or 
WMSI (wall motion score index) score ≤ 1.5. In the 38% (n=48) where m-mode 
measurements were unattainable WMSI method was used to assess LV systolic 
function. LV diastolic function was assessed by measuring mitral inflow doppler 
velocities including E/A ratio and IVRT and DT (deceleration time). Diastolic 
dysfunction was defined as two or more of three abnormal mitral inflow doppler 
velocity parameters (E/A ratio < 0.5, IVRT > 1.0, DT >0.224 sec). 
The study population comprised of 2182 people among whom only 401 were > 80 years 
of age. Over all response rate for the screening questionnaire was 86% in people < 80 
years of age, while only 48% (191 of 401) for people ≥ 80 years. Out of 357 people 
found to have some evidence of heart disease, only 126 (35.3%) people underwent 
echocardiography. People were excluded from echocardiography as they lived in 
nursing homes (n=38), declined the test (n=32), did not respond (n=56) or were unable 
to attend due to medical or physical disability. Of those dropping out 47% were aged 80 
years and above.  
The overall prevalence of heart failure in people aged 50 years and above was 6.5%, 
which increased to 11.9% in people aged 80 years and above. The proportion of heart 
failure with preserved systolic function (HF-PSF) in patients <70 years of age was 57 % 
as apposed to 75% in patients ≥ 70 years of age (p<0.0001). [60] 
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2.5 Pathogenesis 
 
2.5.1 Pathogenesis of Heart Failure with Impaired Systolic Function 
According to the current understanding it develops due to complex interplay of both 
beneficial and harmful affects of endogenous hemodynamic and neurohormonal 
mechanisms. 
Haemodynamic Remodelling 
Impairment of LV function and a subsequent fall in the cardiac output plays a central 
role in the pathophysiology of HF. Myocardium can be damaged by various cardiac 
insults including coronary artery disease, hypertension, cardiomyopathies, severe 
valvular heart disease and cardiotoxic agents. However most commonly myocardial 
injury especially in >50 years old, is related to myocardial infarction leading to 
impaired LV systolic contraction. This impairment of LV systolic contraction leads to 
chain of compensatory mechanisms to maintain cardiac output. These compensatory 
mechanisms are initially beneficial but later these overshoot or become exhausted 
leading to development of heart failure. [61] Myocardial damage impairs the ability of 
the LV to pump enough blood in the circulation leading to increased residual LV 
diastolic LV volume. This leads to increased LV wall stress. The myocardium responds 
to this increased wall tension by Frank-Starling principle by dilatation of LV and 
increasing preload.[62] This compensatory mechanism of stretching and dilatation is 
initially beneficial but progressive dilatation leads to thinning, necrosis and fibrosis of 
LV wall, restricting its ability to normalize stress. [63] This leads to an increase in left 
ventricular end diastolic pressure (LVEDP). Prolonged elevation of LVEDP leads to an 
increased left atrial (LA) pressure and dilation which in turn causes pulmonary capillary 
hypertension, causing pulmonary oedema.  Over period of time pulmonary vascular  
remodelling causes pulmonary hypertension  leading  to increased right ventricle  (RV) 
after load. The right  ventricle deals with this  increased  pressure in a similar way  and 
when RV  decompensates, right atrium  and  systemic  venous  pressures  rise causing  
peripheral  oedema  and  characteristic  features  of  right  heart  failure.                                          
Neurohormonal Activation 
Along with left ventricular haemodynamic remodelling several neurohormonal 
compensatory mechanisms also become activated to maintain cardiac output. Activation 
of the sympathetic nervous system with increased release of noradrenaline leads to 
increased heart rate, increased force of contraction and peripheral vasoconstriction. 
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Again this compensatory response is initially beneficial to restore cardiac output but 
prolonged activation exerts harmful effects. Noradrenaline release also activates renin 
angiotensin aldosterone system (RAAS), leading to arterial and venous constriction 
(increased preload and afterload) increased salt and water retention and further 
noradrenalin release. Angiotensin II acts both locally and systemically and leads to 
vasoconstriction in addition to some other effects as well. It promotes vasoconstriction, 
stimulates aldosterone and anti diuretic hormone (ADH) production, promotes growth 
factors leading to hypertrophy of vascular endothelium and cardiac fibrosis (increased 
cardiac fibroblast production) by acting on AT1 receptors while activation of AT2 
receptors leads to cellular apoptosis.   Apart from salt and water retention, aldosterone 
can also cause a loss of magnesium. Due to its steroid structure, it can also stimulate 
fibrosis by collagen production. This activation of the RAAS finally becomes 
maladaptive and results in fluid overload.[64] Apart from RAAS and noradrenaline, 
vasoconstriction is also caused by locally active endothelin produced by vascular 
endothelium further increases the left ventricular wall stress leading to increased atrial 
and ventricular pressures.[65] In response to atrioventricular stretch natriuretic peptides 
like ANP and BNP are released to counter the effects of noradrenaline. These natriuretic 
peptides also have direct vasodilator and natriuretic effects to reduce haemodynamic 
load on the heart.[66] However prolonged atrioventricular wall stress causes depletion 
of these natriuretic peptides  and this normal compensatory response is blunted in heart 
failure.[67] High concentrations of noradrenaline and angiotensin also have direct toxic 
effects on myocardial cells leading to progressive cardiac dysfunction. It is also 
postulated that these activation of these neurohormonal responses cause release of pro 
inflammatory cytokines (interleukin 6, TNF alpha). These cytokines also increase 
production of increased oxygen free radicals. These cytokines and oxygen free radicals 
are involved in endothelial dysfunction by inhibiting nitric oxide production by vascular 
endothelium. [68] All these events lead to unopposed vasoconstriction and vascular 
dysfunction which in turn increases LV wall tension by affecting afterload. This 
profound neurohormonal activation, inflammatory activity and free radical production 
have been implicated as a major cause of the vascular dysfunction seen in the heart 
failure syndrome. 
It is now believed that neurohormonal imbalance and abnormal haemodynamic 
remodelling are central in the progression of heart failure. 
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2.5.2 Pathogenesis of Heart Failure with Preserved Systolic Function  
Pathophysiology of heart failure with preserved systolic function (HF-PSF) has been 
studied extensively in last two decades but not yet fully characterised. Many experts in 
the field believe that diastolic dysfunction play a major role in the development of HF-
PSF. [69, 70]  Recently it has also been proposed by some that extra cardiac factors 
such as interactions between left ventricle and systemic vasculature “ventriculo – 
vascular interactions”  play an important role in the pathophysiology of HF-PSF. [71, 
72] 
Diastolic Dysfunction 
The diastolic phase of the cardiac cycle mainly comprises of myocardial relaxation and 
filling of left ventricle making it ready for the next ejection. A detailed account of the 
physiology of diastolic function and the pathophysiology of diastolic dysfunction is 
beyond the scope of this introduction but I will summarise some important aspects of 
diastolic dysfunction. Many comprehensive reviews have been written recently by 
various writers.[73, 74] 
Diastolic dysfunction is characterised by impaired relaxation and impaired filling with 
reduced distensibility of the LV. These abnormalities can exist regardless of LVEF and 
symptoms of heart failure. Diastole begins with relaxation of contracted myocardium. 
This is an active and complex process which consumes energy. In the normal heart 
rapid decline in the LV pressure by active relaxation produces a pressure gradient 
between LA and LV promoting the filling of LV chamber. 
At the molecular level calcium (Ca
2+
) haemostasis, active phosphorylation of troponin I 
and actin-myosin cross bridge detachments are major energy consuming events during 
this phase. Active relaxation depends on the restoration of Ca
2+
 levels in cytosol of 
myocardium which allows Ca
2+
 to detach from troponin and myofilaments to return to 
their resting length. This restoration of Ca
2+
 happens primarily through the ATP 
dependant reuptake of Ca
2+
 by the sarcoplasmic reticulum  [74]  These events rely on 
energy consumption and can be affected by myocardial ischemia resulting in impaired 
relaxation and diastolic dysfunction. This possibly explains the high prevalence of 
diastolic dysfunction in coronary artery disease and LVH. [73] It is also noted that 
ageing myocardium also displays prolonged relaxation, poor calcium haemostasis and 
reduced oxidative phosphorylation, possibly explaining increased prevalence of 
diastolic dysfunction in elderly population.[75]  
Passive filling of LV is another important phase of cardiac diastole. It is dependent on 
30 
 
the intrinsic properties of LV wall – “distensibility” or “stiffness”. In the normal heart 
after active relaxation the left ventricle is readily distensible with minimal resistance to 
additional LV filling. Myocardial stiffness is determined by changes in the extracellular 
matrix (ECM) composition with increased interstitial fibrosis. These changes can be 
reactive (increased afterload) or reparative (myocardial infarction). Myocardial ECM is 
composed of 3 important constituents: (1) fibrillar protein, such as collagen type I, 
collagen type III, and elastin; (2) proteoglycans; and (3) basement membrane proteins, 
such as collagen type IV, laminin, and fibronectin. [76] LV stiffness is determined by 
the absolute amount of collagen in ECM, ratio of collagen I to more compliant collagen 
III and the degree of collagen cross-linkages.   
Ageing and diseases like hypertension, LVH and diabetes that are associated with 
diastolic dysfunction also display the altered myocardial ECM composition that is found 
in increased LV stiffness including increased fibrosis, increased collagen cross-linkages 
and decreased collagen I to collagen III ratio. Treatments that are successful in 
controlling diastolic function have also shown the restoration of ECM fibrillar collagen. 
This also strengthen the argument LV stiffness is an important factor in diastolic 
dysfunction. [77] Many other researchers have also found increased prevalence of raised 
LV stiffness in people with HF-PSF by using both invasive and non invasive methods. 
Zile et al carried out cardiac catheterisation to obtain left ventricular pressure-volume 
loops from 47 patients (mean age= 59±12) with HF-PSF.[71, 78] These patients also 
had echocardiographic assessments of LV diastolic function. 10 people (mean 
age=58±16) with no evidence of cardiovascular disease were selected as control. They 
demonstrated that LV diastolic pressure rise per unit rise in LV volume much steeper in 
patients with HF-PSF than health controls, suggesting  increased LV stiffness in patients 
with HF-PSF. [77] 
As a result of diastolic dysfunction LV diastolic pressures become elevated despite 
normal filling volumes. This elevated diastolic pressure can lead to increased 
pulmonary pressure, neurohormonal activation and clinical features of the heart failure 
syndrome. Activation of neurohormonal mechanism remains central to pathophysiology 
of both systolic and diastolic heart failure, probably explaining the frequent coexistence 
of these two clinical syndromes. 
Ventriculo-Vascular Interaction – “Continuity Disease” 
Although diastolic dysfunction plays an important role in the pathophysiology of HF-
PSF, abnormal vascular function and interaction between systemic vasculature and the 
31 
 
left ventricle has also been implicated in pathophysiology of HF-PSF.  Diastolic heart 
failure has also been described as a “continuity disease” characterised by ventricular as 
well as vascular stiffness.[72]  According to this concept, the cardiovascular system is a 
continuous system comprising of heart and peripheral circulation in which pathology in 
one part affects all continuous parts. LV and vascular stiffness are commonly described 
in terms of LV end systolic elastance (Ees) and effective arterial elastance (Ea). Ea is a 
measure of arterial load derived from the ratio of LV end systolic pressure to stroke 
volume. Ees represents the LV end systolic pressure-volume relationship. Ea/Ees ratio 
represents the ventriculo-vascular interaction. [79] Ea and Ees both can be measured 
non-invasively (echocardiography) and invasively (cardiac catheterization). 
A recent large cohort echocardiographic study found both ventricular and arterial 
stiffness more prevalent in elderly females, which is the most likely group to develop 
HF-PSF. In this study Redfield et al conducted a cross-sectional study on the residents 
of Olmsted County (Minnesota) aged 45 (n=2042) and above used non invasive 
techniques (echocardiography) to measure Ees and Ea, looking for age and gender 
related changes in ventriculo-vascular interaction. LV systolic  elastance (Ees, 
mmHg/ml) was 1.86 in males and 2.21 in females at the of 55 years, while at the age 75 
years it was 2.05 in males and 2.58 in females. Ees was significantly (p<0.0001) higher 
in older participants and females. Arterial elastance (Ea) was 0.61 in males and 0.83 in 
females at the of 55 years, while at the age 75 years it was 0.73 in males and 0.97 in 
females. Ea was also significantly (p<0.0001) higher in older participants and females. 
[80] 
Increased arterial stiffness causes elevation in the afterload of LV, which act as a strong 
stimulus for the development of left ventricular hypertrophy (LVH). Two main 
pathological processes are involved in the development of LVH: myocyte hypertrophy 
and interstitial hypertrophy (discussed previously) can lead to the development of 
impaired relaxation and increased ventricular mass. However, the development of LVH  
in response to increased arterial stiffness may not be the only explanation of increased 
HF-PSF in people with increased ventriculo-vascular stiffness.  
In Olmsted County Study Lam et al have shown that despite similar LV mass index HF-
PSF patients had more impaired LV diastolic dysfunction. They compared vascular and 
ventricular structure and function in HF-PSF cohort (n=244, mean age 76years) with 
those observed in healthy (no cardiovascular disease, n=617, mean age 57 years) and 
hypertensive (HTN) controls without HF (n=719, mean age 66 years). They reported 
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that even after adjusting for age, sex and BSA, ventricular stiffness (Ees, mmHg/ml) 
was higher (p<0.05) in people with HF-PSF (2.39 ± 0.87) and HTN controls (2.30 ± 
0.80) as compared to healthy controls (1.99 ± 0.59) but was almost similar in HF-PSF 
and HTN cohort. They have also reported that even after adjusting for age, sex and 
BSA, people with HF-PSF had significantly (p<0.05) more impaired relaxation (E/e´ = 
18.43±9.65), compared to HTN (9.43±3.32) and healthy controls (7.55±2.29). This 
study showed that despite similar LV mass index, HF-PSF cohort (LV mass index = 
102.1±29.0) had more impaired diastolic function (raised E/e´ ratio) compared with 
HTN cohort (LV mass index = 100.2±22.7). [81] 
The exact pathophysiology of diastolic heart failure is not yet fully understood. 
However, this complex interaction between LV stiffness, diastolic dysfunction and 
vascular stiffness possibly play a key role in the pathophysiology of HF-PSF. 
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2.6 Diagnosis 
The very essence of cardiovascular practice is the early detection of heart failure. [82] 
Diagnosis of heart failure is difficult to make especially in elderly female and obese 
subjects. Because most of the signs and symptoms of heart failure are non specific, a 
detailed history, through clinical examination and investigations are needed to establish 
diagnosis. Echocardiography is the single most useful diagnostic test in the evaluation 
of heart failure. [83] It should also be remembered that heart failure is never a sole 
diagnosis and every effort should be made to establish the aetiology and precipitating 
factors of heart failure. 
 
2.6.1 Signs and Symptoms 
Breathlessness, tiredness and oedema are the most typical symptoms of heart failure but 
are non specific. Other symptoms such as orthopnea and paroxysmal nocturnal 
dyspnoea (PND) are more specific but not very sensitive. Shortness of breath is 66% 
sensitive with 52% specificity whereas ankle oedema is 80% specific but only 23% 
sensitive. Tachycardia, basal crepitation, third heart sound , raised JVP, presence of 
ankle oedema and displaced apical beat are important clinical signs with high specificity 
but are not found in many patients with heart failure. [84]. Sometimes these signs are 
very subtle and may not be picked up by clinicians.[85] 
There is a poor relationship between symptoms and the severity of left ventricular 
dysfunction. However the symptoms and exercise capacity of the patient may be used to 
classify severity of heart failure and has prognostic significance.[86, 87] 
 
Table 2.2  New York Heart Association Functional Classification:[86] 
 
NYHA I 
 
NYHA II 
 
 
NYHA III 
 
 
NYHA IV 
 
No limitation during ordinary activity 
 
Slight limitation by shortness of breath and/or fatigue 
during moderate exertion or stress 
 
Symptoms with minimal exertion that interfere with 
normal daily activity 
 
Inability to carry out any physical activity without 
shortness of  breath, which may be present even at rest 
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2.6.2 Diagnostic Techniques 
According to recently published ECS guidelines to diagnose heart failure an 
echocardiogram should be performed to assess underlying cardiac systolic and diastolic 
dysfunction.[24] 
A twelve lead ECG should be performed in every suspected patient with heart failure. 
Left ventricular systolic dysfunction is unlikely in the presence of normal ECG.[88] 
Chest x-ray may also provide useful information.  Cardiomegaly and pulmonary 
congestion may give important clue about the cause of breathlessness. However neither 
finding alone can confirm or refute the presence of left ventricular dysfunction.[89] 
Echocardiography is a widely available non invasive and safe investigation that should 
be done on every suspected patient of heart failure to establish the diagnosis. 
Echocardiography can evaluate systolic function, diastolic function, valvular function 
and cardiac anatomy. A detailed role of echocardiography in heart failure is discussed in 
the later section of this literature review. 
BNP and NT pro BNP assay levels are important tools in diagnosis and management of 
heart failure. Role of BNP in excluding the non cardiac causes of breathlessness has 
been described. [90] Detailed role of BNP in heart failure is discussed in the later 
section of this literature review.  
Cardiac MRI, cardiac CT, Dobutamine and stress echocardiography can also provide 
useful information about cardiac function, anatomy, regional wall motion abnormalities. 
But these tests are limited because of availability and cost. 
Six minute exercise test is also used to assess the functional capacity and to evaluate the 
response to treatment. 
Coronary angiogram should be considered in heart failure patients with suspected 
underlying heart disease. Right heart catheterization is the gold standard investigation to 
assess filling pressures and diastolic function but due to advancement of non invasive 
tissue Doppler imaging it is used less frequently. 
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2.7 Role of Echocardiography In Management of Heart Failure 
2D echocardiography is a well established non invasive modality in the assessment and 
management of heart failure. It can precisely assess LV function and can provide 
detailed information of cardiac anatomy.  
 
2.7.1 Assessment of LV Systolic Function 
2D echocardiography is important in the evaluation of LV systolic function which is 
calculated in terms of LV ejection fraction. 
Four echocardiography methods are particularly of interest to calculate LVEF; M-mode, 
biplane volumetric method, wall motion index and a semi-quantitative 2-D approach 
(also known as ‘eye balling’). 
M-mode is the longest established one dimensional method to calculate LVEF. M-mode 
is one dimensional assessment of LVEF and is dependent on the changes in ventricular 
dimensions during systole and diastole. This method can produce false results in the 
presence of wall motion abnormalities and aneurysms. [91] Therefore, presence of 
regional wall motion abnormalities limits the clinical utility of this method. 
The biplane volumetric method is based on endocardial tracing of LV in apical two and 
apical four chamber views. This method can calculate LV volumes more accurately and 
can calculate LVEF even in the presence of regional wall motion abnormality. However 
endocardial borders may not be visible in majority of patients and this method may also 
not be better than eye balling. [92]  Jensen-Urstad et al studied the usefulness of various 
methods of assessing LVEF for 96 patients (age= 64 ± 9 years) by eyeball assessment, 
wall motion score index (WMI) and biplane volumetric method by using trans-thoracic 
echocardiography and compared these with the reference method radionuclide imaging. 
The echocardiographic study was performed by two experienced physicians, 
independently of each another. Interobserver coefficient of variation for eyeball 
assessment of the EF was 10%, for biplane volumetric method 18%, and for the 
radionuclide EF 5%. In 45 patients (50%) biplane volumetric method was not possible 
due to poor tracing of endocardial borders. Wall motion score index and eyeball 
assessment of the EF correlated best with the radionuclide EF (r = 0.72 and r = 0.71), 
whereas biplane volumetric method had lower correlation with radionuclide EF (r = 
0.51). [93] Regional Wall Motion scoring is a system that divides the left ventricle in 16 
small segments and scores them individually[94] Each segment is scored according to 
both wall motion and thickening. Wall Motion Index (WMI) is a total score divided by 
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number of segments.[95] WMI  X 30 reveals ejection fraction.[96] 
Eye balling is the most commonly used method to assess LVEF in clinical practice. It is 
a visual estimate of global LV systolic function and if performed by an experienced 
person can be competitive to biplane volumetric method with respect to accuracy while 
being measurable in a greater proportion of the population. Eyeballing has also shown 
good correlation with gold standard radionuclide imaging and formal echocardiographic 
methods in previous studies. Royen et al recorded LVEF by eyeball assessment method 
and gold standard radionuclide angiography in 73 stable patients and reported that 
correlation of LVEF determined by both methods was good (r = 0.81) [81, 97] 
 LVEF and LV volumes do not correlate well with heart failure symptoms and exercise 
tolerance but are powerful prognostic indicators for future cardiac events.[98, 99]  
 
2.7.2 Assessment of LV Diastolic Function 
Doppler echocardiography is the most practical method for assessing diastolic function 
abnormalities. Doppler assessment of transmitral velocities provides useful information 
about LV diastolic relaxation and filling of left ventricle. Figure 2.4 shows various 
mitral inflow Doppler patterns which are useful in diagnosing and grading diastolic 
dysfunction. 
 
 
Figure 2.4:  Transmitral Doppler (PW) flow patterns. 
  
A typical transmitral flow consists of following two distinct waves: 
i. E wave- corresponds to early diastolic flow 
ii. A wave- corresponds to transmitral flow during atrial systole 
 
The E velocity represents the early mitral inflow velocity and is influenced by the 
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relative pressure difference between the LA and LV. The A velocity represents the atrial 
contraction component of mitral filling and is mainly influenced by LV compliance and 
LA contractility. Time taken for the peak E velocity to reach baseline is called 
deceleration time, another useful parameter to assess diastolic function. DT correlates 
with the time of pressure equalisation between the LA and LV. Time interval between 
the end of A wave and the beginning of next E wave is called isovolumetric relation 
time (IVRT). PW mitral inflow parameters (E/A ratio, DT and IVRT) have been used to 
diagnose and grade the diastolic dysfunction into mild, moderate and severe categories 
as these can be obtained in nearly all the patients. However, these parameters also have 
few weaknesses as they are highly pre load dependent and difficult to measure at high 
heart rates. Another limitation of this technique is atrial fibrillation (AF) and paced 
rhythms, where A wave is lost and IVRT cannot be measured. Diastolic dysfunction is 
characterised by incomplete or delayed relaxation of LV, resulting in delay in the 
transfer of blood from LA to LV. Early in the evolution of the diastolic dysfunction, the 
delay in emptying is partially compensated by a more vigorous atrial contraction (A), 
resulting in reduced E/A ratio (grade 1 or mild diastolic dysfunction). Later LA pressure 
increases in face of further impaired LV relaxation, resulting in increase in E velocity 
and E/A ratio and mitral inflow velocity profile may look normal (grade 2 or moderate 
diastolic dysfunction – also called pseudo-normalisation).  However, early diastolic 
myocardial velocity of mitral annulus (e´) velocity will remain reduced and will identify 
the underlying diastolic abnormality. With further impairment of LV relaxation, 
impedance to atrial emptying further increases the LA pressure. Along with this further 
increase atrial pressure and dampening of compensatory increase in atrial contraction 
results in very high E/A ratio (>2.0) resulting in grade 3 or severe diastolic dysfunction. 
Mitral annular velocities measured by tissue doppler (TDI) techniques also reflect 
myocardial relaxation and are used alone or in combination with mitral inflow velocities 
to assess diastolic function. [100] 
There are three components of the tissue Doppler profile that are routinely measured: 
the systolic myocardial velocity (S´); the early diastolic myocardial velocity (e´); and 
the late diastolic myocardial velocity (A´). The e´ is essential for classifying the 
diastolic function. Advantage of this technique is that it is not affected by preload and 
can also be used in AF. [101] Another benefit of this technique is that e´ decreases 
progressively with severity of diastolic dysfunction and there is no pseudo-
normalisation. [100] E/e´ ratio correlates with LV filling pressures irrespective of LV 
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systolic function. [102] Due to these obvious  advantages both European Society of 
Cardiology and American Society of Echocardiography have designated e´ and E/e´ 
indices as first line doppler parameter in the diagnosis and classification of diastolic 
dysfunction. [103, 104] However, TDI methodology is also influenced by local changes 
in wall motion (infarction) which may limit its use in some patients. 
Pulmonary vein flow velocities are also used to assess diastolic function. This method 
has advantage over inflow velocity technique as it is not affected by HR and preload. 
However poor image availability of pulmonary veins in a substantial proportion of the 
population is the major limitation.[104] 
LA volume can also provide morphologic and physiological evidence of chronic 
elevation in filling pressure and diastolic dysfunction, however in chronic volume 
overload conditions like anaemia and compensated valvular diseases LA volume can be 
raised in the presence of a normal LV filling pressure. 
 
2.7.3 Assessment of Valvular Function and LV Dimensions 
2D echocardiography also provides useful information regarding LV dimensions, and 
LV mass. Image quality in patients with poor echo window is however a major limiting 
factor in the accuracy of these measurements.[105] 
Combination of 2D and doppler echocardiography reliably evaluate the valve structure 
and function. However poor alignment of Doppler signals can under estimate the valve 
pathology.[105] 
 
2.7.4 Therapeutic Guidance 
Echocardiography can also help to guide therapies in heart failure. For example 
aldosterone antagonism is normally recommended in patients with NYHA functional 
class III-IV with LVEF less than 35%. [106]  Echocardiography is also used in 
monitoring LV systolic function in chemotherapy patients (e.g. Herceptin). Treatment is 
often discontinued if LV systolic function deteriorates. 
Indications for implantable cardioverter-defibrillators (ICDs) and cardiac 
resynchronisation therapy (CRT) are very much reliant on specific cut-off value of 
LVEF measured by biplane volumetric method. 
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2.8 Treatment 
Both the American and European associations have laid down the guidelines for the 
treatment of heart failure.[24, 83]. Like other treatments goal of heart failure treatment 
is symptom control, increased quality of life, decreased hospitalization and prolonging 
life. I will summarize the key points of heart failure management under the following 
headings. 
 
 Life style modification 
 Pharmacological treatments 
 Invasive treatments 
 
2.8.1 Life Style Modification 
Despite recent advances in pharmacological treatment of heart failure life style 
modifications and patient education play a very important role in achieving the goals of 
heart failure treatment. Recently published guidelines for heart failure management 
highlighted the importance of cessation of smoking, weight reduction, dietary restriction 
of sodium, reducing or stopping alcohol consumption and modest aerobic exercise. 
These lifestyle modifications play an important role in heart failure management along 
with pharmacological treatment.[24] 
 
2.8.2 Pharmacological Management 
ACE inhibitors, beta blockers, ARBs, aldosterone antagonists and diuretics are key 
pharmacological agents that play important role in symptom reduction, decreased 
morbidity and mortality. 
ACE inhibitors are the first line drugs recommended to treat heart failure. This group of 
medicines have shown improvement in survival when used in heart failure patients 
(CONCENSUS and SOLVD-treatments). [107, 108] ACE inhibitors have also shown to 
reduce mortality in patients with asymptomatic LV systolic dysfunction. [109] 
However, dry cough, electrolyte imbalance and renal impairment might limit their use. 
Angiotensin receptor blockers (ARBs) can be used if patient is intolerant to ACE 
inhibitors. ARBs have  also shown decrease  in mortality and morbidity when used in 
heart failure patients (CHARM and Val- HEFT).[37, 110] 
Beta blockers are important medications that have shown significant improvement in 
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symptoms and survival in all (NYHA) classes of heart failure and should be added to 
ACE inhibitors. [111]. MERIT –HF, CIBIS, COPERNICUS and SENIOR are important 
randomized controlled trials that have proven beta blockers role in the treatment of heart 
failure. [112-115] However, bradycardia and hypotension are two important side effects 
that may limit their use. 
Spironolactone and Eplerenon (RALES and EPHESUS) are two important medications, 
which act as aldosterone antagonist, have shown improvement in survival in moderate 
to severe heart failure.  [116] However, electrolyte imbalance and renal impairment may 
limit their use and should be used with caution in people with renal failure. 
Diuretics are mainly used to control symptoms of fluid retention and are most 
commonly used medications in heart failure. However diuretics have not shown any 
improvement in survival of heart failure patients. 
Other agents like Digoxin are also used in heart failure patients with AF to control the 
heart rate. However, these have no effect on mortality but may reduce hospitalization. 
[117] Warfarin may also be used in patients with severe heart failure with or without 
atrial fibrillation and proven better than aspirin in reducing hospitalization and co-
morbidity like stroke.[118] Statins may also play a role in reducing hospitalization in 
heart failure patients with ischemic aetiology. [119] 
 
2.8.3 Invasive Treatment 
Limited options of invasive treatment options are available for severe heart failure 
patients with limited benefit. 
Cardiac resynchronization therapy (CRT) has shown benefit in patients with severe 
heart failure that show evidence of asynchrony between both ventricles. CRT 
maximizes the cardiac output by synchronising contraction of both ventricles.  CRT has 
shown improvement in symptoms , quality of life and mortality.[84, 120] 
More than 50% of deaths in heart failure are due to sudden cardiac deaths. Implantable 
cardiac defibrillators (ICDs) are better in preventing sudden cardiac deaths as compared 
to anti arrhythmic drugs. [121] Most of the trials to date on ICD and CRT have been in 
younger patients and the conclusive evidence of the benefits of this therapy in elderly is 
still awaited. However, age alone should not be a contraindication. 
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2.9 Treatment of Heart Failure with Preserved Ejection Fraction 
No treatment has yet been shown to convincingly reduce morbidity and mortality in 
patients with HF-PSF. Unfortunately, very few large randomised controlled trials have 
looked at the patients with HF-PSF as compared with HF-RSF and hence, there is 
insufficient data on mortality benefit of medications used for patients with HF-PSF. [47, 
70, 122, 123]  
HF-PSF is typically common in elderly patients, who suffer with multiple co-
morbidities like hypertension, diabetes, coronary artery disease and atrial 
fibrillation.[18, 37] It is believed among physicians and researchers that treating co-
morbidities might help to improve survival. Therefore, mainstay of treatment remains 
on diuretics to control the symptoms and adequate control of blood pressure and 
ventricular rate. [24, 124] Two trials have suggested that ARBs (CHARM preserved 
trial) and ACE inhibitors (PEP-CHF trial) may reduce the hospitalisation in patients 
with HF-PSF. CHARM preserved trial was a randomised, double blinded controlled 
trial compared the effects of candesartan (vs. placebo) in patients with HF-PSF 
(EF>40%).  The primary outcome for the whole study was cardiovascular death or 
hospital admission for CHF. Mean age of the participants (n=3023) was 67.1 ± 11.1 
years. After 2 years of follow up, cardiovascular death did not differ between groups, 
but fewer patients in candesartan group were admitted to hospital (230 vs 279; p = 
0.01). Again, even in this trial only 407 patients were aged 75 years and above.[70] In 
PEF-CHF trial 850 patients aged 70 years and above (76 ± 5 years) were recruited to see 
the effect of perindopril (vs. placebo) on all cause mortality and hospitalisation due to 
CHF in patients with HF-PSF. Median follow up was 2.1 years, however after 1 year 
most people withdrew from study and only 207 (24.4%) reached the primary end points. 
After 1 year of follow up cardiovascular death did not differ between groups, but fewer 
patients in perindopril group were admitted to hospital (HR 0.692; 95%CI 0.408 – 
0.966; p = 0.033). Although this trial recruited predominantly elderly cohort but drop 
out in the follow up reduces the power of the study. [125]  Still there is lot to learn 
about treatment of heart failure with preserved systolic function. Obviously more trial 
including elderly cohorts and more clinical research looking for treatment of HF-PSF is 
need but it is equally important to screen and treat the comorbidities like hypertension, 
diabetes, atrial fibrillation, chronic kidney disease and coronary artery disease.  
 
 
42 
 
2.10 Challenges In Treating Elderly Heart Failure Patients 
There are many challenges in the treatment of heart failure in elderly population. The 
first challenge in treating elderly population is to correctly identify them. It has already 
been discussed that its quite difficult to diagnose heart failure in elderly population, 
especially in community due to non-specific symptom, multiple co-morbidities 
including COPD, anaemia and renal failure and limited excess to investigations like 
echocardiography. The biggest challenge in treating elderly patients with heart failure is 
that most of them suffer from heart failure with preserved systolic function (HF-PSF) 
and current treatments options have shown small or no benefit in improving morbidity 
and survival related with this condition as discussed previously. [70, 125]  
Elderly people have always been under represented in heart failure (HF-PSF) drug 
trials. Mean age for most major randomised control trials is 58 to 71 years. [126] 
Multiple co- morbidities like renal impairment and polypharmacy in elderly population 
may also increase the frequency and magnitude of heart failure drugs and decrease the 
compliance to the treatment. Polypharmacy in elderly can also lead to drug interaction, 
raising issues of efficacy and safety.  [127, 128] Patients with heart failure may often 
have coexistent COPD leading to difficulty in diagnosis, due to similar symptoms and 
signs. It is important to have low threshold of suspension in this age group. Cognitive 
impairment in many elderly population with heart failure also has implications on drug  
compliance and titration of medication.[129] 
However studies have shown that a multidisciplinary approach including patient and 
family education, social support, involvement of pharmacist and heart failure specialist 
nurse results in improvement in event free survival and quality of life in elderly 
patients.[122, 130-132] In an Australian randomised controlled study, CHF patients 
discharged home after acute hospital admission were randomly assigned usual care 
including (n=100) or a multidisciplinary, home-based intervention (n=100). Usual care 
included both inpatient and community-based contact with a cardiac rehabilitation 
nurse, dietitian, social worker, pharmacist, community nurse and an outpatient follow 
up with the cardiologist. In a multidisciplinary, home-based intervention group all of the 
usual care was included along with a structured home visit by a qualified cardiac nurse 
7–14 days after discharge. During this visit the nurse assessed the patient's clinical 
progress since discharge, patient's adherence to the prescribed treatment regimen, ability 
to recognise changes in symptoms indicative of worsening heart failure, fluid and 
sodium intake, current amount of physical activity. On the basis of this comprehensive 
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home assessment, patients and their families received counselling targeting to improve 
treatment adherence, recognition of fluid overload or worsening of symptoms, 
introduction of a simple exercise regimen and where indicated. If indicated the 
medication regimen was also alter by the cardiac nurse after discussion with the 
cardiologist. Mean age of patients in usual care group was 76.1 ± 9.3 years and in 
intervention group 75.2 ± 7.1. 40% of patients in usual care group and 32% in 
intervention group had LVEF > 40%. During 6 months' follow-up there were 129 
primary endpoint events in the usual care group and 77 in the intervention group 
(p=0·02). Overall, there were fewer unplanned readmissions (68 vs 118; p=0·03) and 
associated days in hospital (460 vs 1173; p=0·02) among intervention group patients. 
Hospital-based costs were Australian $490 300 for the intervention group and $922 600 
for the usual-care group (p=0·16). [131] 
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Chapter 3. Arterial Stiffness 
Arteries stiffen with advancing age and with other cardiovascular risk factors including 
hypertension, diabetes mellitus and coronary artery disease. [133, 134] Increased 
arterial stiffness is an independent risk factor for cardiovascular events.  [133, 135] 
Arterial stiffness is a generalized term to describe rigidity of the arterial tree. Different 
terms are used to describe this property of the arterial system, some of which are 
explained in the following table 3.1.[136] 
 
Table 3.1: Important indices of arterial stiffness 
Term Definition 
Distensibility* Relative change in the diameter/area  for a given pressure change 
Compliance* Absolute change in the diameter/area  for a given pressure 
change 
Elastic modulus* The pressure change required for theoretical 100% stretch from 
resting diameter (inverse of distensibility) 
Young’s 
modulus* 
Elastic modulus per unit area  
Pulse wave 
velocity 
The speed with which pulse wave travels along a length of artery 
Augmentation 
index 
Percentage of central pulse pressure rise due to reflection of 
pressure wave 
*Also requires pressure measurements 
 
To understand pathological arterial stiffness one must understand the main functions of 
the arterial system and mechanisms affecting blood flow through arterial tree. 
Cushioning and Conduit function of elastic vessels 
The principal function of the arterial system is act as a conduit and deliver blood from 
left ventricle blood into the circulation to deliver oxygen and nutrients to metabolising 
tissues and the also transport the waste materials to the organs to eliminate them. 
Another important function of large vessels is to buffer the pulsatile blood flow from 
the left ventricle and convert it to steady and almost continuous flow to the peripheral 
vasculature. This is called the ‘windkessel function’. [137, 138] This function is 
possible because arteries are compliant, with the ability to expand due to pressure and 
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the ability to recoil. Although the windkessel model of the circulation helps to 
understand the importance of elastic and conduit characteristics of arteries, this model 
assumes that the arterial tree has separate elastic and conduit compartments and also 
does not take the existence of wave reflection into account. In fact most of the arterial 
tree has both of these functions combined, although one or the other tends to 
predominate in any given arterial segment. That combination of function leads to 
pressure wave travel and reflection which is discussed in the following section.  
The arterial pressure wave is generated with ventricular ejection which propagates 
through the arterial tree. The speed at which the arterial pressure wave travels along the 
arterial tree is termed the pulse wave velocity.  Young originally described the 
relationship between arterial stiffness and pulse wave velocity in 1808 [139] but it is 
generally described by Moens - Korteweg equation: [140]  
                  
 (Where E is Young’s modulus of the arterial wall, h is thickness of arterial wall, R is radius and   is blood density)   
 
Arterial pressure wave reflection and waveform analysis 
The arterial pressure wave is a combination of a forward wave generated by LV systolic 
ejection and a reflected or backward wave, from impedance points (vessel bifurcations) 
46 
 
 
 
 
 
 
 
 
Figure 3.1: The central (aortic) pressure wave form formation- components, 
effects of arterial stiffness on pressure wave form. 
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of the peripheral arterial tree (Figure 3.1). Reflection of the backward wave depends on 
the speed with which the forward wave travels along the arterial tree, i.e. pulse wave 
velocity (PWV). [141] In youth and health the reflected wave arrives in the proximal 
aorta in diastole. This augments end diastolic aortic pressure and boosts the coronary 
perfusion. [142] However, PWV increases with arterial stiffness resulting in early return 
of the reflected wave in systole. This in turns augments systolic blood pressure, reduces 
diastolic blood pressure and widens the pulse pressure. [143] The proportion of this 
augmented pulse pressure is called augmentation index (AIx). 
This augmentation of systolic pressure and decrease in diastolic pressure results in 
increased tension time index (TTI = area under the systolic half of the pressure 
waveform), increased LV workload (F) with increased oxygen demand. 
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3.1 Mechanisms Underlying Arterial Stiffness 
Arterial stiffness is considered to be the result of simple wear and tear in the elastic 
arteries. With each cardiac ejection aorta distends and this stress is taken up by 
predominantly the elastic fibres in the vessel wall. On average the proximal aorta dilates 
by 10% with each heart beat. Repeated cycles of distension and elastic recoil are 
thought to cause fatigue fracture [140] of elastin in the vessel wall which results in 
depletion of elastin and replacement with collagen which is less elastic. [144] This 
results in increased arterial stiffness. This increase in arterial stiffness results in a 
positive feedback loop of elevated  PWV, early return of reflected waves with further 
augmentation of systolic pressures and more vascular damage [143] Arterial stiffness is 
also influenced by the tone of smooth muscles in the vessel wall which is partly 
regulated by the vascular endothelium. [145] Vascular endothelium exerts that function 
possibly by means of nitric oxide. [146] Decline in endothelial nitric oxide production 
with age also plays some role in the development of age related arterial stiffness. [146] 
The process of arterial stiffness is accelerated in the presence of conditions like 
metabolic syndrome, renal failure and hypertension. [133] A number of genetic 
determinants of arterial stiffness have also been identified. Several genetic 
polymorphisms have been reported to influence PWV, including some in the fibrillin-1, 
angiotensin II type 1 receptor  and endothelin receptor genes which are also related to 
arterial stiffness. [147] Still the precise mechanism underling arterial stiffness remains 
somewhat unclear and more work is needed in this regard.  
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3.2 Determinants of Arterial Stiffness 
Arterial stiffness is influenced by many factors. Major physiological and pathological 
factors listed in the table 3.2 are discussed below. 
 
Table 3.2: Major determinants of arterial stiffness 
Physiological Factors Pathological Factors 
Age Hypertension 
Gender Diabetes Mellitus 
Height Atherosclerosis 
Heart Rate Renal disease 
 
 
3.2.1 Physiological Factors Affecting Arterial Stiffness 
Age is the single strongest determinant of arterial stiffness. This is reflected by increase 
in PWV and AIx with advancing age. This has been described in many population based 
studies using various methods of assessment. Investigators of the Anglo-Cardiff 
Collaborative Trial (ACCT) have studied more that 4000 healthy community based 
participants between 20 to 90 years old. [148] They have showed that PWV, central 
aortic blood pressure, central pulse pressure, augmentation pressure (AP) and 
augmentation index (AIx)  increase significantly with age for  both men and women, 
although values for AP, AIx, central blood pressure and central pulse pressure were 
significantly higher in women than men. This was also shown by previous large cohort 
American studies like the Cardiovascular Health Study (CHS) and the Framingham 
Health Study. [149, 150] Increase in arterial stiffness with age is gradual and continuous 
with increase of 0.1 m/sec per year in PWV. [133] However investigators in ACCT and 
some others have shown that increase in PWV and AIx follow a non linear course, 
being more marked after age of 50. It is also shown that aging exerts differential effects 
on various vascular indexes. [148] For example, increases in central pulse pressure and 
aortic PWV were more marked in older subjects compared with younger subjects, 
whereas the age-related changes in AIx were more prominent in younger subjects. Ten 
years of ageing at 20 years old increases PWV by 0.48 m/sec and 0.35 m/sec in males 
and females respectively whereas a similar time period at 80 years of age raises PWV 
by 1.35 m/sec males and 2.35 m/sec in females. Similarly ten years of ageing, a rise in 
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AIx at the age of 20 years was 9% and 10% in males and females respectively, whereas 
AIx rise in 80 years old males was only 1% and no change was observed in 80 years old 
females. . The exact cause of this non linear rise and gender difference is not known, 
although a possible explanation for the non linear rise is elastin fatigue fracture and 
degradation, with resultant increased loading on stiffer collagen fibres and a marked 
increase in calcification of the aortic media with age, particularly after the fifth 
decade.[148] Augmentation index (AIx) is inversely related to height. [151] Smulyan 
and colleagues studied the relationship of height to various markers of arterial stiffness 
in a study including 402 subjects. 149 subjects had end stage renal failure (ESRF) 
(mean age = 52.9 ± 16.9 years) and 253 subjects had normal kidney function (mean age 
= 48.9 ± 20). AIx is also inversely related to heart rate. [152] Wilkinson and colleagues 
studied the relationship between heart rate and AIx in 20 young people (mean age = 47 
± 20) who attended the hospital for their electrophysiological investigations. 
Investigators found significant reduction in AIx when the subjects’ heart rate was 
increased from 80 beats/min to 120 beats/min with incremental right atrial pacing (r = -
0.70, p < 0.001).  Investigators didn’t observe any change in PWV with this incremental 
heart rate. [152] The relationship between heart rate and PWV is less clear. In a similar 
study, Lantelme and colleagues studied 22 subjects with a mean age of 77.8±8.4 (SD) 
years who attended the hospital for permanent cardiac pacing. In each subject, PWV 
was measured at 5 different pacing frequencies in the same session (60, 70, 80, 90, 100 
beats/min). The average difference between PWV at 100 and 60 beats/min was 1.36 ± 
2.9 m/s. This effect of heart rate on PWV was highly significant (p = 0.01). Those 
investigators believed that the predominance of elderly subjects in their cohort might 
have amplified the overall PWV-heart rate relationship because age is indeed known for 
its effect on arterial compliance.  [153] 
  
3.2.2 Pathological Factors Affecting Arterial Stiffness 
Increased arterial stiffness is widely observed in the hypertensive population. Increased 
wave reflection (Tr) and AIx has also been widely reported among hypertensive 
subjects. [154] Similarly, higher PWV has been reported in hypertensive patients 
compared with normotensive controls across wide ranges of age. [155, 156] Asmar and 
colleagues studied 512 community based subjects to investigate the relationship of age, 
hypertension and PWV. They divided the subjects into three groups: group 1 included 
124 normotensive subjects (mean age = 45 ± 13 years), group 2 included 224 untreated 
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hypertensive patients (mean age = 48 ± 13 years) and group 3 included 164 patients 
with well controlled hypertension (mean age = 59 ± 11 years). In group 2 all subjects 
had essential and uncomplicated hypertension and none of the patients had cardiac, 
neurological or renal involvement or arteriopathy of the lower limbs. Patients with 
valvular heart disease, arrhythmia or carotid artery stenosis were excluded from the 
study. Patients had been free of all medication for one month prior to the study. The 
mean duration of their hypertension was 3.8 ± 5 years (mean ± SD). In group 3 all 
patients were treated and classified as well controlled by antihypertensive medications 
(if their diastolic blood pressure had been below 90 mmHg during the 3 months 
preceding the study). The mean duration of the hypertension was 5.6 ± 4.8 years (mean 
± SD). The mean duration of their treatment was 4.7 ± 4.3 years (mean ± SD). The 
mean duration of normalised diastolic blood pressure was 3.9 ± 4.1 years.  PWV 
(carotid-femoral PWV) was measured in all the subjects. PWV in group1, 2, and 3 were 
8.5 ± 1.5 m/sec, 11.8 ± 2.7 and 10.1 ± 2.1 respectively. Investigators found a significant 
correlation between age and PWV in all three groups (group 1: r = 0.55, p < 0.001; 
group 2: r = 0.48, p < 0.001; group 3: r = 0.48, p < 0.001). The comparison between the 
hypertensive and normotensive relationships of PWV with age shows that, at any given 
age, PWV was significantly higher in group 2 by comparison with group I (p < 0.001). 
Investigators also found that despite an adequate control of diastolic blood pressure, 
pulse wave velocity increased more with age in Group 3 than in group 1. [155] In this 
study effect of different antihypertensive medications on arterial compliance and PWV 
was not studied in detail due to the disparity within the treatment group regarding the 
form and duration of treatment, however pharmacological studies suggest that not all 
antihypertensive treatments improve arterial compliance and stiffness. Calcium channel 
blockers (nifidipine, nicardipine) and angiotensin converting enzyme inhibitors (ACE 
inhibitors like perindopril, captopril and enalapril) have shown to improve arterial 
stiffness and reduce the pulse wave velocity (PWV) in hypertensive patients in contrast 
with agents like beta blockers and diuretics. [157] 
Hasegawa and colleagues measured PWV in 29 patients with hypertension, ranging in 
age from 37 to 73 years, 36 normotensive subjects with the same age range and in an 
additional series of 44 normal subjects aged 18-35 years. They found a linear rise in 
PWV with age for both normal subjects and patients with hypertension. There was a 
statistically highly significant (p < 0.001) increase in PWV in hypertension at all ages 
examined. [156] The exact mechanism for this relationship is not clear. Many believe 
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that this rise in arterial stiffness is due to an increase in the mean arterial pressures 
because if this pressure is normalized statistically or pharmacologically, aortic stiffness 
normalises. [158] 
Arterial stiffness is also increased in individuals with diabetes mellitus (Type 1 & 2), it 
is even seen in people with even impaired glucose tolerance. [133, 159] Diabetes also 
has a differential affect by gender as women with diabetes or the metabolic syndrome 
have stiffer arteries than men. [159] The exact mechanism of this gender difference and 
cause of arterial stiffness in diabetes is unclear, however, one of the main mechanisms 
thought to be involved is the formation of advanced glycation end-products (AGEs) in 
the arterial wall, causing cross-linking of collagen molecules, which may lead to loss of 
collagen elasticity and a subsequent increase in arterial stiffness. [160] Endothelial 
dysfunction seen in diabetics with reduced availability of nitric oxide and increased 
activity of vasoconstrictors such as endothelin-1 may also play a role in the 
pathogenesis of stiff arteries in these individuals. [161-163] 
Population based studies have shown strong association between arterial stiffness and 
atherosclerosis at various sites in the vascular tree. In the Rotterdam study more than 
3000 elderly subjects aged 60 to 101 years were studied to see association between 
arterial stiffness and atherosclerosis.  Significant associations between PWV and 
common carotid intima-media thickness (p < 0.001), plaques in the carotid artery (p < 
0.001), and plaques in the aorta (p < 0.001) were observed even after adjusting for age, 
sex, mean arterial pressure, heart rate, and cardiovascular risk factors. [164] 
Increased arterial stiffness is also seen in the patient with renal failure, and aortic PWV 
is a very strong predictor of cardiovascular mortality in patients with end stage renal 
failure [165], however an exact mechanism of aortic stiffness in renal failure is still 
unclear. Several potential mechanisms for aortic stiffening and dysfunction secondary to 
renal insufficiency have been described. Increased prevalence of abnormalities in 
endothelial function, oxidative stress, calcium homeostasis, activation of the RAAS and 
aortic calcification are often present in patients with renal dysfunction and may 
contribute to increased vascular stiffness in these patients. [165-168] Blancher and 
colleagues studied 110 patients (mean age = 54 ± 16 years) with stable end stage renal 
disease (ESRD) on dialysis and followed them up for 53 ± 21 months (mean ± SD). 
[168]  They measured carotid intima-media thickness, carotid compliance, carotid 
distensibility, aortic pulse wave velocity, and the presence of arterial calcifications 
measured at the sites of the carotid artery, abdominal aorta and ilio-femoral arteries. The 
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presence of calcifications was analyzed semi-quantitatively, using ultrasonography as a 
score (0 to 4) according to the number of arterial sites with calcifications. During follow 
up 25 cardiovascular and 14 non-cardiovascular deaths occurred. Investigators showed 
that the presence and extent of vascular calcifications were strong predictors of 
cardiovascular and all-cause mortality. Risk of death increased with the number of 
vascular sites having calcifications (for 0 to 4 vascular sites with calcifications, risk of 
all-cause mortality was 3%, 17%, 31%, 50%, and 73%, respectively; p < 0.001). 
Adjusted hazard ratios of all-cause and CV mortality for an increase of 1 unit in 
calcification score were 1.9 (95% confidence interval, 1.4 to 2.6) and 2.6 (95% 
confidence interval, 1.5 to 4.4), respectively (p < 0.001 for both). [168] 
There is still sparse data about how different variables of arterial stiffness alter in 
extreme ages in health and disease.  
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3.3 Assessment of Arterial Stiffness 
There are several different methods to assess arterial stiffness. Each method has both 
advantages and limitations which I will discuss briefly in this section. 
 
3.3.1 Pulse Pressure 
Pulse pressure is simply a difference between systolic and diastolic blood pressures. It is 
usually measured by a standard sphygmomanometer.  
Age associated changes in blood pressure tend to widen the pulse pressure beyond the 
age of 50-60 years. [169] Pulse pressure has been recognised as a valuable surrogate 
marker of arterial stiffness. [170] 
Various studies have shown pulse pressure as better predictor of ischemic heart disease 
that either systolic or diastolic blood pressure alone, in elderly patients. [171, 172] In 
Framingham Heart Study (FHS) pulse pressure was shown to be a strong predictor of 
coronary heart disease in an elderly population based cohort (mean age of FHS cohort 
was about 63 years). According to the investigators of FHS there might be a selection 
bias in their study as they excluded people on antihypertensive treatment at baseline, 
which was 30% of their total cohort. Wider pulse pressure has also predicted stroke and 
mortality in elderly hypertensive patients. [173].  This study has demonstrated an 11% 
increase in stroke risk and a 16% increase in risk of all-cause mortality for each 10-mm 
Hg increase in pulse pressure (mean age of the cohort was 72 years). 
Pulse pressure is the simplest method to predict arterial stiffness and is readily available 
in clinical settings however; it has its own limitations. Arterial stiffness is more marked 
in central and elastic arteries than peripheral arteries therefore pulse pressure from the 
brachial artery does not accurately reflect central aortic pulse pressure. [174] Central 
pressure is a more accurate predictor of cardiovascular risk and is a strong determinant 
of left ventricular load and resultant left ventricular hypertrophy. [140, 175] 
The Prospective Studies Collaboration conducted a meta-analysis of over a million 
individual participants’ data on blood pressure and cardiovascular death from 61 
separate prospective studies. They used various blood pressure indices including 
systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (SBP-
DBP), mean arterial pressure (2/3DBP + 1/3SBBP) and mid blood pressure (1/2 SBP + 
½ DBP). Cause-specific mortality was noted during five decades of life (40-49, 50-59, 
60-69, 70-79, and 80-89).  During 12.7 million person-years at risk 56000 vascular 
deaths were noted (12000 stroke, 34000 IHD) at ages 40-89 years.  It was noted that 
55 
 
during ages 40-69 each 20mmHg SBP difference was associated with more than 
twofold difference in stroke, IHD and other vascular death rates. However, at ages 80-
89 these differences were less marked (nearly half) as at the ages 40-69. [176] They also 
found that SBP was better predictor of stroke or IHD mortality as compared to DBP or 
pulse pressure. However, they also reported mid blood pressure (average of both SBP 
and DBP) was informative in predicting stoke and IHD mortality than either alone. 
[176] 
 
3.3.2 Pulse Wave Velocity 
Pulse wave velocity (PWV) is simply the speed at which the pressure wave transited 
from aorta travels through the vascular tree. There are a number of different ways to 
measure PWV. The arterial pulse wave is recorded at proximal artery (carotid) and a 
more distal (brachial or femoral) artery. Time delay between the feet of these two 
waveforms is obtained either by simultaneous (Vicorder & Complior) or separately with 
ECG synchronization (SphygmoCor). The distance travelled by the pulse wave is 
measured over the body surface and PWV is than calculated as distance/time. Different 
devices use various techniques to record pulse wave like pressure sensitive transducer 
(Complior), applanation tonometry (SphygmoCor) and volume displacement technique 
(Vicorder, Arteriograph).[177-179] Pulse wave velocity measured by these devices 
shows a good correlation, however one device might give slightly higher value than the 
other. Vicorder is the most portable and is almost operator independent. The carotid-
femoral PWV (cf PWV) reflects the aortic PWV  and is considered as a “gold standard” 
for the measurement of arterial stiffness. [180] The carotid-femoral PWV has been 
shown to be an independent predictor of cardiovascular morbidity and mortality in the 
general population, hypertensive patients, and renal failure patients and in elderly cohort 
as mentioned in previous sections. Only one previous study has studied relationship of 
PWV with cardiovascular events in elderly cohort (85+ years) in suburbs of Paris. This 
study included 141 hospitalised individuals from geriatric wards with mean age of 
participants 87 years (87.1 ± 6.6 years). This study showed PWV was a strong 
independent predictor of cardiovascular death with an adjusted odd ratio of 4.60 (95% 
confidence interval, 1.4 to 15.7) when PWV was >17.7 m/s. However, that significance 
disappeared with PWV less than 17m/s. [181] 
PWV measurement has become very simple, inexpensive and quick due to modern 
devices. However accurate estimation of path length (arterial distance between 
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recording sites) can be difficult as the aorta tends to become more tortuous with age. 
PWV can also be measured non-invasively by using MRI, which provides actual 
measurement of the path length but this method is more time consuming, expensive and 
not widely available. [182] 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
 
 
Figure 3.2: Pulse wave velocity (PWV) calculation using the foot-to-foot method 
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3.3.3 Pulse Wave Analysis 
Arterial stiffness can be measured by analysing various components of the arterial 
pressure waveform. Different devices use various techniques to record peripheral 
pressure waveform including applanation tonometry and photoplethysmographic (PPG) 
signals. Mostly the radial pressure waveform is recorded, calibrated to brachial blood 
pressure measured with a sphygmomanometer. The central pressure waveform and 
central pressures are derived from this peripheral waveform and blood pressure by using 
a generalized transfer function. [31] Augmentation index (AIx) is calculated from the 
central pressure waveform and central blood pressure values (ratio of augmentation 
pressure to pulse pressure). Generalized transfer factor in SphygmoCor device has been 
validated by simultaneously recording central invasive pressure waveforms and 
peripheral non-invasive waveforms. [31, 183-185] In a validation study 30 patients 
(56±9 years; 21 men) underwent diagnostic coronary angiography and simultaneous 
recordings of the derived central pressure waveform using SphygmoCor device. There 
was good agreement and high correlation between invasive and non-invasive techniques 
with a mean difference (±SD) for central systolic BP of −1.3 ± 3.2 mm Hg. [185] 
Augmentation index also increases with age and traditional cardiovascular risk factors 
including diabetes, hypertension and hypercholesterolemia. [186-188] 
Pulse wave analysis not only provides central pressures and augmentation index (AIx) 
but also measures the duration of systole (ejection duration) and diastole. The diastolic 
phase is characteristically shortened in elderly people and in diastolic heart failure 
[189]. AIx and AP have been shown as strong independent marker for coronary artery 
disease (CAD). Weber and colleagues studied 465 individuals undergoing coronary 
angiography for suspected CAD. Arterial stiffness was assessed by applanation 
tonometry at the radial artery. They reported, a higher AIx was increased risk of CAD 
(OR OR, 4.06 for the difference between the first and the fourth quartile [1.72 to 9.57; 
P<0.01]). This association remained significant  even after controlling for age, height, 
presence of hypertension, HDL cholesterol, and medications (OR, 6.91; P<0.05). [190] 
AIx has been also independently associated with cardiovascular events in patients with 
end stage renal failure, coronary artery disease. [191] Although PWV has larger body of 
evidence to predict mortality, AIx has predicted mortality even in patients with normal 
PWV in small group of patients with end stage renal failure. [192] In this study London 
and colleagues measured arterial PWV and AIx in people with end-stage renal failure 
(ESRF) being treated with haemodialysis.  180 patients were included with mean age 
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54±16 years (range, 14 to 88 years). Risk ratio (RR) for AIx was 1.51 (95% CI, 1.23 to 
1.86) for all-cause mortality and 1.48 (95% CI, 1.16 to 1.90) for CV mortality 
(cardiovascular). When they selected people with normal PWV (<11.0m/sec), risk ratio 
for AIx remained significant (p=0.0058) for CV mortality (RR=1.84). [192] 
PWA is a simple, quick, inexpensive and non-invasive validated measure of arterial 
stiffness. PWA using radial tonometry also requires very little training and has more 
freedom from operator bias. [147] A correctly obtained pressure waveform by radial 
tonometry has been described as virtually identical to waveform recorded with invasive 
techniques including coronary angiography.  [110] 
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Figure 3.3: Features of Central aortic pressure waveform.  
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3.3.4 Arterial Ultrasonography 
Arterial ultrasound and MRI can also be used to measure change in arterial diameter for 
a given pressure change to provide the direct measures of arterial stiffness. Arterial 
distensibility (relative change in diameter for a given pressure change), compliance 
(absolute change in diameter for a given pressure) and elasticity (elastic modulus) are 
important parameters that are calculated with this method. However, interpretation of 
these parameter can be complicated because their dependence on blood pressure. Many 
studies have shown elasticity and distensibility of the carotid artery is important 
predictors of cardiovascular events. [168, 193] However Oliver et al have suggested that 
use of peripheral rather than central BP was major limitation of these studies. [147] 
Ultrasound techniques require substantial expertise and are time consuming. Another 
problem with the use of this modality is limited resolution of vessel wall to detect small 
changes in the arterial diameter. However, the latter problem can be solved by using 
high definition echo-tracking devices, which track the vessel wall by using inbuilt 
software and can detect small changes in the arterial diameter with precision. 
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3.3.5 Invasive Assessment 
Central blood pressure and central pressure waveform can be recorded invasively by left 
heart catheterization. Similarly arterial distensibility and compliance can be measured 
by simultaneously measuring arterial pressure and diameter using intra-luminal 
catheters and intravascular ultrasound. This is the most accurate method of recording 
the central pressure and pressure waveform, however a major limitation is invasive 
nature of the procedure. It is also expensive, time consuming and requires substantial 
training and resources. 
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 3.3.6 Measurement of Intima Media Thickness 
Local arterial stiffness of superficial arteries can be assessed by measuring combined 
thickness of the arterial intima and media layers (IMT). MRI has been used by some 
researchers to measures intima media thickness of deeper arteries like aorta. Carotid 
Intima Media Thickness (CIMT) describes the combined thickness of the inner two very 
thin layers of the lining of the carotid arterial wall – the intima and the media. This 
corresponds to the inner and outer echogenic lines seen on the B-mode ultrasound 
image. In order to standardize measurements between subjects, the ‘region of analysis’ 
has been recommended as the 1cm section of the artery situated 1 cm proximal to the 
start of the bulb by Touboul and colleagues in the Mannheim Intima Media Thickness 
consensus document (Figure 3.5). [194] Most of the recent ultrasound equipment has 
automated computerized edge-detection software that allows faster evaluation of CIMT 
with lesser variability for all carotid segments. The manual measurement of CIMT 
measurement is however the most common technique used in clinical practice, which is 
time-consuming and prone to errors by the lack of expertise. 
 CIMT is considered as a surrogate marker of atherosclerosis [195] but it also provides 
useful information about arterial stiffness. Age dependent increase in IMT has been 
documented even in the absence of atherosclerosis. [196-198] There is a substantial 
body of evidence from large cohort studies to suggest strong association of increased 
CIMT with cardiovascular events including mortality and stroke. In the Cardiovascular 
Health Study (CHS) over 4000 participants 65 years of age or older (mean age 72 years) 
were followed over a median period of 6.2 years, and the baseline CIMT was associated 
with cumulative survival free of myocardial infarction and stroke. For a 1 SD increase 
in baseline CIMT, relative risk for the combined end point increased by 35% to 44% 
(adjusted for age and sex). [199] In the Rotterdam Study nearly 1600 people elderly 
people (mean age 72 years) had assessment of CIMT of the common carotid artery and 
were followed up for a median period of 2.7 years. The risk of stroke increased 
gradually with increasing common carotid intima-media thickness. The odds ratio for 
stroke per SD increase was 1.41 (95% CI, 1.25 to 1.82). In men, the odds ratio per SD 
increase was 1.81 (95% CI, 1.30 to 2.51) and in women, an odds ratio of 1.33 (95% CI, 
1.03 to 1.71) per SD increase was observed. [44] 
Carotid plaque area or volume has also been considered better predictor of 
cardiovascular events than CIMT [200-202] but the evidence is still debatable. [203, 
204] Atherosclerotic plaque appears quite late in the disease and is probably better 
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predictor of cardiovascular events in patients with known cardiovascular disease. [205] 
However, increased CIMT has also shown to be a strong predictor of stroke and 
cardiovascular events even in asymptomatic people. [203, 206] Many researchers argue 
that age associated increased CIMT represents an early stage of atherosclerosis. 
However, recent studies have shown both carotid plaque and increased CIMT were 
independently associated with increased risk of stroke. [203, 207]  
 
 
 
 
 
 
 
 
 
Figure 3.4: Longitudinal view of CCA and carotid bulb. The arrow marks the region of 
analysis  
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3.3.7 Endothelial Dysfunction 
There are several methods for the assessment of arterial endothelial function. Almost all 
of these methods are based on the fact that endothelial derived nitric oxide release due 
to various stimuli results in vasodilatation. Detailed description of the assessment of 
endothelial dysfunction is beyond the scope of this thesis, but I will briefly outline the 
available methods with their pros and cons.  
Intra coronary injection of acetylcholine (endothelial dependent vasodilator) during 
coronary angiography to measure the secondary dilatation is considered as a gold 
standard test for endothelial function. [208] This method allows direct and detailed 
quantification of endothelial function in the vascular bed, however the invasive nature, 
cost and risks associated with coronary catheterization limits its use. 
The most widely used invasive method involves brachial artery catheterization and 
injection of acetylcholine or sodium nitroprusside, combined with forearm venous 
occlusive plethysmography to assess changes in forearm blood flow. [209-211]  
Brachial circulation is more accessible than coronary circulation, probably explaining 
the wider use than coronary catheterization. The main limitation for this technique is 
still the invasive nature and risk associated with procedure like neurovascular damage. 
Brachial artery ultrasound with flow-mediated dilatation (FMD) is most widely used 
non invasive test to assess endothelial dysfunction. This involves Upper-arm occlusion 
with blood pressure cuff for five minutes, which results in reactive hyperaemia after the 
cuff is released and this increase in shear stress results in flow-mediated dilatation. This 
post ischemic reactive hyperaemia is predominantly influenced by arterial endothelial 
function [212]. Main advantage of this technique is the non invasive nature of this test.  
Brachial artery flow-mediated dilatation (FMD) has also been shown to correlate with 
measures of coronary endothelial function. [208] This technique is highly operator 
dependant and requires very high resolution images to detect small changes in the 
vascular diameter. Although flow-mediated dilatation is safer, faster and is a non 
invasive method but still discomfort associated with prolonged cuff occlusion will limit 
its use in elderly frail cohort.  
In elderly population where direct assessment of endothelial function is difficult, 
measures of arterial stiffness such as pulse wave analysis (PWA) and pulse wave 
velocity provide useful insight to their endothelial function.  
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In a recently published work by Saga and colleagues augmentation index (AIx) was 
significantly correlated with flow mediated dilatation (FMD) (r=-0.38, p<0.0001) and 
FMD was a significant independent predictor of augmentation index (p<0.05). [213] 
McEniery and colleagues have also studied relationship between endothelial function 
(brachial FMD) and definitive measures of arterial stiffness and wave reflections such 
as PWV, AIx and central pulse pressure in 309 community based healthy individuals 
(18-81 yrs). They showed significant and inverse correlation between flow-mediated 
dilatation and aortic PWV (r=–0.39; P<0.001) even after correcting the confounding 
variables. [214] 
These findings suggest that increase in arterial stiffness is associated with grade of 
endothelial dysfunction and that AIx and PWV may be an index of not only arterial 
stiffness but also endothelial function.  
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3.4 Consequences of Increased Arterial Stiffness 
Increased arterial stiffness has many clinical implications and is an independent 
cardiovascular risk factor.  
Increased arterial stiffness is associated with increased pulse wave velocity and early 
wave reflection, which results in increased pressure in systole and decrease diastolic 
pressure. Increased systolic pressure and after load causes ventricular remodelling and is 
associated with increased LV mass and LVH. This increase in afterload and LVH 
increases myocardial O2 demand with impaired coronary perfusion on the other hand 
due to decreased diastolic pressure leads to increased predisposition to myocardial 
ischemia and angina. This mechanism links LVH to myocardial ischemia quite 
independently of coronary narrowing. [140, 215] 
Increase in systolic and decrease in diastolic pressure with age related arterial stiffness 
leads to wider pulse pressure, which probably explain the high prevalence of isolated 
systolic hypertension in the elderly population. Data from both Framingham Heart 
Study and NHANES survey has shown widening of pulse pressure with age and that 
isolated systolic hypertension accounts for 60-75% of cases of hypertension in the 
elderly. [169, 216] Persistent increase in ventricular afterload due to increased arterial 
stiffness also induces left ventricular remodelling leading to increased left ventricular 
mass and left ventricular hypertrophy (LVH), an important independent risk factor for 
cardiovascular mortality. [217, 218] LVH is also implicated in the pathogenesis of 
diastolic dysfunction and heart failure with preserved systolic function (HF-PSF). [37] 
The role of altered vascular stiffness and its interaction with ventricular remodelling in 
the pathogenesis of HF-PSF has already been discussed in chapter 2. (Ventriculo-
vascular interaction) 
Increased arterial stiffness is strongly associated with increased incidence of 
cerebrovascular events.  The Rotterdam study has shown that increased aortic PWV was 
a strong and independent predictor of coronary artery disease and stroke in population 
based apparently health people (n = 2835, mean age 71 years). This association 
persisted even when other risk factors of cerebrovascular disease (hypertension, age, 
diabetes, hypercholesterolemia, smoking, CIMT) were accounted for. [219] People who 
lived in nursing homes were not included in this study. 
The exact mechanism how increased large arteries stiffness affects microcirculation of 
the brain is still unknown. It is postulated that once cushioning function of aorta or large 
vessels is lost due to arterial stiffness, pulsatile flow extends into the microcirculation 
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(which normally is steady and continuous) and probably damages the microcirculation.  
[116, 149, 220] Presence of severe microcirculatory lesions in the brain and kidney of 
older people supports this hypothesis. These lesion include endothelial damage with 
thrombosis and damage to media with oedema, haemorrhage and inflammation. [221, 
222] 
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Chapter 4: Brian Natriuretic Peptides in Cardiovascular Disease 
Natriuretic peptides are a group of hormones with potent natriuretic, diuretic and 
vasodilator properties. There are three major peptides in this family: atrial natriuretic 
peptide (ANP), brain natriuretic peptide (BNP) and C type natriuretic peptide (CNP). All 3 
peptides share a common 17-amino acid ring structure and play an important physiological 
role in countering the effects of hypertension and plasma volume expansion. 
 
4.1 Background 
In 1956 Henry and Pearce described an increased urinary flow after mechanically stretching 
the canine left atrium. Twenty five years late, in 1981 de Bold and colleagues made a very 
significant observation that injection of extracts of atrial tissue into rats caused a copious 
sodium excretion and urinary flow (de Bold et al. 1981). This subsequently led to the 
isolation of atrial natriuretic peptide (ANP), a factor with potent natriuretic, diuretic and 
vasodilatory properties. In 1988 a peptide with similar properties was identified in the 
porcine brain and therefore named brain natriuretic peptide (Sudoh et al. 1988). Although 
present in the human brain, highest concentrations are in fact found in the cardiac 
ventricles. Since then, C-type natriuretic peptide, a third compound with similar structure 
and pharmacological spectrum has also been discovered (Sudoh et al. 1990). Plasma levels 
of CNP are very low in humans. 
 
4.2 Physiology 
Both ANP and BNP are released from the heart, ANP preferentially from atria and BNP 
from ventricles. However, both can be secreted from either chamber in certain pathological 
conditions including myocardial infarction and left ventricular dysfunction [223]. The 
ventricle is the main site of BNP secretion. Myocardial wall stretch due to volume 
expansion or pressure overload, acts as a major stimulus for synthesis and release of both 
ANP and BNP [66, 224]. Elevated levels of angiotensin 2 also stimulate secretion of BNP. 
Both of these hormones are realised as prohormones, which subsequently are cleaved by 
the trans-membrane enzyme “Corin” into their active form (carboxyl terminal) and N-
terminal fragment [225]. ProBNP is a 98 amino acid peptide, which is cleaved upon release 
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into an active  32 amino acid BNP and a 76 amino acid containing N-terminal-proBNP 
(NT-proBNP) [224]. 
The biological actions of these natriuretic peptides are mediated through membrane bound 
natriuretic peptide receptors (NRPs) [66]. Three natriuretic peptide receptors have been 
identified in humans [226]. Type A (NRP-A) and type B (NRP-B) are guanylate cyclase 
receptors and both are present in the lung, kidneys and adrenal glands. NRP-A has a greater 
affinity for ANP than BNP and is most abundant in large blood vessels. NRP-B primarily 
binds CNP and is predominately found in the brain. Type C (NRP –C) receptor is mainly 
involved in the clearance of peptides. All three natriuretic peptides bind to NRP-C with 
equal affinity and are subsequently internalized and enzymatically degraded. [224, 227, 
228].  
In the cardiovascular system the natriuretic peptides reduce sympathetic tone in the 
peripheral vasculature causing fluid shifts by increasing the permeability of the vascular 
endothelium and increasing venous capacitance. These actions lead to a decrease in pre-
load and blood pressure. In the kidney the glomerular filtration rate (GFR) is increased 
through a combination of dilation of the afferent renal arterioles, constriction of the efferent 
renal arterioles, and relaxation of the tubular mesangial cells. The peptides have a direct 
natriuretic effect in the renal tubules, but also cause a reduction in plasma renin and 
aldosterone concentrations. In the brain stem, the natriuretic peptides serve to decrease 
sympathetic tone and inhibit vasopressin secretion. Centrally there is suppression of thirst 
and salt appetite [66, 224]. 
BNP has a plasma half-life of 22 minutes. The NT proBNP in contrast has a longer half life 
of approximately 60-120 minutes, leading to higher circulating levels and slower 
fluctuations compared with BNP [227]. Its concentration increases with age and is higher in 
women than in men [229, 230]. BNP is less affected by age and renal function than its 
precursor pro-BNP which can also be measured in plasma [227, 231]. 
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4.3 Normal Value of NT-pro BNP 
Plasma levels of natriuretic peptides increase with age and are usually higher in female 
gender. [229, 232, 233]. However, in elderly cohort (aged ≥ 75 years) natriuretic peptide 
levels have been reported higher in male gender. [229, 230, 234] This effect of age and 
gender is independent of the age associated increase in prevalence of diastolic dysfunction 
and renal impairment. This is the reason that age and gender specific cut-off values of 
natriuretic peptides are used in the detection of various cardiovascular diseases including 
heart failure. Many studies have reported the normal range of NT-proBNP across various 
age groups, however little is known about the normal reference range of NT-proBNP in the 
85+ years old fraction of the population for LV systolic and diastolic function. 
Glasko and colleagues [232] studied a random sample subjects aged 45 and above (n = 
1205, 671 male, 534 female, median age 61 years, range 45–91 years) from the general 
population to establish the normal range of NT-proBNP across various age groups. All 
patients had a full risk factor assessment including lipid profiles, a full biochemical profile 
including renal and liver function tests and an echocardiogram with measurement of their 
ejection fraction. This was one of the first clinical studies to calculate the upper reference 
values (97.5th percentile) for NT-proBNP. 
A population with no cardiovascular risk factors, no structural heart disease and a LVEF of 
greater than 50% was defined and used as a reference normal population. They identified 
389 individuals who had no risk factors, creatinine < 120 μmol/l, no ECG changes, no 
evidence of structural abnormalities or wall motion abnormalities on echocardiography and 
with an LVEF >50%. It was also important to note that only 111 participants of this sample 
were aged 65 or above (mean age = 55 ± 8 years) and none of the participants was aged 80 
or above. They defined the age and gender specific upper reference cut-off values of NT-
proBNP in this “normal” population. The study found the following cut-off values: 100 
pg/ml and 172 pg/ml for men aged 45-59 years and 60+ years respectively. The cut-off 
values for women aged 45-59 years were 164 pg/ml and 225 pg/ml respectively. 
Investigators of the study believed that possible explanation for increased NT-proBNP 
levels with age was increased age related subtle diastolic dysfunction. Although the normal 
subjects had diastolic heart failure excluded, normal subjects ≥ 60 years old still had 
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significantly lower E/A ratios than the normal subjects < 60 years old (1.0 vs. 1.2; p 
<0.0001). The underlying cause for higher levels of NT-proBNP in females was unclear. 
Another study of the community based residents aged 45 years and above (mean age = 62 ± 
10) in Olmsted County, Minnesota has shown similar results [229, 230]. The investigators 
considered participants as clinically “normal” when they had no history of cardiovascular, 
pulmonary, or renal disease; had no diabetes; took no cardiovascular medications; had 
normal echocardiograms for systolic and diastolic function; and were in normal sinus 
rhythm.        
NT-proBNP levels in normal participants were higher in females and also increased with 
increasing age (Figure 1). In normal participants (n = 746), female gender (r =0.287, p < 
0.0001) and increasing age (r =0.537, p < 0.0001) were the strongest independent predictors 
of higher NT-proBNP levels. It was also interesting to note that even in that study there 
were only 20 people aged 75 years and above in the normal group and nearly 250 people in 
the overall study. Investigators of the study believed that the possible explanation for 
increased natriuretic peptide levels in females was probably related to use of oestrogen as 
BNP levels were 21% higher in women on HRT than in women not on HRT (CI 6% to 
40%, p < 0.005). Investigators of the Dallas heart study (Texas, USA) studied 682 
community based young women (35 years to 49 years) for any possible association 
between gonadal hormones (including estrogens and testosterone) and natriuretic peptides 
[235]. Subjects with heart failure and renal disease (creatinine >2 mg/dl) were excluded. 
Investigators found no significant difference in NT-proBNP levels of pre-menopausal and 
post-menopausal women. Among post-menopausal women, there was no difference in NT-
proBNP levels among estrogen users and non users. The median NT-proBNP levels in 
estrogen users were 38.8 pg/dl (interquartile range 22.0 to 79.0) and 38.4 pg/dl 
(interquartile range 18.4 to 74.1) in nonusers (p = 0.70). Investigators from this study 
suggested a strong inverse relationship between serum testosterone levels and natriuretic 
peptide levels (for BNP: r = -0.155, p < 0.0001; NT-proBNP: r = -0.233, p < 0.0001). 
However, an exact explanation for higher NT-proBNP levels in females is still unclear.  
Costello-Boerrigter et al also studied NT-proBNP levels as its ability to detect LVSD in 
community dwelling 45 years and above cohort. The also reported ‘normal’ cut off values 
of NT-proBNP for different age ranges. Participants were considered clinically normal 
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when they had no history of cardiovascular, respiratory, or renal disease; had no diabetes; 
were not taking cardiovascular medications; had for systolic and diastolic function; and 
were in normal sinus rhythm. In this study 275 people were aged 75 years and above out of 
which only 20 participants were in ‘normal’ group. In this age group values of NT-proBNP 
levels were 124pg/ml; 42 - 587 pg/ml (Median; 5th–95th Percentile) in females (n=18) and 
57pg/ml; 46 - 68pg/ml (Median; 5th–95th Percentile) in males (n=2).[230]  
 
 
 
 
 
 
Figure 4.1: Age and gender specific median levels of NT-proBNP levels in “healthy 
population”.  
(Blue) males, (red) females; Total number of people in each age group are mentioned at 
the bottom of each bar. [230] 
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Apart from age and gender, many other factors including renal function, valvular heart 
disease, coronary artery disease, arrhythmias, pulmonary hypertension and sepsis also 
cause increase in plasma levels of natriuretic peptides.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
4.4 Diagnostic and Prognostic Role of NT-ProBNP In Heart Failure 
Plasma natriuretic peptide (BNP/NT-proBNP) levels have reliably shown to identify the 
left ventricular systolic dysfunction (LVSD), left ventricular diastolic dysfunction (LVDD) 
and also have been shown to have an important diagnostic role in patients with heart 
failure. Plasma BNP/NT-proBNP levels are also strongly correlated with the severity of the 
symptom (NYHA status) of the heart failure patient.  
BNP and NT-proBNP plasma concentrations have been shown to be reliable markers of 
CHF, displaying similar diagnostic accuracy [236-239]. Reference intervals and decision 
limits of BNP and NT-proBNP have already been described in old healthy subjects [240]; 
however, the diagnostic accuracy of BNP and NT-proBNP has been little investigated in 
85+ years old patients especially in community settings. 
The PRIDE study [239] was a prospective and blinded study of 600 patients (mean age = 
64.8  ± 14.8) presenting to the emergency department at Massachusetts General Hospital 
with complaints of dyspnoea. Exclusion criteria for the study were severe renal 
insufficiency (serum creatinine level > 2.5 mg/dl, dyspnoea after chest trauma, dyspnoea 
secondary to severe coronary ischemia that was identified as > 0.1 mV ST-segment 
elevation or ST-segment depression on a 12-lead electrocardiogram if performed at 
presentation), > 2-hour delay after urgent intravenous loop diuretic administration and 
unblinded natriuretic peptide level measurement.  
Patients were assessed clinically by taking a detailed history, performing a clinical 
examination and diagnostic studies in the emergency department, such as ECG, chest x-ray, 
and standard blood tests. An additional blood sample was collected for NT-proBNP 
measurement as well. At the end of the standard clinical assessment and with the 
knowledge of the results of all clinical tests except NT-proBNP levels, the managing 
emergency department attending physician was asked to estimate the likelihood that acute 
heart failure (HF) was the cause of the patient's dyspnoea. The emergency department 
discharge diagnosis was also recorded. The diagnosis for each patient was later confirmed 
by the study cardiologists after reviewing all hospital records (including admit/discharge 
notes, results of laboratory and radiologic testing, cardiac tests such as echocardiograms). 
Patients were classified by diagnosis at presentation into 1 of 3 categories: acute HF, 
noncardiac dyspnoea in a patient who had previous HF, or no HF. NT-proBNP was found 
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to be sensitive and specific for the diagnosis of  acute HF with the area under the receiver 
operating characteristic curve (AUC) = 0.94. Figure 2 shows NT-proBNP also had higher 
diagnostic accuracy than the ED physician in diagnosing CHF with AUC = 0.96 (p = 
0.006). Patients with acute heart failure had median NT-proBNP over 4000 pg/ml 
(interquartile range 1,675 to 10,028), compared with 115 pg/ml (interquartile range 46 to 
433) in those without heart failure (p < 0.001). The difference remained significant when 
comparing NT-proBNP levels of those who had acute HF with those who had noncardiac 
dyspnoea and previous HF (whose median NT-proBNP level was 1,175 pg/ml, p = 0.02). 
Multivariate analysis showed an increased NT-proBNP level was the strongest predictor of 
acute HF (OR 44.0, 95% CI 21.0 to 91.0, p <0.0001). 
An NT-proBNP cut-point of 300 pg/ml was proposed to ‘rule-out’ a diagnosis of HF, 
whereas the optimal cut-points for ruling in acute CHF were suggested as 450 pg/ml (for < 
50 years) and 900 pg/ml (for ≥ 50 years), with an excellent area under each receiver-
operating characteristic curve (0.98 and 0.93, respectively; p <0.0001). 
 
NT-proBNP levels also significantly correlate with the NYHA functional class in patients 
with heart failure and increase with the severity of symptoms (Figure 3). In the patients 
with NYHA II median levels of NT-proBNP were 1591pg/ml (interquartile range 1066 
pg/ml to 2488 pg/ml), NYHA III median levels of NT-proBNP were 3438 pg/ml 
(interquartile range 1337 pg/ml to 9502 pg/ml) and NYHA IV median levels of NT-
proBNP were 5564 pg/ml (interquartile range 2274 pg/ml to 12187 pg/ml). [69, 239] 
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Figure 4.2. Receiver-operating characteristic (ROC) curve comparison of NT-proBNP 
versus clinician-estimated likelihood for the emergency department diagnosis of acute 
CHF. (adapted from Januzzi et al) [239] 
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Figure 4.3: Correlation between median NT-proBNP levels and symptom severity based on 
New York Heart Association symptom classification. Boxes, interquartile ranges; whiskers, 
5th and 95th percentiles. Data from the PRIDE study. (adapted from Januzzi et al) [239] 
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The International Collaborative of NT-proBNP Study (ICON) [69] is an international 
pooled analysis of 1256 patients (mean age = 68.3 ± 15 years) presenting in Emergency 
Department (ED) from four similar studies of NT-proBNP testing from Christchurch (New 
Zealand), Barcelona  (Spain), Boston MA (USA) and Maastricht (Netherlands).  NT-
proBNP diagnostic cut-points for diagnosing acute HF were determined with the use of 
logistic regression analyses, with resulting receiver operating characteristic (ROC) curves.  
Of the 1256 dyspnoeic subjects in this pooled analysis, 720 (57.3%) had acute HF, whereas 
536 (42.7%) did not. Of those without acute HF exacerbation at the time of enrolment, 55 
subjects (4.4% overall) had a prior diagnosis of HF. The median NT-proBNP concentration 
of those patients with acute HF exacerbation (4639 pg/ml) was significantly higher than 
those with neither acute nor prior HF (108 pg/ml, p < 0.001). Among those patients <50 
years (n = 184), 50–75 years (n = 537), and >75 years of age (n = 535), NT-proBNP had an 
area under the ROC curve of 0.99, 0.93, and 0.86 for the diagnosis of acute HF (all p < 
0.0001).  
Investigators suggested an age-independent approach for ‘ruling out’ acute HF with a single 
cut-point of 300 pg/ml (95% CI=241–369) demonstrating a sensitivity of 99%, a specificity 
of 60%, and an NPV of 98%. The optimal cut-points of NT-proBNP levels for diagnosing 
acute HF (with 95% CI) were suggested by ROC curve analysis to be 450 pg/ml (145, 1463 
pg/ml), 900 pg/ml (676, 1244 pg/ml), and 1800 pg/ml (1281, 2641 pg/ml) for the 
identification of acute HF in subjects aged <50, 50–75, and >75 years, respectively. 
Investigators didn’t find any gender difference in NT-proBNP levels in patients with acute 
HF so they based the cut-off limits only based on age. This was the first study that included 
more than 500 people with age 75 years and above but so for no study has described the 
optimal cut-off NT-proBNP levels for the diagnosis of chronic heart failure in 85+ year old 
community residents. 
The predictive value of natriuretic peptides in detecting in LVSD has been studied across 
different age ranges; however 85+ years old, especially in community settings were 
probably under represented in such studies. Redfield and colleagues studied the role of NT-
proBNP in detecting LVSD in a random sample of 2042 participants aged > 45 years (mean 
age = 62±10 years), who were residents of Olmsted county, Minnesota [230]. Medical 
records review and detailed two-dimensional and colour Doppler echocardiography were 
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done on participating residents (n = 2042). Plasma NT-proBNP levels were available in 
1869 participants. Participants who had no history of cardiovascular, pulmonary, renal 
disease or diabetes, who took no cardiovascular medications, who had normal 
echocardiograms for systolic and diastolic function and who were in normal sinus rhythm 
were considered clinically normal (n = 749, mean age = 57±10 years). Participants with 
LVEF < 50% were considered to have left ventricular systolic dysfunction (LVSD). There 
were 115 participants with LVEF less than 50% and 37 participants were identified to have 
LVEF below 40%. A receiver operating characteristic (ROC) curve analysis was performed 
to establish the predictive value of NT-proBNP for detecting LVSD. The results of ROC 
analysis for the detection of LVSD showed the AUC was higher in the overall population 
for the detection of LVEF ≤ 40% (AUC = 0.94; sensitivity = 86.5 and specificity = 86.0; 
NT-proBNP cut-off levels of 228 pg/ml) than LVEF blow 50% (AUC = 0.78; sensitivity = 
73.9 and specificity = 73.8; NT-proBNP cut-off levels of 129 pg/ml).  
 In another study Tschöpe and colleagues [241] studied the role of NT-proBNP in 
diagnosing isolated diastolic dysfunction. They investigated 118 patients who had 
preserved LV function (LVEF ≥ 50%) and normal LV dimensions as determined by 
echocardiography and ventriculography. Sixty-eight patients (mean age 51±9) had 
exertional dyspnoea and isolated diastolic dysfunction while the remaining 50 patients 
(mean age 49±10) had normal diastolic function (control group). Patients with atrial 
fibrillation, lung diseases, renal dysfunction, significant heart valve disease, or other severe 
concomitant diseases were excluded from the study. Medications that can influence 
haemodynamics (diuretics, beta-blockers, calcium-blockers, and ACE inhibitors) were all 
stopped for 48 hours before examinations were performed. LV systolic and diastolic 
function was assessed by echocardiography, tissue doppler imaging (TDI), and left and 
right heart catheterization. Plasma NT-proBNP levels were determined simultaneously. 
NT-proBNP levels were four-fold elevated in patients with diastolic abnormalities when 
compared with control patients (189.54 pg/ml vs 51.89 pg/ml; p < 0.001). NT-proBNP 
levels also increased significantly according to the severity of overall diastolic dysfunction 
(figure 4). In mild diastolic dysfunction or impaired relaxation (grade 1) median NT-
proBNP levels were 151.6 pg/ml (interquartile range from 90.6 pg/ml to 278.1 pg/ml), 
moderate diastolic dysfunction or pseudonormal filling (grade 2) 308.1 pg/ml (interquartile 
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range from 261.7 to 568.2) and severe diastolic dysfunction or restrictive filling (grade 3) 
2307.1 pg/ml (interquartile range from 1592.0 to 6440.1).  
Diagnostic accuracy of NT-proBNP in diagnosing isolated diastolic dysfunction was almost 
as good as the LVEDP (invasive) and TDI and better than the E/A ratio of Doppler 
echocardiography. ROC curve analyses revealed an AUC for NT-proBNP of 0.83, between 
the AUCs of LVEDP (0.84) and TDI (0.81), whereas AUC for IVRT, DT and E/A were 
0.63, 0.59 and 0.70 respectively. At a cut-off value of 110 pg/ml, NT-proBNP showed a 
high sensitivity of 72%, a specificity of 97%, a positive predictive value of 84%, and the 
negative predictive value of 94%. Because this was study done in relatively young subjects, 
this cut off value may not be valid in the older age groups. 
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Figure 4.4: NT-proBNP levels in the patients with LV diastolic dysfunction are 
significantly elevated and correlate with the severity of disease. (adapted from  Tschöpe et 
al, Eur Heart J. Nov 2005; 26(21): 2277-2284) [241] 
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BNP and NT-proBNP have been shown to be important prognostic indicators. McDonagh 
and colleagues [65] assessed the long-term prognostic role of BNP concentration in 1653 
subjects aged 25–74 randomly sampled from north Glasgow. Patients were followed up for 
4 years during which 80 people died resulting in all-cause mortality of 4.9%. The median 
BNP concentration in those patients who died was significantly higher than in survivors 
(16.9 vs. 7.8 pg/ml) and a BNP level of greater than 17.9 pg/ml (p  =  0.006, hazard ratio 
2.2 (95% CI 1.2 to 3.8), was an independent predictor of mortality in sub-group analysis.  
In another study analysing the prognostic value of natriuretic peptides, Wang and 
colleagues [242]  studied a cohort of patients from the Framingham offspring study, 
excluding patients with a history of heart failure or biochemical renal impairment. BNP and 
NT-pro BNP concentration were measured in 3346 patients who were regularly monitored 
for the occurrence of cardiovascular events or death. Follow-up was prospective and 
investigators were blinded to plasma natriuretic peptide levels. Median follow-up was 5.2 
years during which 119 participants died and 79 had a first cardiovascular event. In 
multivariate analysis, increasing plasma natriuretic peptide levels were significantly 
associated with an elevated risk of death, stroke, first cardiovascular event, atrial fibrillation 
and heart failure, the association being strongest with the last two. After adjustment for 
cardiovascular risk factors, each increment of 1 SD in log B-type natriuretic peptide levels 
was associated with a 27%  increase in the risk of death (p = 0.009), a 28% increase in the 
risk of a first cardiovascular event (p = 0.03), a 77% increase in the risk of heart failure (p < 
0.001), a 66% increase in the risk of atrial fibrillation (p < 0.001), and a 53% increase in the 
risk of stroke or transient ischemic attack (P=0.002). There was however no association 
between natriuretic peptide levels and coronary heart disease events (MI, unstable angina). 
 
 
 
 
 
 
 
 
84 
 
4.5 BNP Versus NT-pro BNP 
Although NT-proBNP has different pharmacokinetics as described earlier, its performance 
characteristics are similar to BNP. There are not many studies with head to head 
comparison of BNP and NT-proBNP. In general, BNP and NT-proBNP levels are 
reasonably correlated, and either can be used. However the absolute values of these assays 
are not interchangeable.  
One recent community based study from Olmsted County has suggested NT-proBNP 
performed at least equivalently to BNP in detecting LV dysfunction and was superior in 
some subgroups (elderly, females) in detecting LV systolic dysfunction [230]. 
Sanz and colleagues [243] have compared the diagnostic accuracy of NT-proBNP and BNP 
to detect the LVSD in patients presenting with dyspnoea to the emergency department with 
ROC analysis. They found no significant difference (p < 0.001) in the AUC for NT-
proBNP (0.98) and BNP (0.975).  They also described a strong correlation between NT-
proBNP levels and BNP levels in the detection of LVSD (r = 0.89).  In a similar study 
Lainchbury and colleagues [244] also described the similar results with strong correlation (r 
= 0.902, p <0.001) between the results of the N-terminal brain natriuretic peptide (N-BNP) 
assay and the  brain natriuretic peptide assay (BNP). (Figure 5) 
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Figure 4.5: Correlation between the results of the Roche N-terminal brain natriuretic 
peptide (N-BNP) assay and the Biosite brain natriuretic peptide (BNP) assay ( adapted from 
Lainchbury, et al) [244] 
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 Data from the Olmsted county study suggest that NT-proBNP is probably better in 
detection of LVSD in people older than 65 years of age and in female patients [230]. For 
comparison purpose they divided the cohort (n = 1869) into smaller sub groups: people < 
65 years, people ≥ 65 years, males, females and also people with LVEF ≤ 50% and LVEF ≤ 
40%. Results from ROC curve analysis showed that for detecting an LVEF ≤40%, NT-
proBNP had a significantly higher AUC in comparison with BNP in the total population 
(0.94 vs. 0.89; p = 0.0087) and for the subgroups of male patients (0.95 vs. 0.91; p =0.01) 
and patients ≥65 years old (0.92 vs. 0.87; p = 0.036). For detecting an LVEF ≤50%, the 
AUC for NT-proBNP was significantly higher than that for BNP in all patients (0.78 vs. 
0.72; p < 0.001), patients ≥65 years old (0.85 vs. 0.79; p = 0.001), patients <65 years old 
(0.65 vs. 0.56; p < 0.0001), male patients (0.80 vs. 0.73; p < 0.001), and female patients 
<65 years old (0.75 vs. 0.64; p = 0.02).  
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Figure 4.6: The receiver operating characteristic (ROC) curves of amino-terminal pro-B-
type natriuretic peptide (NT-proBNP) (red) and BNP (green) for detecting an ejection 
fraction (EF) 40% for the entire population (all) (A), patients 65 years old (B), male 
patients (C), and female patients (D). (adapted from  Costello-Boerrigter et al) [230] 
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Diagnostic performance of natriuretic peptides to detect LVSD and heart failure in elderly 
population has been reported as less robust as compared with younger population. In a 
meta-analysis of natriuretic peptides in diagnosis of heart failure and screening of LVSD in 
community Ewald et al have reported the age related decrease in the performance of NT-
proBNP and BNP. At a given cut point, which would give sensitivity of 85% for BNP to 
detect underlying LVSD, the associated specificity would decrease from 90% in people  
aged  55 years  to 54% in people aged 85 years. The values for NT-proBNP decrease more 
steeply. [245] In another systemic review, Vaes et al also found limited evidence of 
diagnostic utility of natriuretic peptides to detect LVSD and heart failure in community 
dwelling elderly patients aged 75 and over. [246] Hildebrandt et all have recently suggested 
to use age specific cut off of NT-proBNP to detect LVSD in community dwelling residents 
(median age 62 years, range 18-100) from different pooled studies, which collected data on 
NT-proBNP or BNP and LV systolic function on echocardiographic assessment. 19% of 
cohort was aged 75 yrs and above. They suggested that NT-proBNP is probably better in 
detection of LVSD if different cut-off values are used rather than a single value for all age 
groups. They overall area under the curve (AUC) was 0.89 when a single cut-off NT-
proBNP value was used. When looking at different age groups, AUC was highest (0.95) for 
<50 years and lowest (0.82) for aged 75 years and above. [247] However, no study in 85+ 
year old community dwelling people has so far been reported to assess NT-proBNP 
diagnostic ability to detect LVSD, diastolic dysfunction and heart failure.  
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4.6 NT-proBNP and Arterial Stiffness 
As discussed in the previous section of this chapter both increased levels of NT-
proBNP/BNP and increased markers of arterial stiffness including PWV, augmentation 
pressure and augmentation index are associated with increased cardiovascular morbidity 
and mortality. BNP/NT-proBNP are predominantly released due to increased LV wall 
stress and increased arterial stiffness is also associated with increased LV afterload. 
Excessive and premature wave reflection has a deleterious effect on left ventricular systolic 
and diastolic function, leading to atrial and ventricular remodelling and hypertrophy. Little 
is known about the relations of natriuretic peptides and arterial wall stiffness in the 
community in any age group especially in the 85+ years old. 
Levy and colleagues [248] have studied the relationship of plasma N-terminal atrial 
natriuretic peptide (NT-ANP) and brain natriuretic peptide (BNP) to arterial stiffness in 
participants in the Framingham Heart Study. Different variables of arterial stiffness 
including PWV and central pulse pressure were assessed in a total of 1962 participants 
(mean age, 61 years; 856 men, 1106 women). Plasma levels of NT-ANP and BNP were 
also measured in all individuals. They described increasing levels of NT-ANP and BNP 
were associated with carotid-femoral PWV (men: r = 0.043 and p < 0.001, respectively; 
women: r = 0.037 and p = 0.04). Plasma BNP levels were also associated with central pulse 
pressure (men: r = 0.129 and p = <0.001).  
Shroff and colleagues [249] have also reported similar findings. They studied 55 (mean age 
= 51 ± 11 years) consecutive patients with chest pain and negative troponins admitted to a 
cardiology observation unit in a tertiary care hospital. Patients with acute coronary 
syndrome, decompensated heart failure, unstable arrhythmias and patients with end-stage 
renal disease were excluded from the study. A venous blood sample was taken of all the 
participants for measurement of hs-CRP and BNP. Carotid distensibility was measured 
using B-mode-guided M-mode ultrasonography and Stiffness index β (marker of carotid 
artery stiffness) was calculated. They reported suggested a strong relationship between 
carotid stiffness index β and age (r = 0.56, p < 0.0001), BNP (r = 0.45, p < 0.004) and hs-
CRP (r = 0.26, p = 0.06), respectively. This relationship between arterial stiffness and BNP 
existed even after controlling for age and hs-CRP. Shroff and colleagues believe that the 
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relationship between arterial stiffness and BNP is probably due to altered ventriculo-
vascular coupling leading to the development of diastolic dysfunction and increase in BNP 
levels as I have discussed in previous section in detail. 
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4.7 Aims 
This Thesis will look at the following questions: 
 
1- What is the prevalence of LV systolic and diastolic dysfunction in community 
dwelling 85+ years old? 
2- What is the extent of symptomatic LV dysfunction? 
3- What is the extent of undiagnosed and mis-diagnosed LV dysfunction? 
4- Is there any association of markers of arterial stiffness and LV systolic and diastolic 
function? 
5- What is the prevalence of valvular heart disease in community dwelling 85+ years 
old? 
6- Feasibility of domiciliary echocardiography? 
7- What is the normative range of NT-proBNP in community dwelling 85+ years old? 
8- What is the diagnostic performance of NT-proBNP to detect LV dysfunction in 
community dwelling 85+ years old? 
9- What is the prevalence of vascular disease in community dwelling 85+ years old? 
10- What is the extent of undiagnosed and mis-diagnosed vascular disease? 
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Chapter 5. Materials and Methods 
This chapter describes a brief outline of the core Newcastle 85+ study and a full description 
of the design and measures used in the cardiac sub-study which is the subject of this thesis.  
The cardiac sub-study was nested in the core study and took place during the 1st and 2nd 
follow-up assessments of the core study. 
 
5.1 Core Newcastle 85+ Study  
The Newcastle 85+ study is a population-based longitudinal study of an inception cohort of 
85 year olds living in Newcastle upon Tyne and North Tyneside in north east England.   
The main aims of the study are to study in detail the health spectrum of an unselected 
cohort of the ‘oldest old’: 
 to follow health trajectories and outcomes as the cohort ages 
 to enhance the understanding of factors contributing to healthy ageing 
 to enhance understanding of the biological mechanisms of ageing.  
 
Participants were recruited through general practices. All 64 general practices in Newcastle 
upon Tyne and North Tyneside NHS Primary Care Trusts (PCTs) were approached to 
participate in the study and 53 (83%) agreed; participating and non-participating practices 
were similar across key practice variables. All people born in 1921, who turned 85 in 2006 
when recruitment commenced, and permanently registered with a participating general 
practice constituted the sampling frame. General practitioners (GP) were asked to review 
patient lists before mail-out and to exclude only those with end stage terminal illness and 
those who might pose a safety risk to a nurse visiting alone. Excepting these exclusions, all 
those remaining in the sampling frame were invited to participate in the study, whether 
living at home or in an institution and regardless of their state of health. Written informed 
consent was obtained from participants and where the participant lacked the capacity to 
consent, an opinion was sought from a “consultee” in accordance with the UK Mental 
Capacity Act.[250] Participation in the core study at baseline entailed a detailed 
multidimensional health assessment and a review of medical records held by the general 
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practice; participants could decline elements of the protocol. 851 participants (59% of those 
eligible) were recruited for both health assessment and review of general practice (GP) 
medical records; an additional 188 (13% of those eligible) were recruited to GP record 
review only and three people (0.2%) agreed to health assessment only (Appendix 1-2). 
Participants were assessed in their current place of residence (home or institution) by a 
research nurse. The assessment was detailed and multi-dimensional including an extensive 
range of questionnaires, measurements, functional tests and blood tests. Details of the core 
study assessments at baseline are outlined in appendix 3.  
In addition to the multi-dimensional health assessment at baseline, the research nurse 
reviewed the participants’ general practice medical records and extracted data on pre-
existing diagnosed diseases including heart failure, hypertension, ischaemic heart disease 
(angina or myocardial infarction or coronary artery bypass grafts or coronary angioplasty or 
coronary stent), cerebrovascular disease ( stroke or transient ischaemic attack or carotid 
endarterectomy), peripheral vascular disease and diabetes mellitus and current medication 
and use of general practice services.  
The recruited core study cohort was assessed at baseline, 18 months (phase 2) and 36 
months (phase 3). Figure 5.1 shows the timelines of the core Newcastle 85+ Study. Phase 2 
(18 months from baseline) spanned 18 months during which recruitment and re-assessment 
took place of surviving participants; 630 participants were recruited to phase 2 of the study. 
Phase 3 (36 months from baseline) again spanned 18 months; a total of 484 participants 
were recruited to Phase 3. Drop out for non-death reasons between the first two phases was 
around 10% but reduced to 7.6% between phases 2 and 3 with the remaining loss due to 
deaths.  Re-assessment of the participants in Phases 2 and 3 took place in a similar manner 
to baseline with some minor changes. General practice medical records were not reviewed 
in this phase 2 but Phase 3 included a repeat review for the entire cohort recruited at 
baseline (estimated n=1021, taking account of withdrawals) to capture incident 
disease/events and use of GP services.   Appendix 4 details the assessments for the core 
Newcastle 85+ Study in each of the three phases. 
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Figure 5.1: Different phases and recruitment timeline of the core Newcastle 85+ study[249] 
(Adapted from The Newcastle 85+ study: biological, clinical and psychosocial factors associated 
with healthy ageing: study protocol. BMC Geriatrics – An open access journal) 
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5.2 Cardiovascular Phenotyping of Newcastle 85+ Cohort 
The cardiovascular phenotyping sub-study was divided into the following three phases.   
1- Training phase (3 months):  
2- Data collection phase (14 months):  
3- Data preparation and analysis phase (7 months) 
Training phase involved training, piloting and designing the protocols. Before commencing 
this research project I had three years experience of heart scanning and had passed the 
British Society of Echocardiography written examination. During the initial three months I 
received additional training as follows: 
 To standardize my echo technique I spent 40 hours in the Freeman Hospital (FRH, 
The Newcastle upon Tyne Hospitals NHS Foundation Trust) echocardiography 
department (annual caseload 5000 cases/year) under the supervision of Dr 
Antoinette Kenny.  
 I received hands on training in carotid intima media thickness CIMT measurement 
in the Vascular Physics Department of the Freeman Hospital under the supervision 
of Mr. Crispian Oates (Chief Vascular Physicist, FRH). 
 I received training in vascular assessment using the SphygmoCor and Vicorder 
technologies from a representative (Mr Simon Dickinson) from Smart Medical UK. 
 
Following this training, I designed a cardiovascular phenotyping protocol in collaboration 
with Professor Bernard Keavney and performed five test runs on healthy volunteers at the 
Institute of Ageing and Health (Newcastle University) to master the technique. Once I had 
perfected conducting these assessments within 60 minutes I arranged five ‘dummy’ test 
runs within the community on six healthy volunteers aged between 65 and 85. 
The Cardiovascular phenotyping of the Newcastle 85+ study cohort took place during 
phase 2 or phase 3 (2nd or 3rd follow-up visits) of the core Newcastle 85+ study. The 
original plan had been to phenotype a sub-set (n= approximately 400) of the core Phase 2 
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participants i.e. those participants recruited in the final 12 months of Phase 2. However, due 
to a delay in securing funding the start date for the cardiac study was delayed and an 
insufficient number of participants were recruited to the cardiac study during Phase 2. 
Therefore the decision was made to extend recruitment into Phase 3 and those participants 
not offered the opportunity to participate in the cardiac study in Phase 2, who were still 
alive and participating in the core study at Phase 3, were invited to join the cardiac study in 
Phase 3.  
The core study participants from phase 2 and phase 3 were invited to take part in the 
cardiac study as a part of their invitation to take part in the core 85+ study. The research 
nurse team sent surviving participants from baseline a letter of invitation along with a 
detailed information pack and photographs of the research staff involved in home visits. 
The information pack detailed the nurse-conducted multidimensional health assessment and 
in addition the cardiovascular assessments. Participants were subsequently approached by a 
research nurse, either by a phone call or home visit, to ensure that they had received all the 
information to enable them to make an informed decision about whether to participate and 
to answer any queries regarding their participation and the tests involved. If they wished to 
participate, written informed consent (Appendix 13 & 14) was then obtained by the 
research nurse in the same manner as at baseline; in participants who lacked the capacity to 
consent, a ‘consultee’ (a carer or relative) approval was obtained according to the 
requirements of the UK Mental Capacity Act.[250] Consent for the cardiac study was 
included as part of the consent process for the core Newcastle 85+ Study. [251]. Those 
participants who agreed to remain in the core study were specifically asked whether they 
also wished to take part in the cardiac sub-study. Only those core study participants 
agreeing to remain in the core study could take part in the cardiac study. Verbal approval 
was also taken at the start of home assessment (by myself) to see if participants were still 
happy to go ahead with the cardiovascular assessments. 
Participants were visited in their homes or their places of residence. The community based 
sample and domiciliary design of the study were very important. In previous cardiac studies 
of a similar age group, participants were assessed in hospital settings, creating a potential 
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selection bias. In the Newcastle 85+ pilot study around 50% of the participants said they 
would have refused to attend hospital setting for assessment. [252] 
Each visit comprised a detailed cardiac assessment including an echocardiogram, carotid 
scan to measure carotid intimal media thickness (CIMT) and a comprehensive vascular 
assessment including pulse wave analysis, pulse wave velocity and ankle brachial pressure 
index (full details are mentioned in the subsequent sections of this chapter). The time 
burden on participants had to be taken into account imposing a total limit of 60 minutes for 
all the cardiovascular assessments. A chaperone accompanied me on certain visits, if 
requested by the participant. Details of the visit were noted down on a visit information 
sheet (Appendix 17). These details included three patient identifiers (PID, date of birth and 
gender), duration of visit, missing assessments and reasons for refusal or not doing the 
assessment. It also included the heart rhythm at the time of assessment and any notifiable 
echocardiographic finding to the general practitioners (Appendix 6).  
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5.3 Details of Cardiac Assessment by Echocardiography 
The Vivid i (Vivid i BT06, GE Healthcare, USA) with i2 Performance Package was used to 
perform detailed cardiac imaging.  The i2 Performance Package allowed us to conduct a 
full range of quantitative analyses, including tissue doppler imaging (TDI). 3S-RS sector 
phased array cardiac ultrasound probe was used, which had a small footprint (21 x 15mm), 
a broad bandwidth (1.5 – 4Mhz) and a 90 degree field of view (GE healthcare, USA) for 
imaging. This cardiovascular imaging system was a fully featured and high performance 
machine in a very lightweight (only 5 Kg) and miniaturized design. These features made it 
highly portable, which was a core necessity for assessing the study participants in their own 
home. 
Participants were placed in the left lateral decubitus position. Most of the scanning was 
done in that position apart from the subcostal view, which was done in the supine position. 
If the participant was too immobile to achieve an appropriate position for study, the actual 
position was noted but the data, as far as possible, were recorded. 
An echocardiogram for each participant was recorded according to a standardized protocol 
based on the British Society of Echocardiography (BSE) guidelines 2009.[253, 254] It was 
initially recorded in a cineloop format on the hard drive of Vivid I and later backed up in 
three copies according to the study protocol. Analysis was performed in three consecutive 
sinus beats (five in the case of atrial fibrillation) using an inbuilt Vivid I image-analysis 
system equipped with customized computer algorithms. Each examination was comprised 
of parasternal, apical 4 chamber, apical 2 chamber, apical long axis and subcostal views. 
 
5.3.1 Assessment of LV Systolic Function 
LV systolic function is normally expressed in terms of LV ejection fraction (LVEF). Four 
different echocardiographic methods were used for assessment of LV ejection fraction 
(LVEF); M-Mode, Simpson biplane volumetric method, Wall Motion Index (WMI) and 
semi-quantitative 2D (“eyeball”) method. 
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M-Mode measurements of systolic and diastolic chamber dimensions and wall thickness 
were obtained according to the recommendations of the British Society of 
Echocardiography.[253] Left ventricular volumes were calculated using the Teicholz 
formula (Where D stands for diameter): [255, 256]  
                        
LVEF was then derived using the following formula: 
                                                                                
The biplane method was initially developed to calculate LV volumes during       contrast 
ventriculography and subsequently applied in echocardiography as well. In this method left 
ventricular endocardial borders are manually traced in diastole and systole in paired apical 
4 and 2 chamber views. The traced area is divided into a series of discs, stacked on each 
other. The volume of each disc is calculated by using the formula: 
                                                  
LV volumes are then calculated by summing all these discs. The left ventricular end 
diastolic volume (LVEDV) and the left ventricular end diastolic volume (LVESV) in apical 
4 chamber and apical 2 chamber views were used to calculate the ejection fraction by 
Biplane Simpson’s method.[95] Biplane ejection fraction is calculated as: 
                                                  
The Vivid I software is designed to define and calculate each disc automatically once 
endocardial borders of LV are traced in both apical 2 and 4 chamber views. This method 
was at times  difficult due to inadequate endocardial resolution of LV anterior wall. This 
method was only used if more than 80% of the endocardial border was visible. 
Regional Wall Motion scoring is a system that divides the left ventricle in 16 small 
segments and scores them individually.[94] Each segment is scored according to both wall 
motion and thickening. Each segment is graded as 1 = normal, 2 = hypokinetic, 3 = 
akinetic, 4 = dyskinetic and 5 = aneurysmal. Wall Motion Index (WMI) is a total score 
divided by number of segments.[95] (3-WMI) multiplied by 30 gives LVEF. [96] This 
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method gives information about both the regional and global contractility of the left 
ventricle. 
“Eyeballing” is a visual estimation of LVEF from a combination of parasternal and apical 
views. The eye of an experienced observer has been considered highly comparable with 
more sophisticated methods of EF calculations.[257, 258] However, it might be biased by 
other measures of LVEF estimation if these were performed by the operator prior to making 
the eyeball assessment. In order to prevent this bias, eyeball assessment was always done 
prior to other estimations of LVEF. 
 
5.3.2 Assessment of LV Diastolic Function 
LV diastolic function can be assessed by using different echocardiographic modalities by 
means of  Pulsed Wave Doppler (PWD) and Tissue Doppler Imaging (TDI).  Transmitral 
blood velocities using PWD were assessed from the apical 4 chamber view and four 
variables were recorded: E wave (peak early diastolic transmitral flow velocity), A wave 
(peak late diastolic transmitral flow velocity), E/A ratio, IVRT (isovolumetric relaxation 
time) and DT (early filling deceleration time). 
Mitral valve annular motion using TDI from the apical 4 chamber view was also assessed 
and four variables were recorded: s´ lateral (peak systolic wave, lateral annulus), s´ septal 
(peak systolic wave, septal annulus), e´ lateral (early diastolic wave, lateral annulus) and e´ 
septal (early diastolic wave, septal annulus). E/e´ ratio was automatically calculated by the 
software. Lateral annular e´ velocity  was used in analyses as it has been shown more 
reproducible than e´ septal [259] unless the participant had a lateral wall infarct. In case of 
lateral wall infarct, septal variable (e´ septal) was used provided there was no septal infarct.  
If both lateral and septal infarcts were present, e´ was not recorded. Mitral annular TDI 
early diastolic velocity (e´) is essential for classifying diastolic function. A major advantage 
of this technique is that it is not affected by preload and can also be used  in AF. [101] 
Another benefit of this technique is that E/e’ decreases progressively with severity of 
diastolic dysfunction and there is no pseudo-normalization. [100] E/e´ ratio correlates with 
LV filling pressures irrespective of LV systolic function. [260] Due to these advantages 
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both European Society of Cardiology and American Society of Echocardiography have 
raised e´  and E/ e´  indices as first line doppler parameter in the diagnosis and 
classification of diastolic dysfunction. [103, 104] 
 LV diastolic function was classified into normal, mild, moderate and severely impaired 
using combination of transmitral flow velocity (E/A, DT, IVRT) and mitral annular motion 
variables.  Participant in whom only one criterion suggestive of moderate/severe, were 
classified as indeterminate diastolic function.  Participants with paced rhythm were 
excluded from analysis. Classification scheme is shown in figure 5.2 and 5.3.  The 
classification scheme was based upon the recommendations of the British and American 
Societies of Echocardiography [refs] and was very similar to that used in the Olmsted 
County community-based study of heart failure. [18] However, owing to the difficulty of 
obtaining reliable pulmonary venous flow signals in these elderly participants in the home 
setting, which we had established in a previous pilot study, pulmonary venous flow, which 
was used in the Olmsted County study, did not constitute part of the scheme.  The rationale 
of the diastolic function classification scheme is that E/e’ is used as the “top level” 
classifier, and thereafter agreement is required between two out of three of the parameters 
E/A ratio, DT, and IVRT for diastolic function to be assigned to a particular class.  Where 
such agreement was not present, diastolic function was classified indeterminate. 
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Figure 5.2: Classification scheme for diastolic function (Sinus Rhythm) 
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Figure 5.3 Classification scheme for diastolic function (Atrial fibrillation)
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5.3.3 Assessment of RV Systolic Function 
RV function was assessed qualitatively by eyeballing in various views. M-Mode 
measurement Tricuspid Annular Plane Systolic Excursion (TAPSE) in the apical 4 
chamber view also recorded. To determine TAPSE, the M-mode cursor was oriented to 
the junction of the tricuspid valve plane with the RV free wall using the apical 4 
chamber view. TAPSE has been shown as a very reproducible index of RV 
performance, which has strong prognostic value in patients with chronic heart 
failure.[261] 
 
5.3.4 Chambers Quantification 
Two dimensional M-mode measurements of systolic and diastolic LV chamber 
dimensions and wall thickness were obtained according to the recommendations of the 
British Society of Echocardiography (BSE).[253] LV volumes and mass were derived 
automatically by inbuilt formulae. LV mass was also calculated by using both the Penn 
formula[262] and ASE  (American Society of Echocardiography) formula [263].   
                                                             
                                                                  
(Where LVID = left ventricle internal dimension in diastole, PWT = LV posterior wall thickness 
in diastole and IVST = interventricular septal thickness in diastole) 
The internal dimensions of RV were recorded according to latest BSE guidelines. Three 
variables RVD1 (basal RV diameter), RVD2 (mid RV diameter) and RVD3 (base to 
apex length) were measured from apical 4 chamber view at ventricular end systole. 
 M-mode left atrial (LA) diameter was recorded from the parasternal long axis view.  
LA volume was also measured using the biplane volumetric method from apical 4 
chamber and apical 2 chamber views at ventricular end systole. 2D diameter of (right 
atrial) RA in apical 4 chamber view, extending from lateral border of RA to interatrial 
septum in a plane perpendicular to long axis of RA. 
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5.3.5 Assessment of Valves 
All four valves were assessed in accordance with the latest recommendations of the 
British Society of Echocardiography.[253] 
 
 Mitral Valve 
The morphology of the mitral valve annulus and both leaflets was looked at in detail 
and any prolapsed, thickening, fusion or calcification was commented on. I also 
commented on Mitral valve stenosis (MS) by using 2D, M-Mode, continuous wave 
doppler (CW) and pulse wave Doppler (PW) assessments in various views. MS was 
graded as absent, mild, moderate or severe. Mitral valve area (MVA) was also 
calculated by pressure half time (PHT) method (empirical formula): 
              
Mitral regurgitation was also graded as absent, mild, moderate or severe semi – 
quantitatively by looking at the LA size (2D), regurgitant jet area (colour flow), vena 
contracta width,  jet density (CWD) and mitral inflow profile (PWD). 
 
 Aortic Valve 
Morphology of the aortic valve (AV) was looked at in detail and cusp count, thickening, 
calcification and cusp mobility was commented on. I also commented on AV stenosis 
(if present) by using 2D, M-Mode, continuous wave doppler (CW) and pulse wave 
doppler (PW) assessment in various views. Aortic stenosis (AS) was graded as absent, 
mild, moderate or severe. The severity of AS was assessed by using AS jet velocity, 
mean pressure gradient across AV and aortic valve area (AVA).  AS jet velocity was 
measured by CWD aligned parallel to the antegrade systolic flow across the aortic 
valve. The Bernoulli equation was used to measure the pressure gradient across the 
aortic valve; 
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The mean pressure gradient was auto-calculated by the software from the velocity 
curve. AVA was calculated both by continuity equation (AVAVTI) and simplified 
continuity equation (AVAVmax): 
 
                                         
                                     
(where CSA = cross sectional area, VTI = velocity time integral, LVOT = left ventricular 
outflow tract and Vmax = maximal velocity across the valve) 
Aortic regurgitation was also graded as absent, mild, moderate or severe semi – 
quantitatively by looking at the LV size (2D, M-mode), regurgitant proximal jet width 
(colour flow), jet cross-sectional area in LVOT (Colour Flow & Colour M- mode), jet 
density (CWD) and jet deceleration time - PHT (CWD). 
 
 Tricuspid and Pulmonary Valves 
The morphology of both the tricuspid and the pulmonary valves was assessed from 
various views. Tricuspid regurgitation was also graded as absent, mild, moderate or 
severe semi – quantitatively by looking at the right atrial & right ventricle (RV) size 
(2D), inferior vena cave (IVC) size (M-mode), jet area (colour flow), jet density and 
contour (CWD). 
Pulmonary regurgitation was graded as absent, mild, moderate or severe semi – 
quantitatively by looking at the RV size (2D), jet width and length (colour flow). 
 
5.3.6 Reproducibility  
If a measurement such as echocardiography cannot be consistently replicated by the 
same observer or between different observers trained to the same standards, errors can 
be introduced. These errors can be (i) systematic (e.g. when one observer always reports 
higher than other) (ii) random or (iii) both. 
In our pilot study intra-operator agreement has been tested, which showed good 
agreement and compared with the studies in hospital. In pilot study people (n=67) who 
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consented for echocardiography were examined at the place of their residence by a 
trained echocardiographer. One month later 19 participants were visited again for a 
second echocardiographic examination performed by a different trained 
echocardiographer. Two examinations were reported independently. Reproducibility of 
domiciliary echocardiography was assessed by calculating the correlation coefficient, 
coefficient of variation, and repeatability coefficient. The reproducibility of M-mode EF 
measured in the home was similar to previously published hospital-based data in mixed 
populations (r=0.85; CV=12.5%; repeatability coefficient 16.62%). [252] We were 
therefore satisfied with respect to the protocol for data acquisition in domiciliary 
settings. In order to check my interpretation of data acquired during domiciliary 
echocardiography assessments, 25 randomly selected echocardiograms (from 
participants performed during my study) were independently analyzed by me (FY) and a 
very experienced BSE (British Society of Echocardiography) accredited technician (Ms 
Julie Schuster) at the Freeman Hospital. The following echocardiographic variables 
were measured by both FY and JS (on the same scans performed by FY) were analyzed 
for agreement. 
 LV systolic function by M-mode, visual estimate or eyeball method, and wall 
motion score index. 
 LV diastolic function by measuring E/e´ (lateral) 
 RV structure and function by semi-quantitative method (graded as normal, mild, 
moderate or severely impaired/dilated) 
 
We used kappa statistics (Cohen’s kappa – κ) to assess the repeatability for categorical 
data (RV structure and function) in this comparison exercise. [264] Kappa values 
measure the level of agreement in excess of what would be expected by chance. Kappa 
values can range from -1 to 1, with values close to zero indicating the agreement is 
close to that expected by chance. Values below zero suggest a negative agreement and 
those closer to 1 indicated a better agreement. (Table 2.1) 
Bland Altman plot and Pearson’s correlation was used to assess degree of agreement 
between two reviewers (FY and JS) for numerical variables (LV systolic and diastolic 
function .i.e. EF (m-mode, eyeball, wall motion score index) and E/e´. [265, 266] The 
bias or mean difference and 95% confidence interval (1.96 SD) were calculated. 
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Table 5.1: A Guide to Cohen’s kappa value (κ) 
Kappa Value (κ) Strength of agreement 
< 0.0 No agreement 
– 0.20 Poor 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Good 
0.81 – 1.00 Very good 
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5.4 Measurement of Carotid Intima Media Thickness 
Vivid i (Vivid i BT06, GE Healthcare, USA) with the IMT analysis package was used 
to measure carotid intima-media thickness (CIMT). A12L-RS high-frequency linear 
array transducer was used for the carotid imagining.  
Participants were placed in a supine position with the head rotated by 45° to the 
left/right, with their arms rested at their sides. If the participant was too immobile to 
achieve an appropriate position for study, the position was noted but the data, as far as 
possible, were still recorded. 
Carotid Intima Media Thickness (CIMT) describes the combined thickness of the inner 
two very thin layers of the lining of the carotid arterial wall – the intima and the media. 
This corresponds to the inner and outer echogenic lines seen on the B-mode ultrasound 
image. In order to standardize measurements between subjects, the ‘region of analysis’ 
(Figure 5.4)  was set as the 1cm section of the artery situated 1 cm proximal to the start 
of bulb as suggested by Touboul and colleagues in the Mannheim Intima Media 
Thickness consensus document.[194] CIMT assessment was performed in the plaque-
free arterial wall (an atherosclerotic plaque being defined as an echogenic structure 
protruding into the vascular lumen with a thickness greater by at least 50% than 
neighbouring sites.[21] 
Firstly, a transverse image showing the carotid artery in the short axis as a rounded 
vessel was obtained. Next the common carotid artery (CCA) and its bifurcation were 
identified in a transverse image. Then a longitudinal image showing the carotid artery in 
its long axis as four parallel lines was obtained. Finally the ‘region of analysis’ as 
mentioned above was identified. 
The automated edge detection software in the Vivid – I CIMT analysis module was 
used to calculate CIMT. CIMT was measured on the both near and far walls of the CCA 
in the ‘region of analysis’. Mean, maximum and minimum CIMT readings were 
calculated for both carotid arteries. 
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Figure 5.4: Longitudinal section of common carotid artery and ‘region of analysis’ 
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5.5 Assessment of Vascular Stiffness 
Vascular stiffness was assessed by pulse wave analysis (PWA) and measuring pulse 
wave velocity (PWV). Ankle brachial index (ABI) was also recorded to look for any 
peripheral vascular disease. All these assessments were performed in supine position. 
 
5.5.1 Pulse Wave Analysis 
Pulse wave analysis (PWA) was done using a hand-held tonometer probe (Millar 
tonometer, Houston, TX, USA) attached to a SphygmoCor device (SCOR-Px; AtCor 
Medical Pty, Sydney, Australia). The SphygmoCor device takes a 10 second snapshot 
of the radial arterial pressure wave and, by using an inbuilt conversion algorithm 
derives the ascending aortic pressure wave. It provides important cardiovascular 
measurements including central blood pressure, central augmentation pressure, aortic 
augmentation index, ejection duration and subendocardial viability ratio (SEVR). 
Previous studies have shown good repeatability and low interobserver variation for 
tonometry and its derived indices.[267-269] Blood Pressure (BP) was measured using a 
validated automatic oscillometric BP machine (Omron 705 IT IntelliSense BP monitor; 
Omron Healthcare Europe BV, Kruisweg, Hoofddorp, Netherlands). BP was measured 
at the right brachial artery. The BP cuff was placed on the right arm 1-2 cm above the 
cubital fossa and measurement was taken in accordance with manufacturer’s 
instructions. The BP was measured twice and the mean value was used for the PWA 
analysis. 
PWA was undertaken by placing the hand held tonometer probe on the strongest pulse 
at the radial artery of the participant’s wrist. The tonometer was gently pressed 
(applanated) into the skin, perpendicular to the wrist until a waveform signal appeared 
on the screen. Waveforms were captured for 10 seconds after achieving a consistent 
waveform. The SphygmoCor software automatically derived central aortic waveform 
and displayed the required measurements i.e. aortic systolic pressure, aortic pulse 
pressure, central augmentation pressure, central augmentation index, ejection duration 
and SEVR. 
The quality of PWA was assessed using the device’s in-built quality index score 
‘Operator Index’. We used examinations with an operator index of 80 or above for our 
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analyses as suggested by the manufacturer. Participants with poor quality trace (operator 
index < 80) were excluded from analysis. 
 
5.5.2 Pulse Wave Velocity 
 Vicorder system (Skidmore Medical, Bristol, UK) was used for measuring pulse wave 
velocity. It measures simultaneous pressure waveforms by a volume displacement 
technique, using blood pressure cuffs placed around the sites of interest. Pulse wave 
velocity (PWV) is defined as the time taken by a pressure or flow wave to travel a given 
distance (Velocity = Distance/Time).  Femoral and the carotid artery flow waveforms 
were simultaneously recorded by using the equipment. The Vicorder system calculates 
transit time by using a foot-to-foot methodology with the distance measured along the 
surface of the body between the recording points with a tape measure. It requires very 
little operator training and is almost operator independent.[270] 
Measurements were obtained using the Vicorder device by placing a 100mm wide 
blood pressure cuff around the upper thigh to measure the femoral pulse and a 30 mm 
partial cuff around the neck at the level of the carotid artery. Both cuffs were 
simultaneously inflated to 65mmHg, and high-quality waveforms were recorded 
simultaneously for 3 seconds using a volume displacement method. Path distance “L”  
the distance between Supra-sternal notch and the top of thigh cuff in centimetres was 
measured  with a measuring tape. The foot-to-foot transit time ‘TT’ was determined 
using an in-built cross-correlation algorithm. PWV is automatically calculated by the 
software as the distance (L) between the two recording sites divided by the time delay 
(TT) between the feet of the two waveforms at each site. (Velocity = Distance/Time). 
Participants with Atrial Fibrillation were excluded. 
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5.5.3 Ankle Brachial Index 
Vicorder system (Skidmore Medical, Bristol, UK) was also used for measuring the 
ankle brachial pressure index (ABPI). It uses a digitally filtered 
photoplethysmoghraphic (PPG) signal displaying the linear characteristics of the flow 
wave. During the deflation cycle of the measurement, the system automatically selects 
the first appropriate PPG flow signal and references the cuff pressure.  
The dual channel features of the Vicorder allow rapid collection of bilateral PPG waves, 
providing a quick method of obtaining systolic pressure measurements bilaterally, 
thereby speeding up ABPI measurements.  
 Wide blood pressure cuffs  (100mm ) were placed on both arms (just above the cubital 
fossa) and PPG sensors on the largest finger on each hand. Both cuffs were 
simultaneously inflated. Once systolic pressure was achieved the PPG signal 
disappeared and reappeared when the cuff again reached systolic pressure in its 
bleedback phase. During the deflation cycle of the measurement, the system 
automatically selects the first appropriate PPG flow signal and references the cuff 
pressure. Although automatically picked, the first appropriate PPG flow signal could 
also be selected manually. Measurements from both legs were also recorded by 
applying cuffs just above the both ankles and PPG sensors on both big toes. ABPI for 
both left and right sides were automatically calculated by the software by using the 
following formula: 
ABPI = Ankle systolic pressure/Brachial systolic pressure 
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5.6 Electrocardiogram (ECG) 
A 12 lead electrocardiogram was recorded on a Burdick Atria 6100 ECG machine 
(Bothell, WA, USA) and transmitted to the ECG Core Laboratory at Glasgow Royal 
Infirmary for automated Minnesota Coding, a service set up by Professor Peter  
MacFarlane.[271] [272]The portable size and inbuilt modem in this machine made it 
ideal for domiciliary use and subsequent transmission of the ECG for Minnesota coding. 
Electrocardiograms were recorded in a supine position by a trained research nurse 
according to the study protocol. Firstly the procedure was explained the participant. 
Afterwards they were asked to lie down on the bed or sofa as per their convenience. 
Four limb electrodes were attached to the outer surface of wrists and ankles. Six chest 
electrodes (V1 – V6) were also attached to the chest after cleaning the skin with a sterile 
wipe as described below in figure 5.5. 
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Figure 5.5: Position of ECG chest and limb leads 
Limb leads: 
aVL: Outer aspect of left wrist. 
aVR: Outer aspect of right wrist. 
aVF: Outer aspect of left ankle. 
N: Outer aspect of right ankle. 
Chest leads: 
V1 - Right sternal margin in the 4th intercostal space. 
V2 - Left sternal margin in the 4th intercostal space. 
V3 - Midway between V2 and V4. 
V4 - Left midclavicular line in the 5th intercostal space. 
V5 - Left anterior axillary line V4 level 
V6 - Left midaxillary line V4 level 
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Finally 12 lead ECG was recorded automatically by machine once the electrodes were 
attached to the machine. A paper copy of the ECG was stored in participant’s file and 
was also electronically transmitted to the ECG Core Laboratory in Glasgow Royal 
Infirmary for automated Minnesota Coding .  
Clinically significant arrhythmia (such as AF) and specific types of heart block were 
reported to the General practitioner according to the study protocol. (Appendix  5) 
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5.7 Measurement of NT-proBNP (N-terminal pro-brain natriuretic peptide) 
Venous blood samples for plasma NT-proBNP assay were taken during Newcastle 85+ 
study core assessment and transported to laboratory (Royal Victoria Infirmary, 
Newcastle upon Tyne) by trained research nurses according to the study protocol.  
Plasma NT-proBNP was measured by electrochemiluminescence immunoassay 
‘ECLIA’ using the  Elecsys NT-proBNP II assay (Elecsys® proBNP II, Roche 
Diagnostics, Indianapolis, IN, USA) performed on a Roche Elecys E170 analyzer. This 
assay has a measuring range from 5 – 35,000 pg/ml.  
This assay contains two monoclonal antibodies which recognize epitopes located in the 
N-terminal part of the proBNP. This is a two-step sandwich assay. During the first 
incubation an antigen in the sample, a biotinylated monoclonal NT-proBNP-specific 
antibody, and a monoclonal NT-proBNP-specific antibody labeled with ruthenium 
complex form a sandwich complex. During the second incubation, after the addition of 
streptavidin-coated microparticles, the complex becomes bound to the solid phase via 
interaction of biotin and streptavidin. Subsequently this reaction mixture is aspirated 
into the measuring cell where the microparticles are magnetically captured onto the 
surface of the electrode. Unbound substances are removed with proCell. Application of 
a voltage to the electrode then induces chemiluminescent emission which is measured 
by a photomultiplier. Results are determined via a calibration curve with a measuring 
range of 5-35,000 pg/ml.  
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5.8 New York Heart Association (NYHA) functional severity grading 
A dyspnoea questionnaire (Appendix 7) was administered during phase 2 and 3 of the 
core study and participants were assigned to New York Heart Association (NYHA) 
functional severity classes: NYHA grade I (asymptomatic), II (mild limitation), III 
(moderate limitation), or IV (severe limitation).  
Participants were assigned NYHA grade using following scheme. 
NYHA grade 1: If questions 1, 3 and 5 ALL = ‘no’ or ‘limited for reason unrelated to 
shortness of breath’. 
NYHA grade 2: If (q1 = ‘no’ and q3 = ‘yes’) and (q4 = ‘a bit’ OR ‘a lot’) or (q1 = ‘no’ 
and q3 = ‘no’ and q5 = ‘yes’). 
NYHA grade 3: If (q1 = ‘yes’) and (q2 = ‘a bit’ OR ‘a lot’) or (q1 = ‘no’ and q3 = ‘yes’ 
and q4 = ‘completely unable to walk outdoors’). 
NYHA grade 4: If (q1 = ‘yes’ and q2 = ‘completely unable to move around the home’). 
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5.9 Data Storage And Data Cleaning 
All the electronic data from the cardiac measurements was backed up onto DVDs and 
was stored according to Newcastle 85+ study policy. Data was also stored on the main 
Newcastle 85+ study database. All datasets were matched against the PIDs 
(participant’s unique 8 digit study ID), date of birth and gender of the participants. All 
the datasets were cleaned by performing logic and range checks by the study data 
manager.  
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5.10 Reporting Results to General Practitioner 
According to our study protocol (Appendix 5) the following abnormal results found on 
echocardiograms were reported back to GPs. 
 Significant impairment of LV function (ejection fraction less than 35%) 
 Significant valvular heart disease defined as: 
o Severe Aortic stenosis/regurgitation 
o Severe Mitral stenosis/regurgitation 
o Severe Tricuspid stenosis/regurgitation 
 
 Significant other findings such as hypertrophic obstructive cardiomyopathy 
(HOCM), and  atrial myxoma  
 
Results for carotid intima media thickness (CIMT), pulse wave velocity and pulse wave 
analysis, which help us to assess the vascular stiffness and extent of atherosclerosis 
were not fed back to GPs as at present all these parameters are not used in routine 
clinical practice.  
Clinically significant arrhythmias and heart block found on 12 lead ECG were also fed 
back to GPs as per study protocol (Appendix 6 ). 
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 5.11 Statistical Methods 
Normally distributed data are presented as means and standard deviations and non-
normally distributed data as medians and interquartile ranges. Differences between 
groups were assessed by t-tests (normally distributed continuous data), Wilcoxon-
Mann-Whitney U tests (non-normally distributed continuous data) or χ2 tests 
(categorical data). Differences in levels of particular variables (for example, left 
ventricular dysfunction, which could be graded absent, mild, moderate or severe) were 
assessed by logistic regression and are presented as odds ratios with 95% confidence 
intervals.  All p-values are two-sided with Bonferroni correction where appropriate to 
account for multiple testing.  Missing values were excluded from the analysis (though 
numbers of participants with missing data are reported throughout) and I therefore 
present data based on the number of valid responses. With respect to the analyses of 
symptomatic left ventricular dysfunction, I considered the possibility that dyspnoea may 
have been due to respiratory disease rather than heart failure.  Accordingly, I conducted 
a sensitivity analysis excluding participants with significant intrinsic lung disease 
identified using spirometric criteria of a forced expiratory volume in one second of less 
than 60% of the predicted value (for age, sex and height) or a forced vital capacity less 
than 70% of the predicted value. The above analyses were performed using Stata 11.0 
(StataCorp. 2011. Statistical Software: Release 11.0. College Station, TX: Stata 
Corporation); and I was assisted in these by Mr. Andrew Kingston, the 85+ study 
statistician.  
The diagnostic performance of NT-proBNP in the identification of left ventricular 
systolic and diastolic dysfunction was evaluated by receiver-operating characteristic 
(ROC) curve analysis, described by DeLong et al.[273] The optimal discriminatory 
value for each assay was estimated by the point along the ROC curve that provided the 
minimum Euclidean distance between that of a perfect assay with 100% sensitivity and 
specificity. The positive predictive value and negative predictive values were calculated 
for the optimal discriminatory values. Statistical significance was accepted at p ≤ 0.05. 
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5.12 Power Calculation 
The Newcastle 85+ cardiac study aimed to recruit 400 participants. Sample size was 
determined by the requirements of planned longitudinal analyses i.e. detecting 
associations by logistic regression between cardiovascular phenotypes and subsequent 
non-fatal cardiovascular events over 18 month follow-up; under the assumption that a 
25% baseline prevalence of diastolic dysfunction (as in our pilot data) in 400 
participants would have 80% power at a 5% significance level of detecting an odds ratio 
of at least 2.0 with an event rate among those without diastolic dysfunction of 25-30%. 
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Chapter 6: Cohort Demographics; Feasibility and Reproducibility of 
Assessments 
6.1 Recruitment 
Of the 854 people who participated in the baseline Newcastle 85+ Study 631 were re-
assessed in phase 2, of whom 484 were seen again in phase 3. It was initially planned to 
conduct the cardiac sub-study on a subset (almost 400 people) of phase 2 cohort. 
However, due to delay in securing the funding, cardiac assessments were delayed and 
only 316 people were recruited from the phase 2 cohort. The cardiac sub-study was 
extended to phase 3 and the people at the time who were still alive and had not already 
been offered the cardiac assessments, were invited to participate. A further 111 people 
for the cardiac substudy were recruited from phase 3 cohort. Figures 3.1 and 3.2 explain 
the recruitment of cardiac sub-study cohort. Five hundred and seventy one participants 
(phase 2 = 405, phase 3 =166) were invited to undergo cardiovascular assessments. Four 
hundred and twenty seven participants (74.8%) took part in cardiac sub-study.  
Of the 461 people who were mailed out for both phase 2 and cardiac sub-study, 87.8% 
(405/461) agreed to take part in phase 2. Further 87.6% (355/405) people, who 
consented for phase 2 assessments also agreed to take part in cardiac sub-study. Cardiac 
assessments were performed in 89 % of the people (316/355), who consented for 
cardiac sub-study. Of the 36 people in whom cardiac visit could not be completed 13 
people passed away, 6 were too ill to participate and 9 people did not give any reason 
for refusal. In on case cardiac tests were declined by the consultee of patient due to fear 
of distress. 
Of the 200 people who were mailed out for both phase 3 and cardiac sub-study, 87.5% 
(175/200) agreed to take part in phase 3. Nine of the 175 phase 3 participants also 
received invitation for cardiac sub-study in phase 2 so leaving 166 phase 3 participants, 
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who were asked to participate in cardiac sub-study. 150 people from invited cohort 
(90.4%, 150/166) agreed to take part in cardiac substudy. In 29 people cardiac substudy 
invitation was withdrawn as the target for cardiac substudy was achieved. Cardiac 
assessments were performed in 91.7 % of the people (111/121), who consented for 
cardiac sub-study.  (Figure 6.1 & 6.2) 
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Figure 6.1: Cardiac Sub-study recruitment profile from Phase 2 
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Figure 6.2: Cardiac Sub-study recruitment profile from Phase 3  
** Phase 3 non cardiac mail out were still on going even after recruitments for cardiac substudy stopped
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6.2 Characteristics and Representative Nature of Cardiac Cohort 
Characteristics of 427 cardiac sub-study and 631 phase 2 (core 85+ study) participants 
are presented in Table 6.1. It also shows the characteristics of cardiac substudy 
participants assessed in the phase 2 (P2) and phase 3 (P3) of core 85+ study. Mean age 
of cardiac sub-study cohort was 87.9 years, 60.9% (260/427) were females, 99.3% 
(424/427) were white ethnic origin, and 5.4% (24/427) lived in an institution. Mean 
ages of cardiac P2 and P3 participants were 87.9 years and 88.3 years respectively. 
81.3% of cardiac substudy and 77.5% of phase 2 core 85+ study rated their health good 
or above. Disability score was slightly higher in core 85+ phase 2 participants (6.2 ± 
4.9) than cardiac sub-study cohort (5.6 ± 4.5). Hypertension (56.9%, 243/427), 
Ischaemic heart disease (32.3%, 138/427) and cerebrovascular disease (19.0%, 81/427) 
were common in cardiac sub-study participants. Core 85+ phase participants also had 
similar prevalence of hypertension (57.9%), ischaemic heart disease (32.1%) and 
cerebrovascular disease (19.8%). Cardiac P3 participants also had similar prevalence of 
hypertension (61.0%), ischaemic heart disease (31.7%) but less cerebrovascular disease 
(14.6%). Majority of both cardiac sub-study (62.2%) and core 85+ phase 2 (61.2%) 
participants were either current or former regular smokers. (Table 6.1) 
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Table 6.1  Characteristics and representative nature of cardiac cohort 
     
 Phase2 "core 85+  
cohort" 
Phase2 
cardiac 
phase3 
cardiac 
Phase2/phase3 
cardiac 
 n=631 n=316 n=111 n=427 
Sociodemographics     
Age  years (mean ± sd) 87.9 ± 0.44 87.9 ± 0.40 88.3 ± 0.33 87.9 ± 0.44 
Gender ( females %, n) 62.9 % (397 ) 60.20% 62.60% 60.9 % (260) 
Ethnicity (whites %) 99.5 % (628) 99.30% 99.20% 99.3 % (424) 
Housing (institutionalized %, n) 9.2 % (58) 7.20% 1.60% 5.6 % (24) 
Non cardiac health characteristics     
Disease count (mean ± sd) 4.6 ± 1.8 4.7 ± 1.8 4.2 ± 1.5 4.5 ± 1.7 
Disability score (mean ± sd) 6.2 ± 4.9 5.8 ± 4.7 5.1 ± 3.9 5.6 ± 4.5 
MMSE (mean ± sd) 26.6 ± 4.3 26.8 ± 3.9 27.7 ± 2.3 27.0 ± 3.6 
Self rated health (good or above) %, n 77.5 % (475) 79.40% 86.40% 81.3 % (347) 
Depression (severe)  %, n 7.9 % (48) 6.00% 6.50% 6.1 % (26) 
Cardiac risk factors     
Smokers or ex smokers %  61.20% 63.80% 58.20% 62.20% 
BMI (mean ± sd) 24.7 ± 4.4 24.9 ± 4.5 25.0 ± 3.9 24.9 ± 4.3 
Waist hip ratio (mean ± sd) 0.88 ± 0.08 0.88 ± 0.08 0.88 ± 0.07 0.88 ± 0.08 
Diabetics % 12.70% 15.10% 7.30% 12.90% 
Total cholesterol mmol/l (mean ± sd) 4.2 ± 1.2 5.0 ± 1.2 5.0 ± 1.3 5.0 ± 1.2 
HDL  mmol/l (mean ± sd) 1.4 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 
Pre-existing diagnosis     
Myocardial infarction % (n) 14.6 % (92) 14.10% 13.80% 14.1 % (60) 
Angina % (n) 29.8 % (188) 30.30% 30.10% 30.2 % (129) 
Ischaemic heart disease - IHD % (n) 32.1 % (202) 32.60% 31.70% 32.3 % (138) 
Hypertension % (n) 57.9 % (365) 55.30% 61.00% 56.9 % (243) 
Heart failure % (n) 9.5 % (60) 10.50% 4.90% 8.9 % (38) 
Peripheral vascular disease - PVD % (n) 6.5 % (41) 6.30% 4.10% 5.6 % (24) 
Cerebrovascular disease  - CVD % (n) 19.8 % (125) 20.70% 14.60% 19.0 % (81) 
Any atherosclerotic disease 
(IHD/PVD/CVD) 
47.3 % (298) 47.70% 43.10% 46.4 % (198) 
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6.3 Feasibility of Domiciliary Cardiovascular Assessments 
 
6.3.1 Feasibility of Domiciliary Echocardiography 
Echocardiography could be performed in 419 of 427 participants of which 5.6% (24) 
were institutionalized.  Three people refused to have the echo performed while only five 
were too frail to attempt measurement.  A full study was possible in 87% (n =367) of 
participants. In 12.4% participants partial study was possible due to lack of either 
parasternal (PS) or apical views (AP). Mostly it was due to poor echo windows (n= 39). 
In 12 individuals either of PS or AP view was missing because participant could not be 
positioned appropriately. (Figure 6.3) 
 
6.3.2 Feasibility Of Domiciliary Ankle Brachial Index (ABI) Assessment 
114 (26.7%) participants were excluded from ABI assessment due to presence of atrial 
fibrillation (20.8%, n=89), paroxysmal atrial fibrillation (4.7%, n=20) or frequent 
multiple ectopics (1.2%, n=5). Out of remaining 313 eligible participants ABI 
measurement was available in 84.0% of participants (n=263). 20 participants refused to 
have ABI assessment done predominantly (n=15) because they didn’t like BP cuffs. In 
30 participants ABI assessment was not performed as it was difficult to position them 
appropriately (n=11) or legs were too swollen due to peripheral oedema (n=9). (Figure 
6.4) 
 
6.3.3 Feasibility Of Domiciliary Pulse Wave Analysis (PWA)  
81 (19.0%) participants were excluded from PWA measurement due to presence of 
atrial fibrillation (16.4%, n=70), paroxysmal atrial fibrillation (2.6%, n=11). 28 
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participants with atrial fibrillation / paroxysmal atrial fibrillation (19,9) and operator 
index above 80 were also included in the PWA analysis as per manufacturer’s 
recommendation (Personal communication with Miss Sandrine Millasseau, Clinical 
Manager for Europe, Atcor Medical) 
 Out of remaining 346 eligible participants PWA measurement was available in 86.1% 
of participants (n=298). 15 participants refused to have PWA measurement done 
because they didn’t like BP cuffs. In 11 participants PWA measurement was not 
performed as it was difficult to position them appropriately and in 7 participants PWA 
measurements were discarded because of low operator index (<80). (Figure 6.5) 
 
6.3.4 Feasibility Of Domiciliary Pulse Wave Velocity (PWV) Measurement 
114 (26.7%) participants were excluded from ABI assessment due to presence of atrial 
fibrillation (20.8%, n=89), paroxysmal atrial fibrillation (4.7%, n=20) or frequent 
multiple ectopics (1.2%, n=5). Out of remaining 313 eligible participants PWV 
measurement was available in 76.7% of participants (n=240). 15 participants refused to 
have PWV assessment done because they didn’t like BP cuffs. In 26 participants PWV 
wasn’t measured because participants had termers (shakes) in limbs or neck, a main 
cause of artefacts in PWV measurement. In 11 participants PWV measurements were 
unavailable because of difficulty in lying flat. (Figure 6.6) 
 
6.3.5 Feasibility Of Domiciliary Carotid Intima Media Thickness (CIMT) 
Measurement 
In 96.7% (n=413) participants CIMT measurement were available. Only two people 
refused this assessment. In 9 (2.1%) participants CIMT measurement was not available 
because of difficulty to obtain common carotid artery images. (Figure 6.7) 
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Figure 6.3 Feasibility of domiciliary Echocardiography 
 
 
135 
 
 
 
 
 
 
Figure 6.4  Feasibility of domiciliary Ankle Brachial Index (ABI) assessment 
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Figure 6.5 Feasibility of domiciliary Pulse Wave Analysis (PWA) 
*28 participants with AF/PAF (19,9) with operator index above 80 were also included in the PWA 
analysis 
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Figure 6.6 Feasibility of domiciliary Pulse wave velocity (PWV) measurement 
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Figure 6.7     Feasibility of domiciliary Carotid intima media thickness (CIMT) measurement 
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6.4 Prevalence Of Cardiac And Non-Cardiac Health Characteristics 
Table 6.2 and 6.3 represent the cardiac and non-cardiac health characteristics of the 
study cohort. NYHA functional classification was assigned to 281 participants. Most 
participants exhibited NYHA class I (n=119, 42.4%) and NYHA II, 120 (42.7%). Only 
42 (14.9%) participants were assigned NYHA III. None of the participants exhibited 
NYHA class IV. The majority of the males (51.4%, 57/111) exhibited no symptoms of 
breathlessness (NYHA I) while 36.5% females were assigned NHYA class I. 63.5 % 
(n=108) females exhibited either NYHA class II or III. Only 10.4% (n=34) participants 
mentioned presence of chest pains which were exertional in nature in nearly half of the 
cases. Some degree of ankle odema was also present in 22.8% (n=72) people. However, 
it was severe only in 5.7% (n=18) participants. 
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Table 6.2   Prevalence of cardiac health characteristics 
   Men (n, %) Women (n, %) Total (n, %) 
Shortness of breath  (352)*    
  NYHA I  57 (51.4) 62 (36.5) 119 (42.4) 
 NYHA II  39 (35.1) 81 (47.6) 120 (42.7) 
 NYHA III  15 (13.5) 27 (15.9) 42 (14.9) 
 NYHA IV  0 (0) 0 (0) 0 
 NYHA I/II  25 (18.4) 46 (21.3) 71(20.2) 
Chest pains (315)ⱡ      
 Present    13 (38.2) 21 (61.8) 34 (10.8) 
 Exertional nature 5 (27.8) 13 (72.2) 18 (5.7) 
 Limits function 3 (21.4) 11 (78.6) 14 (4.4) 
Ankle odema (316)ⱡ    
 Present   20 (27.8) 52 (72.2) 72 (22.8) 
 Severe   4 (22.2) 14 (77.8) 18 (5.7) 
 
* Based on phase2 and 3 questionnaire 
ⱡ  Baseline symptoms 
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Table 6.3     Prevalence of non-cardiac health characteristics 
Variables    Men (n, %) Women (n, %) Total (n, %) 
Categorised MMSE     
  26-30 (normal)  136 (39.8%) 206 (60.2%) 342 (80.1%) 
  22-25 (mild)  24 (41.4%) 34 (58.6%) 58 (13.6%) 
  18-21 (moderate)  2 (13.3%) 13 (86.7%) 15 (3.5%) 
  0-17 (severe)  5 (41.7%) 7 (58.3%) 12 (2.8%) 
       
Categorised GDS      
  No Depression 149 (42.1%) 205 (57.9%) 354 (82.9%) 
  Mild Depression 10 (23.8%) 32 (76.2%) 42 (9.8%) 
  Moderate Depression 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  Severe Depression 6 (24.0%) 19 (76.0%) 25 (5.9%) 
Categorised Disability     
  None  58 (56.3%) 45 (43.7%) 103 (24.1%) 
  1-6  88 (36.2%) 155 (63.8%) 243 (56.9%) 
  7-12  14 (21.2%) 52 (78.8%) 66 (15.5%) 
  13-17  7 (46.7%) 8 (53.3%) 15 (3.5%) 
Self Rated Health      
  Excellent  21 (43.8%) 27 (56.3%) 48 (11.2%) 
  Very Good 66 (46.2%) 77 (53.8%) 143 (33.5%) 
  Good  59 (36.9%) 101 (63.1%) 160 (37.5%) 
  Fair  19 (28.8%) 47 (71.2%) 66 (15.5%) 
  Poor  0 (0.0%) 6 (100.0%) 6 (1.4%) 
Housing       
  Standard  150 (41.7%) 210 (58.3%) 360 (84.3%) 
  Sheltered  13 (24.1%) 41 (75.9%) 54 (12.6%) 
  Institutional 4 (30.8%) 9 (69.2%) 13 (3.0%) 
      
142 
 
 
 
The majority of participants had either normal cognitive function (80.1%, n=342) or 
only mild cognitive impairment (13.6%, n=58). Only 6.2 % (27/427) had moderate or 
severe cognitive impairment. The majority of participants had either no (82.9%, n=354) 
or only mild depression (9.8%, n=42). Only 5.9% (25/427) had moderate or severe 
cognitive impairment. 
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6.5 Reproducibility 0f Echocardiography Assessments 
LV systolic function was assessed by calculation of LVEF by three different methods 
including m-mode, eyeball assessment and wall motion score index (WMSI) by both 
reviewers (FY and JS). LV diastolic function was assessed by calculating E/e´ ratio. 
Table 3.4 shows a very strong correlation between measurements of LV systolic 
function and diastolic function performed by both reviewers. Correlation coefficient (r) 
for LVEF (m-mode), LVEF (eyeball), LVEF (WMSI) and E/e´ were 0.921, 0.978, 0.935 
and 0.989 respectively. (Table 6.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
 
Table 6.4:  Means and co-relational analysis for LV systolic and diastolic function 
  FY JS   
Variable n Mean St Dev Mean St Dev r p value 
LVEF(m-mode) 25 71.28 12.77 70.3 11.21 0.921 <0.0001 
LVEF(Eye Ball) 24 53.5 9.57 54.48 8.27 0.978 <0.0001 
LVEF(WMSI) 24 55.65 8.16 55.03 7.69 0.935 <0.0001 
E/e´ ratio 25 12.098 4.83 12.213 4.858 0.989 <0.0001 
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Figure 3.8 (a-d) shows Bland Altman plots considering the agreements between both 
reviewers for assessing LV systolic function (LVEF) by m-mode (a), eyeball method (b) 
and WMSI (c) method and LV diastolic function by E/e´ (d). Mean difference or bias 
between both reviewers for LVEF (m-mode), LVEF (eyeball method), LVEF (WMSI) 
and E/e´ was -0.98, -0.10, -0.62 and 0.11 respectively. Limits of agreement between 
both reviewers for LVEF (m-mode), LVEF (eyeball method), LVEF (WMSI) and E/e´ 
was quite tight (-6.7% to 4.7%, 6.5% to 6.3%, -6.3% to 5.1% and -1.3 to 1.5 
respectively). Mean bias of less than 1.0% and tight limits of agreement suggest good 
agreement between both reviewers. It is also important to note that limits of agreement 
between reviewers remains similar for both low and high values of LVEF and E/e´. 
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Figure 6.8 (a): Bland–Altman plots showing the mean difference (green lines) and the limits of 
agreement (red lines) between observers for LVEF (m-mode) 
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Figure 6.8 (b): Bland–Altman plots showing the mean difference (green lines) and the limits of 
agreement (red lines) between observers for LVEF (eyeball) 
 
147 
 
 
Figure 6.8 (c): Bland–Altman plots showing the mean difference (green lines) and the limits of 
agreement (red lines) between observers for LVEF (WMSI) 
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Figure 6.8 (d): Bland–Altman plots showing the mean difference (green lines) and the limits of 
agreement (red lines) between observers for E/e´ 
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We used Cohen’s kappa (κ) statistic to measure agreement between two reviewers on 
grading RV structure and function. We found both reviewers have substantial agreement 
(κ = 0.78) in grading RV structure and almost perfect agreement (κ = 1.00) in grading 
RV function.  
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6.6 Agreement Between Various Methods of LVEF Assessment 
Left ventricular systolic function could be assessed in 86% of participants using M-
mode measurements, 94% of participants by eyeball, 81% of participants by wall 
motion score index (WMSI) and 64% by biplane volumetric method.  
All three methods for assessment of LVSF by calculating EF including eyeball, biplane 
and WMSI showed quite substantial agreement (к > 0.71) with each other, except m-
mode method.  LVEF by eyeball assessment method will be used in further analyses in 
this thesis because it was available in most participants and showed good agreement 
with other methods of LVEF assessments methods (Table 6.5). Cumulative distribution 
of LV systolic function as assessed by four methods is displayed in figure 6.9 and 
convincingly demonstrates a good agreement between various methods throughout the 
range of LVEF. 
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Table 6.5     Agreement between different methods of assessing LVEF using kappa statistics (к) 
 Eyeball Biplane WMSI M-mode 
Eyeball - 0.72 0.75 0.22 
Biplane 0.72 - 0.73 0.29 
WMSI 0.75 0.73 - 0.27 
M-mode 0.22 0.29 0.27 - 
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 Figure 6.9: Cumulative distribution plot of left ventricular ejection fraction measured 
by Simpson’s biplane volumetric method, 16-segment wall motion score index, M-
mode, and semi-quantitative 2-D visual estimate  
(Note: The maximum possible LV ejection fraction by wall motion score index was 
60% and by semi-quantitative 2-D visual estimate greater than 55%. M-mode and 
Simpson’s biplane are quantitative throughout the range of LV ejection fraction.) 
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Chapter 7: Prevalence, Diagnosis and Associations of Left Ventricular Dysfunction 
In the 85+ Cohort 
 
7.1 Prevalence of Left Ventricular Dysfunction 
LV systolic (LVSF) and diastolic (LVDF) function were available for 398 and 386 
participants respectively. In 376 participants both LVSF and LVDF were available. 
Nearly half (50.5%, 201/398) of participants had normal LV systolic function (LVEF 
more than 55%). More females tended to have normal LV systolic function (56.0%, 
135/241) as compared to men (42.0%, 66/157). Whereas, moderate to severe LV 
systolic dysfunction (LVSD) was more prevalent in male (27.4%, 343/157) compared to 
females (14.5%, 35/241). Overall, 19.6% (78/398) participants had moderate to severe 
LVSD.  
Almost three quarters (72.1%, 106/147) of male participants had either normal or mild 
diastolic dysfunction while 67.4% (161/239) females had normal or mildly impaired 
diastolic function. Overall, moderate or severe diastolic dysfunction was present in 
30.8% (119/386) participants. Nearly half (n=65) of those with moderate or severe 
diastolic dysfunction also had some degree of systolic dysfunction. Isolated moderate or 
severe diastolic dysfunction (IDD) was prevalent in 14.4% (54/376) of participants. In 
female participants prevalence of IDD was 15.5% while in males it was 12.6%. Slightly 
more than half (55.2%) of the male participants had some degree of LVSD whereas 
only 44.2% females had some degree of LVSD (Table 3.6). 
Participants (29, 6.8%), in whom LV systolic function was not available were similar to 
the rest of the cohort in terms of major cardiovascular risk factors for heart disease 
(Table 7.2). Participants (41, 10.6%), in whom LV diastolic function was not available 
were also similar to the rest of cohort in terms of major cardiovascular risk factors 
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except renal disease and ischaemic heart disease (IHD). People with missing LV 
diastolic function had significantly more prevalence of moderate/severe renal 
impairment (p=0.001) and IHD (p=0.02). (Table 7.1) 
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Table 7.1: Prevalence of cardiac dysfunction in 85+ years old 
Variables  
Male (n, %) Female (n, %) Total (n, %) 
SYSTOLIC  FUNCTION   
      
Normal LVEF   
66 (42.0) 135 (56.0) 201 (50.5)  
Mild LVSD   
48 (30.6) 71 (29.5) 119 (29.9) 
Moderate LVSD   
34 (21.7) 32 (13.3) 66 (16.6) 
Severe LVSD   
9 (0.57) 3 (0.01) 12 (3.0) 
    
157 (39.5) 241 (61.5) 398 (100) 
DIASTOLIC FUNCTION   
      
Normal diastolic function 
25 (17.0) 19 (8.0) 44 (11.4) 
Mild diastolic dysfunction    
81 (55.1) 142 (6) 223 (57.8) 
Moderate diastolic dysfunction   
31 (21.1) 65 (67.7) 96 (24.9) 
Severe diastolic dysfunction   
10 (6.80) 13 (56.5) 23 (5.9) 
    
147 (38.1) 239 (61.9) 386 (100) 
COMBINED      
      
Normal    
46 (32.9) 94 (67.1) 140 (37.2) 
Isolated diastolic dysfunction 
18 (33.3) 36 (66.7) 54 (14.4) 
Systolic dysfunction  
79 (43.4) 103 (56.6) 182 (48.4) 
    
143 (38.0) 233 (62.0) 376 (100) 
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Table 7.2                           Characteristics of participants with & without measurements of systolic function (LVEF) 
      
Variables   Systolic Function Available Systolic Function Unavailable p Value 
   (n, %) (n, %)  
      
Gender  n= (398, 29) - - 0.60 
 Male - 157 (39.4) 10 (34.5)  
 Female - 241 (60.6) 19 (65.5)  
Smoking (smokers/Ex) n= (397, 29) 243 (61.2) 22 (75.8) 0.13 
OBESE (BMI) obese/above n= (391, 24) 40 (10.2) 4 (16.7) 0.08 
Diabetes  n= (398, 26) 52 (13.1) 3 (10.3) 0.67 
Hypertension n= (398, 29) 227 (57.0) 16 (55.3) 0.84 
Renal Impairment - MDRD (moderate/above) n= (389, 28) 231(59.4) 22 (78.6) 0.28 
Ischemic Heart Disease n= (398, 29) 125 (31.4) 13 (44.8) 0.14 
Cerebrovascular Disease n= (398, 29) 74 (18.6) 7 (24.1) 0.46 
Atherosclerotic disease n= (398, 29) 180 (45.2) 18 (62.1) 0.08 
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Table 7.3:                                 Characteristics of participants with & without measurements of diastolic function   
Variables   Diastolic Function Available Diastolic Function Unavailable p Value 
   (n, %) (n, %)   
Gender  n= (386/41)   0.18 
 Male  147 (38.1) 20 (48.8)  
 Female  239 (61.9) 21 (51.2)  
Smoking (smokers/Ex) n= (385/41) 239 (62.1) 26 (63.4) 0.66 
OBESE (BMI) obese/above n= (378/37) 38 (10.0) 6 (16.2) 0.27 
Diabetes  n= (386/41) 46 (11.9) 9 (22.0) 0.07 
Hypertension n= (386/41) 221 (57.3) 22 (53.7) 0.66 
Renal Impairment - MDRD (moderate/above) n= (377/40) 220 (58.4) 33 (82.5) 0.001* 
Ischemic Heart Disease n= (386/41) 118 (30.6) 20 (48.8) 0.02* 
Cerebrovascular Disease n= (386/41) 73 (18.9) 8 (19.5) 0.93 
Atherosclerotic disease n= (386/41) 174 (45.1) 24 (58.5) 0.10 
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7.2 Prevalence of Symptomatic Left Ventricular Dysfunction (SLVD) 
73.9% (278/376) participants had data on NYHA functional grading and both LV 
systolic and diastolic function. NYHA functional grading was not available in 98 
(26.1%) participants mainly because limitation of activity was reported by causes 
other than breathlessness. Participants in whom NYHA grading was not available 
were similar to the rest of cohort in terms of presence of systolic or diastolic 
dysfunction or other chronic disease including COPD, IHD and anaemia. (Table 7.4) 
 Symptomatic left ventricular dysfunction (SLVD) was defined as presence of NYHA 
class 2 or above in the presence of underlying systolic (mild/moderate/severe) or 
diastolic dysfunction (moderate/severe). 
Prevalence of any SLVD was 37.4% (104/278), in which systolic SLVD was 29.5% 
(82/278) being more prevalent than isolated diastolic SLVD (7.9%, 22/278). 
Symptomatic systolic dysfunction was more prevalent in females than males [OR 
(95% CI)] 2.52 (1.15-5.54), p =0.01. Symptomatic diastolic dysfunction was also 
more prevalent in females than males [OR (95% CI)] 6.16 (1.13-36.4), p =0.02. 
Further 23.0 % (64/278) participants (64/278) had evidence of systolic or diastolic 
dysfunction but no symptoms of breathlessness (NYHA I), consistent with preclinical 
heart failure. (Table 7.5) 
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Table 7.4             Characteristics of participants with & without NYHA grading 
Variables  
NYHA grading 
available 
NYHA grading 
not available 
p value 
Gender Male 83 84 
0.16 
 Female 111 149 
Systolic dysfunction Yes 93 104 
0.56 
 No 89 112 
Diastolic dysfunction Yes 62 57 
0.87 
 No 114 153 
Isolated diastolic dysfunction Yes 24 30 
0.94 
 No 146 174 
COPD Yes 29 38 
0.70 
 No 165 95 
IHD Yes 55 83 
0.11 
 No 139 150 
Anaemia Yes 42 49 
0.79 
 No 140 174 
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Table 7.5:  Prevalence of Symptomatic LV Dysfunction (SLVD) in 85+ year Olds 
 
* SLVD figures are shown in bold font. 
 
 
  NORMAL 
ISOLATED DIASTOLIC 
DYSFUNCTION SYSTOLIC DYSFUNCTION TOTAL 
 Male Female Total Male Female Total Male Female Total  
NYHA 1 18 (48.6) 36 (49.3) 54 (49.1) 9 (64.3) 5 (9.8) 14 (38.9) 29 (50.0) 21 (28.4) 50 (29.9) 118 (34.0) 
NYHA 2 15 (40.5) 32 (43.8) 47 (42.7) 3 (21.4)* 10 (19.6) 13 (36.1) 20 (34.5) 38 (51.4) 58 (34.7) 118 (34.0) 
NYHA 3 4 (10.8) 5 (6.8) 9 (8.2) 2 (3.9) 7 (13.7) 9 (25.0) 9 (15.5) 15 (20.3) 24 (14.4) 42 (12.1) 
NYHA 4 
 
 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Total 37 (33.6) 73 (66.3) 110 (39.6) 14 (33.3) 22 (66.7) 36 (12.9) 58 (43.9) 74 (56.1) 132 (47.5) 278 (100) 
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7.3 Extent of Undiagnosed Symptomatic Left Ventricular Dysfunction (SLVD) 
37.4% participants (n=104; 32.7% men & 67.3% women) who had no formal 
diagnosis of heart failure were symptomatic with NYHA class II or above and had 
underlying isolated diastolic dysfunction (7.9%, n=22) or systolic dysfunction 
(29.5%, n=82). Five participants with known diagnosis of HF (23.8%, 5/21 ) had no 
echocardiographic evidence of underling systolic or diastolic dysfunction. (Table 7.6)
161 
 
 
 
Table 7.6:  Extent of Un-Diagnosed and Mis-Diagnosed Symptomatic Left Ventricular Dysfunction (SLVD) 
 
  
NO PRE-EXISTING HEART FAILURE DIAGNOSIS 
  Normal Isolated Diastolic Dysfunction Systolic Dysfunction Total 
 Male Female Total Male Female Total Male Female Total  
NYHA 1 18 (50.0) 34 (49.3) 52 (49.5) 9 (64.3) 5 (22.7) 14 (38.9) 26 (49.1) 20 (31.7) 46 (39.7) 112 (43.6) 
NYHA 2 14 (38.9) 31 (44.9) 45 (42.9) 3 (21.4) 10 (45.4) 13 (36.1) 19 (35.8) 34 (54.0) 53 (45.7) 111 (43.2) 
NYHA 3 4 (11.1) 4 (5.8) 8 (7.6) 2 (14.3) 7 (32.8) 9 (25.0) 8 (15.1) 9 (14.3) 17 (14.6) 34 (13.2) 
NYHA 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 36 (34.3) 69 (65.7) 105 (40.9) 14 (38.9) 22 (61.1) 36 (14.0) 53 (45.7) 63 (54.3) 116 (45.1) 257 (100) 
  
 PRE-EXISTING HEART FAILURE DIAGNOSIS 
  Normal Isolated Diastolic Dysfunction Systolic Dysfunction Total 
 Male Female Total Male Female Total Male Female Total  
NYHA 1 0 (0.0) 2 (50.0) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (60.0) 1 (9.1) 4 (25.0) 6 (28.5) 
NYHA 2 1 (100.0) 1 (25.0) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 4 (36.4) 5 (31.2) 7 (33.3) 
NYHA 3 0 (0.0) 1 (25.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 6 (54.5) 7 (43.8) 8 (38.1) 
NYHA 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 1 (20.0) 4 (80.0) 5 (23.8) 0(0.0) 0 (0.0) 0 (0.0) 5 (31.2) 11 (68.8) 16 (76.2) 21 (100) 
*SLVD figures are shown in bold font 
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7.4 Prevalence of Valvular Heart Disease and Echocardiographic Characteristics of 
85+ Years Old 
 
Valvular heart disease was not very common in 85+ year olds. Moderate and severe 
aortic stenosis (AS) were present in 1.8% (7/382) and 0.3% (1/382) of participants 
respectively. Moderate aortic regurgitation (AR) was present in 5.5% (21/382) 
participants. Moderate and severe mitral stenosis (MS) was very rare and present in 
0.3% (1/376) participants. Moderate mitral regurgitation was present in 6.6% (25/378) 
participants. Moderate tricuspid regurgitation (TR) was the most common valvular 
pathology in 85+ year olds. Moderate TR was present in 17.6% (65/369) participants. 
Severe TR was present in 0.8% (3/369) participants. (Table 7.7) 
Table 7.8 shows the echocardiographic characteristics of 85+ year olds. Majority of the 
participants (90.1%, 337/374) had normal sized left ventricular size (LVIDd). Left 
ventricle (LV) was moderately or severely dilated in 3.5% (13/374) and 0.3% (1/374) 
participants respectively. LV systolic function was moderately or severely impaired in 
16.8% (66/398) and 2.8% (11/398) participants respectively. 9.6% (26/270) and 33.0% 
(89/370) participants exhibit moderate and severe LV hypertrophy (LV mass) 
respectively. Right ventricular (RV) structure and function was normal in majority of 
participants. Only 2.3 % (6/266) participants had moderate or severely dilated RV, 
whereas 93.7% (325/347) participants had normal RV systolic function. 12.8% (42/343) 
and 11.3% (29/257) had moderate or severely dilated left atrium (LA) and right atrium 
(RA) respectively. 
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Table 7.7 Prevalence of Valvular Heart Disease in 85+ year olds. 
      
   Men (n, %) Women (n, %) Total (n, %) 
Aortic Stenosis (AS)       
  no AS   132 (38.3) 213 (61.7) 345 (90.3) 
  mild AS   11 (37.9) 18 (62.1) 29 (7.6) 
  moderate AS   3 (42.9) 4 (57.1) 7 (1.8) 
  severe AS   0 (0.0) 1 (100) 1 (0.3) 
     146 (38.2) 236 (61.8) 382 (100) 
Aortic Regurgitation (AR)       
  no AR   100 (37.0) 170 (63.0) 270 (70.7) 
  mild AR   39 (42.9) 52 (57.1) 91 (23.8) 
  moderate AR   6 (28.6) 15 (71.4) 21 (5.5) 
  severe AR   0 (0.0) 0 (0.0) 0 (0.0) 
    145 (38.0) 237 (62.0) 382 (100) 
Mitral Stenosis (MS)       
  no MS   142 (38.4) 228 (61.6) 370 (8.4) 
  mild MS   1 (25.0) 3 (75.0) 4 (1.1) 
  moderate MS   0 (0.0) 1 (100) 1 (0.3) 
  severe MS   1 (100) 0 (0.0) 1 (0.3) 
     144 (38.3) 232 (61.7) 376 (100) 
Mitral Regurgitation (MR)       
  no MR   89 (42.0) 123 (58.0) 212 (56.1) 
  mild MR   48 (34.0) 93 (66.0) 141 (37.3) 
  moderate MR   8 (32.0) 17 (68.0) 25 (6.6) 
  severe MR   0 (0.0) 0 (0.0) 0 (0.0) 
    145 (38.4) 233 (61.6) 378 (100) 
Tricuspid Regurgitation (TR)       
  no TR   58 (40.6) 85 (59.4) 143 (38.8) 
  mild TR   54 (34.2) 104 (65.8) 158 (42.8) 
  moderate TR   26 (40.0) 39 (60.0) 65 (17.6) 
  severe TR   0 (0.0) 3 (100) 3 (0.8) 
     138 (37.4) 231 (62.6) 369 (100) 
Pulmonary Regurgitation (PR)       
  no PR   90 (39.5) 138 (60.5) 228 (83.2) 
  mild PR   12 (31.6) 26 (68.4) 38 (13.9) 
  moderate PR   4 (50.0) 4 (50.0) 8 (2.9) 
  severe PR 0 (0.0) 0 (0.0) 0 (0.0) 
   106 (38.7) 168 (61.3) 274 (100) 
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Table 7.8: Echocardiographic characteristics of 85+ years old 
  
    Men (n, %) Women (n,%) Total (n, %) 
Right Ventricular Function         
  Normal  120  (36.9) 205 (63.1) 325 (93.7) 
  Mild Impairment 11 (61.1) 7 (38.9) 18 (5.2) 
  Moderate Impairment 1 (25.0) 3 (75.0) 4 (1.2) 
  Severe Impairment 0 (0.0) 0 (0.0) 0 (0.0) 
    132 (38.0) 215 (62.0) 347 (100) 
Left Ventricular Function         
  Normal  65 (32.8) 133 (67.2) 198 (50.3) 
  Mild Impairment 48 (40.3) 71 (59.7) 119 (30.2) 
  Moderate Impairment 34 (51.5) 32 (48.5) 66 (16.8) 
  Severe Impairment 9 (81.8) 2 (18.2) 11 (2.8) 
    156 (39.7) 238 (60.4) 394 (100) 
Right Atrial Size         
  Normal 61 (30.0) 142 (70.0) 203 (79.0) 
  Mildly dilated 14 (56.0) 11 (44.0) 25 (9.7) 
  Moderately dilated 12 (57.0) 9 (43.0) 21 (8.2) 
  Severely dilated 4 (50.0) 4 (50.0) 8 (3.1) 
    91 (35.4) 166 (64.6) 257 (100) 
Left Atrial Size         
  Normal 93 (33.7) 183 (66.3) 276 (80.5) 
  Mildly dilated 10 (27.0) 13 (73.0) 23 (6.7) 
  Moderately dilated 22 (59.0) 15 (41.0) 37 (10.8) 
  Severely dilated 3 (43.0) 4 (57.0) 7 (2.0) 
    128 (37.3) 215 (62.7) 343 (100) 
Right Ventricular Size         
  Normal 70 (31.7) 151 (69.3) 221 (83.1) 
  Mildly dilated 21 (53.8) 18 (46.2) 39 (14.7) 
  Moderately dilated 2 (40.0) 3 (60.0) 5 (1.9) 
  Severely dilated 1 (100) 0 (0.0) 1 (0.4) 
    94 (35.3) 172 (64.7) 266 (100) 
Left Ventricular Size (LVIDd)         
  Normal 133 (39.5) 204 (60.5) 337 (90.1) 
  Mildly dilated 3 (13.0) 20 (87.0) 23 (6.0) 
  Moderately dilated 7 (53.8) 6 (46.2) 13 (3.5) 
  Severely dilated 0 (0.0) 1 (100) 1 (0.3) 
    143 (38.2) 231 (61.8) 374 (100) 
Left Ventricular mass         
  Normal 42 (38.5) 67 (61.5) 109 (40.4) 
  Mild 13 (28.3) 33 (71.7) 46 (17.0) 
  Moderate 15 (57.7) 11 (42.3) 26 (9.6) 
  Severe 29 (32.6) 60 (67.4) 89 (33.0) 
    99 (36.7) 171 (63.3) 270 (100) 
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7.5 Use of Heart Failure Medication In those with Pre-Existing Heart Failure 
Diagnosis 
Of those with a pre-existing diagnosis of heart failure in the general practice medical 
records: 73.7% (28/38) were taking a diuretic; 71.1% (27/38) an angiotensin converting 
enzyme inhibitor or angiotensin II receptor blocker; 34.2% (13/38) a beta blocker; 
23.7% (9/38) an angiotensin converting enzyme inhibitor/angiotensin II receptor blocker 
in combination with a beta blocker; and 18.4% (7/38) a cardiac glycoside. No 
statistically significant gender differences were found in the use of heart failure 
medication (p values all greater than 0.05).   
 
7.6 Exclusion of Cases With Significant Intrinsic Lung Disease 
Spirometric criteria for significant intrinsic lung disease were met by 9.6% (36/376) of 
participants and an additional 1.3% (5/376) did not have spirometry data. A sensitivity 
analysis excluding these cases resulted in prevalence rates for LV systolic and diastolic 
dysfunction and levels of undiagnosed dysfunction which matched to within 2% of the 
figures reported for the whole sample.  
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7.7 Cardiac Dysfunction And Arterial Stiffness 
Participants with LV systolic dysfunction had higher carotid-femoral PWV (10.77 ± 
2.06 m/sec) and LV mass index (113.44 ± 34.3) as compared to people with normal 
systolic function, but it was not statistically different. CIMT was significantly higher in 
patients with LV systolic dysfunction (p = 0.04). Participants with LV diastolic 
dysfunction also had stiffer arteries as compared to participants with no diastolic 
dysfunction with PWV 10.75 ± 1.97 m/sec. Participants with diastolic dysfunction also 
had higher augmentation index, augmentation pressure and central systolic blood 
pressure as compared to participants with normal diastolic function, but it was also not 
statistically significant. (Table 7.9 & 7.10) 
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Table 7.9                                                         Markers of vascular stiffness and systolic function 
 SYSTOLIC FUNCTION  
Variables No Yes  
 Mean SD Mean SD p Value 
Pulse wave velocity (PWV) 10.70 1.84 10.77 2.06 0.79 
Ankle brachial index (ABI) Left 1.06 0.21 1.11 0.21 0.12 
Ankle brachial index (ABI) Right 1.08 0.20 1.10 0.24 0.37 
Peripheral Systolic Blood Pressure (P-SBP) 157.38 18.65 156.13 20.07 0.59 
Peripheral Diastolic Blood Pressure (P-DBP) 72.22 10.35 74.42 11.26 0.09 
Augmentation Pressure (AG) 25.90 10.92 24.02 10.56 0.14 
Augmentation Pressure @ 75 22.32 8.45 20.33 9.38 0.06 
Augmentation Index (AGPH) 34.88 9.44 34.09 10.43 0.72 
Augmentation Index @ 75 31.73 9.19 30.44 10.37 0.16 
Central Systolic Blood Pressure (C-SBP) 145.28 19.31 143.80 19.80 0.54 
Central Diastolic Blood Pressure (C-DBP) 73.31 10.66 75.39 11.43 0.11 
Central Pulse Pressure (C-PH) 71.92 15.85 68.41 16.37 0.06 
SEVR 123.73 23.26 134.44 31.31 0.001* 
LV Mass Index (BSA) 107.27 29.72 113.44 34.87 0.94 
CIMT Mean Left Posterior 0.83 0.18 0.87 0.20 0.04* 
CIMT Mean Right Posterior 0.83 0.16 0.82 0.16 0.35 
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Table 7.10                                                              Markers of vascular stiffness and diastolic function 
 DIASTOLIIC FUNCTION  
Variables No Yes  
 Mean SD Mean SD p Value 
Pulse wave velocity (PWV) 10.68 1.90 10.92 2.14 0.42 
Ankle brachial index (ABI) Left 1.10 0.21 1.03 0.21 0.10 
Ankle brachial index (ABI) Right 1.10 0.22 1.05 0.20 0.10 
Peripheral Systolic Blood Pressure (P-SBP) 156.07 19.07 161.07 20.92 0.06 
Peripheral Diastolic Blood Pressure (P-DBP) 72.52 10.67 75.33 11.39 0.06 
Augmentation Pressure (AG) 24.84 10.31 26.97 11.74 0.14 
Augmentation Pressure @ 75 21.46 8.51 22.77 9.75 0.28 
Augmentation Index (AGPH) 34.29 9.31 36.15 10.56 0.16 
Augmentation Index @ 75 31.16 9.18 32.47 10.44 0.31 
Central Systolic Blood Pressure (C-SBP) 143.92 19.39 149.00 20.54 0.06 
Central Diastolic Blood Pressure (C-DBP) 73.61 10.97 76.33 11.50 0.07 
Central Pulse Pressure (C-PH) 70.31 15.93 72.67 17.32 0.29 
SEVR 127.05 22.74 127.64 34.34 0.86 
LV Mass Index (BSA) 110.49 31.80 109.49 33.82 0.82 
CIMT Mean Left Posterior 0.85 0.20 0.83 0.19 0.38 
CIMT Mean Right Posterior 0.99 0.21 1.01 0.18 0.73 
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7.8 ‘Normal Value’ For Plasma NT-proBNP In ‘Healthy 85+ Year Old Community 
Dwelling Participants 
Participants were considered clinically normal when they had no history of ischaemic heart 
disease (no angina, myocardial infarction, coronary intervention and coronary artery bypass 
graft), hypertension, or renal disease; had no diabetes; had normal ECG (no definite changes 
for IHD; had normal echocardiograms for systolic and diastolic function; and were in normal 
sinus rhythm. 
27 participants (9 males, 18 females) were considered ‘normal and healthy’ 85+ year old 
community dwelling individuals. Mean (SD) and median (IQR) values of NT-proBNP in 
‘normal and healthy’ 85+ year old cohort are 189±140 pg/mL and 163 (108) pg/mL 
respectively. There was no significant gender difference in NT-proBNP levels. (Table 7.11) 
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*two means were compared with indpendent t test, while medians were compared with Mann-Whitney Test 
Table 7.11            ‘NORMAL VALUE’ for Plasma NT-proBNP in ‘Healthy’ 85+ years old 
All n 
Mean (SD) 
pg/mL 
95% CI 
mean 
Median (IQR) 
pg/mL 
95% CI 
median 
p value 
(mean,median)* 
All 27 189 (140) 133-244 168 (107) 111-200 
0.42, 0.68 Males 9 157 (84) 92-201 180 (125) 65-206 
Females 18 204 (161) 124-284 163 (158) 109-239 
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Figure 7.1: Box plot for the comparison of medians for NT-proBNP values in 
males and females 
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7.9 Association Between Left Ventricular Function and Plasma NT-ProBNP In          
85+ Years Old 
Both echocardiographic data on LV systolic function and NT-proBNP levels both were 
available in 364 participants. We reported mean NT-proBNP levels of 324 ± 275 pg/mL in 
participants with normal LV systolic function (LVEF ≥55%), which significantly increases 
with progression of LV systolic dysfunction (p <0.00001). Table 7.12 
Both echocardiographic data on LV diastolic function and NT-proBNP levels both were 
available in 354 participants. We reported mean NT-proBNP levels of 355 ± 333 pg/mL in 
participants with normal LV diastolic function (LVEF ≥55%), which significantly increases 
with impairment of LV diastolic function (p <0.00001). Table 7.12 
345 participants had echocardiographic data on LV systolic and diastolic function and NT-
proBNP level available. Plasma NT-proBNP levels were 280 ± 240 pg/mL in 131 (39.8%) 
participants in whom no underlying LV systolic and diastolic dysfunction (No SD, No DD) 
was noted. However, a significant rise in NT-proBNP levels was noted in people with 
isolated diastolic dysfunction (No SD, Yes DD) and Systolic dysfunction (Yes SD ± DD). 
Table 7.12 
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Table 7.12         Association of Left Ventricular Function (LVF) with NT-proBNP  in 85+ years old 
Systolic Function 
n   Mean (pg/mL) SD 
      p (ANOVA) 
Normal 
190 324.1 275.1 
<0.00001 
Mild impairment 
110 487.2 462.1 
Moderate impairment 
54 608.0 411.2 
Severe impairment 
10 721.6 573.2 
 
   
 
Diastolic Function 
n Mean (pg/mL) SD 
     p (ANOVA)    
Normal 
248 355.3 333.1 
<0.00001 
Impaired(Moderate/Severe) 
106 537.8 451.3 
 
   
 
LV Systolic/Diastolic Function n Mean (pg/mL) SD p (ANOVA)    
No SD, No DD (normal) * 131 281.1 240.2 
<0.00001 
No SD, Yes DD (isolated DD) 52 415.6 327.7 
Yes SD, No DD  111 452.6 403.1 
Yes SD, Yes DD  51 675.2 528.4 
 
*SD = Systolic dysfunction, DD = Diastolic dysfunction 
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7.10 Association Between NT-ProBNP and The Severity of Symptoms Suggestive of 
Heart Failure 
Plasma NT-proBNP levels and NYHA functional status of dysponea both was available in 
307 participants. Plasma NT-proBNP levels were 476 ± 676 pg/mL in 124 (40 %) 
participants with no symptoms of shortness of breath (NYHA I). we reported a significant 
rise in NT-proBNP levels with worsening NYHA functional status with NT-proBNP levels of 
1057 476 ± 1918 pg/mL in people with NHYA function class III. Table 7.13 
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Table 7.13        Association between NYHA functional status and NT-proBNP in 85+ years 
old 
NYHA functional status n Mean (pg/mL) SD p (ANOVA) 
NYHA I 124 476.0 676.2 
0.0017 
NYHA II 124 527.4 671.6 
NYHA III  49 1057.1 1918.8 
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7.11     Association Between Markers Of Arterial Stiffness And Plasma NT-proBNP in 
85+  Year Olds 
Plasma NT-proBNP levels and data on pulse wave velocity (PWV) were available in 226. 
There was no significant correlation between PWV and NT-proBNP levels (Pearson 
correlation = 0.24, p = 0.72). NT-proBNP levels also didn’t change significantly with 
increasing tertiles of PWV.  
Plasma NT-proBNP levels and data on Augmentation Index (AIx) and Augmentation 
pressure (AP) were available in 278 participants.. There was no significant correlation 
between AIx levels (Pearson correlation = 0.04, p = 0.42) or AP levels (Pearson correlation = 
0.02, p = 0.77) and plasma NT-proBNP. NT-proBNP levels also didn’t change significantly 
with increasing tertiles of AIx or AP. Table 7.14 
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Table 7.14       Association between arterial Pulse Wave Velocity (PWV) and NT-proBNP in  
                        85+ years old 
Pulse Wave Velocity (PWV) n   Mean (pg/mL) SD       p (ANOVA) 
Lower Tertile 71 378 352 
0.74 Middle Tertile 71 360 316 
Upper Tertile 74 403 351 
Augmentation Pressure n   Mean (pg/mL) SD       p (ANOVA) 
Lower Tertile 90 383 350 
0.94 Middle Tertile 97 388 361 
Upper Tertile 91 399 332 
Augmentation Index n   Mean (pg/mL) SD       p (ANOVA) 
Lower Tertile 88 361 298 
0.62 Middle Tertile 98 407 413 
Upper Tertile 92 391 315 
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7.12  Association Between Peripheral Vascular Disease (PVD) and NT-proBNP in 85+ 
Years Olds 
Participants with ankle brachial index (ABI) less than 0.9 were considered to have PVD. ABI 
assessment and plasma NT-proBNP levels were available in 242 participants. Plasma NT-
proBNP levels were significantly higher in participants with PVD (465 ± 334 pg/mL, p value 
= 0.05) as compared to participants with no PVD .Out of 242 participants  88 participants had 
no underlying systolic or diastolic dysfunction on echocardiographic assessments. Even in 
this group levels of plasma NT-proBNP were significantly higher in participants with PVD. 
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Table 7.15           Association of Peripheral Vascular Disease (PVD) with NT-proBNP in  
                            85+ years old 
Peripheral Vascular Disease n Mean (pg/mL) SD      P value    
No PVD 191 362.5 319 
0.05 
Definite PVD 51 465.1 334 
     
After adjusting for Systolic and diastolic function  
Peripheral Vascular Disease n Mean (pg/mL) SD      p value   
No PVD 71 235 174 
0.03 
Definite PVD 17 344 232 
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7.13  Diagnostic Performance of NT-proBNP in Detection of Left Ventricular 
Dysfunction In 85+ Year Olds 
With the aim of evaluating the diagnostic potential of NT-proBNP in 85+ years old 
population to detect left ventricular functional abnormalities, we classified people in 
following 4 groups. 
A- Left ventricular systolic dysfunction (LVSD) 
B- Left ventricular systolic/diastolic dysfunction (LVD – any) 
C- Symptomatic Left ventricular systolic dysfunction (SLVD – systolic) 
D- Symptomatic Left ventricular / diastolic dysfunction (SLVD – any) 
LVSD group had underling LV systolic dysfunction, LVD – (any) group included people 
with either underlying LV systolic and or moderate-severe diastolic dysfunction, SLVD – 
systolic group included people with underlying systolic dysfunction with symptom of 
breathlessness (NYHA II / III) and SLVD – (any) group included people with underling 
systolic or moderate to severe diastolic dysfunction with symptoms of breathlessness (NYHA 
II / III). Based on the severity of underlying systolic dysfunction (LVEF <55%, LVEF <45% 
and LVEF <35%) each group was further sub-divided in to three subgroups and NT-proBNP 
performance to detect these abnormalities was tested separately for each group. We did not 
perform separate ROC curve analysis for different gender because there was no statistical 
difference between normal values of NT-proBNP between them. 
NT-proBNP level of 725 pg/mL can detect LVSD (LVEF <55%) with sensitivity 33%, 
specificity 93% and area under the curve (AUC, 95%CI) is 0.67 (0.64-0.78). However the 
performance of NT-proBNP to detect LVSD at lower cut-off (LVEF<45%) increases with 
area under the curve 0.74 (0.68-0.77). For detection of LVSD (LVEF <45%) an NT-proBNP 
level of 285% has sensitivity 80.5%, specificity 55% and NPV 92%. (Table 7.16, Figure 7.2-
7.4) 
For detection of any LV dysfunction (LVEF <55% ± moderate-severe diastolic dysfunction), 
ROC curve analysis provided NT-proBNP cut-off value 386 pg/mL with AUC = 0.68. This 
level has sensitivity 0f 49.8%, specificity 78%, NPV 47% and PPV 79.9%. However the 
performance of NT-proBNP to detect LVD at lower cut-off (LVEF<45% ± moderate – severe 
diastolic dysfunction) increases with area under the curve 0.70 (0.50-0.65). For detection of 
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LVD (LVEF <45%) an NT-proBNP level of 413 pg/mL has sensitivity 58%, specificity 80% 
and NPV 69.3%. (Table 7.17, Figure 7.5-7.7) 
For detection of symptomatic LV systolic dysfunction (SLVD- systolic; LVEF <55% and 
NYHA II/III), ROC curve analysis provided NT-proBNP cut-off value 445 pg/mL with AUC 
= 0.64 (0.56-0.72). This level has sensitivity 0f 50.6%, specificity 80%, NPV 59% and PPV 
74%. However the performance of NT-proBNP to detect SLVD (systolic) at lower cut-off 
(LVEF<45%) increases with area under the curve 0.71 (0.63-0.78). For detection of SLVD-
systolic (LVEF <45%) an NT-proBNP level of 399 pg/mL has sensitivity 70%, specificity 
70% and NPV 88.4%. (Table 7.18, Figure 7.8-7.10) 
For detection of any symptomatic LV dysfunction (SLVD- any; LVEF <55% ± moderate-
severe diastolic dysfunction and NYHA II/III), ROC curve analysis provided NT-proBNP 
cut-off value 442 pg/mL with AUC = 0.68 (0.60-0.75). This level has sensitivity 0f 49%, 
specificity 88%, NPV 45% and PPV 89.5%. However the performance of NT-proBNP to 
detect SLVD (systolic) at lower cut-off (LVEF<45%) increases with area under the curve 
0.72 (0.64-0.79). For detection of any SLVD (LVEF <45% ± moderate – severe diastolic 
dysfunction and NYHA II/III) an NT-proBNP level of 389 pg/mL has sensitivity 61%, 
specificity 78% and NPV 70.1%. (Table 7.19, Figure 7.11-7.13) 
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*Cut point of NT-proBNP which gives highest accuracy. 
ϯNote the limited number of subjects with LVEF <35% in this subgroup. 
AUC = area under curve, PPV = positive predictive value, NPV = negative predictive value 
 
 
Table 7.16       Test Characteristics for NT-proBNP for the detection of Left Ventricular Systolic Dysfunction (LVSD) in 85+ year old 
                              population 
Population 
LVEF 
 cut-off 
n 
Positive 
group 
AUC (95% CI) Cut point* Sensitivity (95% CI) Specificity (95% CI) PPV NPV 
All <55% 385 192 0.67 (0.64-0.78) 725 32.8 (26.2 - 39.9) 92.8 (88.1 - 96.0) 81.8 58.1 
 <45% 385 77 0.74 (0.68-0.77) 285 80.5 (69.9 - 88.7) 54.9 (49.1 - 60.5) 30.8 91.8 
 <35% 385 12 0.69 (0.64-0.73) 830 58.3 (27.7 - 84.8) 83.9 (79.8 - 87.5) 10.4 96.4 
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Figure 7.2: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting LVSD (LVEF ≤55%) for entire cohort. 
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Figure 7.3: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting LVSD (LVEF ≤45%) for entire cohort. 
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Figure 7.4: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting LVSD (LVEF ≤35%) for entire cohort. 
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Table 7.17       Test Characteristics for NT-proBNP for the detection of Left Ventricular Systolic/Diastolic Dysfunction (LVD -any) in 85+ 
                               year old population 
Population 
LVEF  
cut-off 
n Positive group AUC (95% CI) Cut point* Sensitivity (95% CI) Specificity (95% CI) PPV NPV 
All <55% +/  DD 363 231 0.68 (0.63-0.73) 386 49.8 (43.2 - 56.4) 78.0 (70.0 - 84.8) 79.9 47.0 
 <45% +/ DD 375 168 0.70 (0.65-0.74) 413 58.1 (50.2 - 65.7) 80.0 (69.6 - 81.6) 66.8 69.3 
 <35% +/ DD 369 124 0.64 (0.59-0.69) 413 58.4 (45.7 - 63.8) 69.8 (63.6 - 75.5) 47.9 75.3 
 
*Cut point of NT-proBNP which gives highest accuracy. 
AUC = area under curve, PPV = positive predictive value, NPV = negative predictive value 
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Figure 7.5: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting Left ventricular dysfunction-LVD 55 (LVEF 
≤55% & or any moderate-severe diastolic dysfunction) for entire cohort. 
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Figure 7.6: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting an Left ventricular dysfunction-LVD 45 (LVEF 
≤45% & or any moderate-severe diastolic dysfunction) for entire cohort. 
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Figure 7.7: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting an Left ventricular dysfunction-LVD 35 (LVEF 
≤35% & or any moderate-severe diastolic dysfunction) for entire cohort. 
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Table 7.18           Test Characteristics for NT-proBNP for the detection of Symptomatic Left Ventricular Systolic Dysfunction (SLVD - Systolic) in 85+  
                             year old population 
Population 
LVEF 
cut-off 
n 
Positive 
group 
AUC (95% CI) Cut point* Sensitivity (95%CI) Specificity (95% CI) PPV NPV 
All <55% 156 83 0.64 (0.56-0.72) 445 50.6  (39.4 - 61.8) 79.5 (68.4 - 88.0) 73.7 58.6 
 <45% 156 36 0.71 (0.63-0.78) 399 69.4 (51.9 - 83.7) 69.4 (60.4 - 77.5) 40.3 88.4 
 <35% 156 3 ϯ 0.71 (0.64-0.78) 830 66.7 (9.4 - 99.2) 82.5 (75.5 - 88.1) 6.9 99.2 
 
*Cut point of NT-proBNP which gives highest accuracy. 
ϯNote the limited number of subjects with LVEF <35% in this subgroup. 
AUC = area under curve, PPV = positive predictive value, NPV = negative predictive value 
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Figure 7.8: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting a Symptomatic Left ventricular systolic 
dysfunction-SLVD  55 (LVEF ≤55% & NYHA 2/3) for entire cohort. 
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Figure 7.9: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting a Symptomatic Left ventricular systolic 
dysfunction-SLVD  45 (LVEF ≤45% & NYHA 2/3) for entire cohort. 
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Figure 7.10: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting a Symptomatic Left ventricular systolic 
dysfunction-SLVD  35 (LVEF ≤35% & NYHA 2/3) for entire cohort. 
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Table 7.19      Test Characteristics for NT-proBNP for the detection of Symptomatic Left Ventricular Dysfunction ((SLVD – any) 85+ year old                     
                       population 
Population 
LVEF 
 cut-off 
n 
Positive 
group 
AUC (95% CI) Cut point* Sensitivity (95% CI) Specificity (95% CI) PPV NPV 
All <55% +/  DD 155 105 0.68 (0.60-0.75)  442 48.6 (38.7 - 58.5) 88.0 (75.7 - 95.5) 89.5 44.9 
 <45% +/ DD 151 70 0.72 (0.64-0.79) 389 61.4 (49.0 - 72.8) 77.8 (67.2 - 86.3) 70.5 70.1 
 <35% +/ DD 150 51 0.68 (0.60-0.75) 389 58.8 (44.2 - 72.4) 69.7 (59.6 - 78.5) 50.0 76.7 
 
*Cut point of NT-proBNP which gives highest accuracy. 
ϯNote the limited number of subjects with LVEF <35% in this subgroup. 
AUC = area under curve, PPV = positive predictive value, NPV = negative predictive value 
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Figure 7.11: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting a any Symptomatic Left ventricular 
dysfunction-SLVD 55 (LVEF ≤55%  & or moderate – severe diastolic dysfunction & NYHA 2/3) for entire cohort. 
196 
 
 
 
NTproBNP - SLVD 45 (any)
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
S
e
n
si
ti
v
it
y
 Sensitivity: 61.4
 Specificity: 77.8
 Criterion : >389
Figure 7.12: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting a any Symptomatic Left ventricular 
dysfunction-SLVD 45 (LVEF ≤45%  & or moderate – severe diastolic dysfunction & NYHA 2/3) for entire cohort. 
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Figure 7.13: The receiver operating characteristic (ROC) curves of NT-proBNP for detecting a any Symptomatic Left ventricular 
dysfunction-SLVD (LVEF ≤35%  & or moderate – severe diastolic dysfunction & NYHA 2/3) for entire cohort. 
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Chapter 8: Atrial Fibrillation and Peripheral Vascular Disease 
 
8.1 Atrial fibrillation: Prevalence and extent of under-diagnosis 
109 participants (25.5%) had atrial fibrillation (AF). 49 participants (49/167 =29.3%) 
were males and 60 (60/260 = 23.0%) were females. We did not find any significant 
gender difference in the prevalence of atrial fibrillation/ paroxysmal atrial fibrillation 
(odds ratio [95% confidence interval] males: females 1.38 [0.87 to 2.20]; p=0.17). 
53.2% (58/109 participants) of these participants had no previous GP diagnosis of AF. 
Atrial fibrillation was significantly more common in participants with heart failure 
(OR [95%CI]; 2.32 ,[1.11-4.82], p = 0.01), ischaemic heart disease (1.70 [1.06-2.74], 
p = 0.02) and any atherosclerotic disease (1.77 [1.11-2.81], p = 0.01). There was a 
suggestion that it was commoner.in people with hyperthyroidism (2.14 [0.58-7.69]), 
although it was not statistically significant and very few people had hyperthyroidism 
in our cohort.. (Table 8.1) 
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Table 8.1  Characteristics of People with Atrial Fibrillation and Sinus Rhythm 
Variables  Sinus Rhythm AF OR (95% CI) p- value 
Gender      
 Male 118 49 
1.38 (0.87-2.20) 0.15 
 Female 200 60 
Heart Failure      
 No  296 93 
2.32 (1.11-4.82) *0.01 
 Yes 22 16 
Hypertension      
 No 134 50 
0.86 (0.54-1.36) 0.49 
 Yes 184 59 
Diabetes      
 No 276 95 
0.96 (0.48-1.93) 0.92 
 Yes 42 14 
IHD      
 No 225 64 
1.70 (1.06-2.74) *0.02 
 Yes 93 45 
CVD      
 No 263 83 
1.50 (0.85-2.62) 1.13 
 Yes 55 26 
Atherosclerotic disease      
 No 182 47 
1.77 (1.11-2.81) *0.01 
 Yes 136 62 
Hyperthyroid      
 No 311 104 
2.14(0.58-7.69) 0.19 
 Yes 7 5 
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8.2 Stroke Risk Stratification and Thromboprophylaxis 
72.4% (n=80) participants with AF were CHADS2 score 2 or greater. 37 (33.9%) 
participants were CHADS2 score 3 or more.  (Table 8.2) Our entire cohort being 
above 75 years of age was CHA2DS2-VASc score 2 or above. 87.2% participants 
(n=95) with AF were CHA2DS2-VASc score 3 or above (Table 8.3). It is obvious 
that majority of our cohort with AF have higher CHADS2 or CHA2DS2-VASc score 
and fall in high risk category for thromboembolism or stroke according to NICE 
guidance for AF management published in 2006. [274] 
In our cohort only 13.8% (n=15) participants with CHADS2 score 2 or above were 
taking warfarin (Table 8.4). In our cohort only 15.6% (n=17) participants with 
CHA2DS2-VASc score 2 or above were taking warfarin.  84.4% (92) participants 
with AF, who were not on warfarin, only 42.4% participants (n=39/92) were either on 
aspirin (n=33) or clopidogrel (n=5). Only one participant was on a combination of 
aspirin and dipyridamol. (Table 8.5) 
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Table 8.2 CHADS2 score in patients with Atrial Fibrillation (AF) 
CHADS2 score 1 2 3 4 5 6  
Male (n) 16 19 5 6 3 0 49 
Female (n) 13 24 13 9 1 0 60 
 29 43 18 15 4 0 109 
 
 
 
 
Table 8.3   CHA2DS2-VASc Score in patients with Atrial Fibrillation (AF) 
CHA2DS2-
VASc Score 
2 3 4 5 6 7 8  
Male (n) 14 15 10 7 1 2 0 49 
Female (n) 0 10 23 14 8 4 1 60 
 14 25 33 21 9 6 1 109 
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Table 8.4   CHADS2 Score and thromboprophylactic medications 
CHA2DS2 
Score 
 1 2 3 4 5 6  
Warfarin Yes 
(n) 
2 8 3 4 0 0 17 
 No 
(n) 
30 39 9 13 1 0 92 
  32 47 12 17 1 0 109 
         
Aspirin Yes 
(n) 
7 13 6 8 0 0 34 
 No 
(n) 
25 34 6 9 1 0 75 
  32 47 12 17 1 0 109 
         
Clopidogrel Yes 
(n) 
1 3 1 0 0 0 5 
 No 
(n) 
31 44 11 17 1 0 104 
  32 47 12 17 1 0 109 
         
Dipyridamol Yes 
(n) 
0 1 0 0 0 0 1 
 No 
(n) 
32 46 12 17 1 0 107 
  32 47 12 17 1 0 109 
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Table 8.5 CHA2DS2-VASc Score and thromboprophylactic medications 
CHA2DS2-VASc 
Score 
 2 3 4 5 6 7 8  
Warfarin Yes (n) 1 5 5 5 0 1 0 17 
 No (n) 14 22 29 16 6 5 0 92 
  15 27 34 21 6 6 0 109 
          
Aspirin Yes (n) 3 5 12 7 4 3 0 34 
 No (n) 12 22 22 14 2 3 0 75 
  15 27 34 21 6 6 0 109 
          
Clopidogrel Yes (n) 0 1 3 1 0 0 0 5 
 No (n) 15 26 31 20 6 6 0 104 
  15 27 34 21 6 6 0 109 
          
Dipyridamol Yes (n) 0 0 1 0 0 0 0 1 
 No (n) 15 27 33 21 6 6 0 108 
  15 27 34 21 6 6 0 109 
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8.3 Prevalence of Peripheral Vascular Disease (PVD) 85+ Study Cohort 
ABI was available in 263 (61.6%) participants and had a mean value of 1.083 ± 0.21. 
It was significantly lower (p<0.005) in females (1.05 ± 0.19; n=147) than males (1.12 
± 0.23; n=116). Participants were categorised into the following four categories based 
on their ABI values.  
a. Definite PVD (<0.9) 
b. Borderline PVD (>= 0.9 - <1.0) 
c. Low normal ABI (>=1.0 - <=1.1) 
d. Normal or No PVD (>1.10) 
22.1% participants (n=58) had definite PVD. There was no significant gender 
difference in prevalence of PVD (13.3%, n=35) and males (8.7%, n=23).  Odds ratio 
[95% confidence interval] female: male 1.26 [0.67 to 2.30]; p=0.45. 15.2% (n=40) 
participants had borderline PVD (Table 8.6). 
People, in which ABI assessment was not available, had significantly higher 
prevalence of risk factors for PVD including hypertension, high BMI and current 
smokers. This might lead to underestimation of PVD in our cohort. (Table 8.9) 
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Table 8.6 Prevalence of Peripheral Vascular Disease –based on ABI assessment  
 Definite PVD Borderline PVD Low normal ABI No PVD Total 
Male 23 (8.7%) 13 (4.9%) 18 (6.8%) 62 (23.6%) 116 (44.1%) 
Female 35 (13.3%) 27 (10.3%) 35 (13.3%) 50 (19.0%) 147 (55.9%) 
 
58 (22.1%) 40 (15.2%) 53 (20.2%) 112 (42.6%) 263 (100.0%) 
 
 
 
Table 8.7 Prevalence of Peripheral Vascular Disease – GPRR 
PVD (GPRR) Male Female Total 
No 155 (36.2%) 248 (58.1%) 403 (94.4%) 
YES 12 (2.8%) 12 (2.8%) 24 (5.6%) 
 167 (39.1%) 260 (60.9%) 427 (100%) 
 
Note: GPRR = General practice record review 
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Table 8.8 Potential determinants of Peripheral Vascular Disease (PVD)  
Variables 
PVD 
(ABI<0.9) 
No PVD 
(ABI≥0.9) 
Odds ratio (95% CI) p value 
Gender     
 Male 23 (19.8%) 93 (80.2%) 
1.26 (0.67-2.39) 0.46 
 Female 35 (23.8%) 112 (73.2%) 
Hypertension     
 Yes 33 (23.7%) 106 (76.3%) 
1.23 (0.68-2.21) 0.48 
 No 25 (20.2%) 99 (79.8%) 
Stroke     
 Yes 9 (37.5%) 15 (62.5%) 
2.32 (0.89-6.01) *0.05 
 No 49 (20.5%) 190 (79.5%) 
Dementia     
 Yes 4 (66.7%) 2 (33.3%) 
7.51 (1.15-60.9) *0.02 
 No 54 (21.0%) 203 (79.0%) 
Diabetes     
 Yes 6 (18.2%) 27 (81.8%) 
0.76 (0.26-2.07) 0.37 
 No 52 (22.6%) 178 (77.4%) 
IHD     
 Yes 18 (22.0%) 64 (78.0%) 
0.99 (0.50-1.94) 1.00 
 No 40 (22.1%) 141 (77.9%) 
CVD     
 Yes 15 (30.6%) 34 (69.4%) 
1.75 (0.83-3.70) 0.08 
 No 43 (20.1%) 171 (79.9%) 
Smoking     
 Never 16 (18.2%) 72 (81.8%) 
1.64 (0.82-3.30) 0.08 
 Current/Ex 42 (26.8%) 115 (73.2%) 
Hyperlipidaemia     
 Yes 37 (25.7%)  110 (74.3%) 
1.32 (0.58-3.02) 0.30 
 No 11 (17.0%) 43 (83.0%) 
 
IHD= Ischaemic heart disease, CVD = cerebrovascular disease 
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Table 8.9 Characteristics of participants with & without measurements of ABI 
 
Variables (n, %) 
ABI available 
(n=263) 
ABI unavailable 
                          (n=164) 
P value 
Gender    
Male 116 (44.1%) 51 (31.1%) 
*0.01 
Female 147 (55.9%) 113 (68.9%) 
Hypertension     
Yes 139 (52.9%) 104 (63.4%) 
*0.04 
No 124 (47.1%) 60 (36.6%) 
Stroke    
Yes 24 (9.1%) 21 (12.8%) 
0.29 
No 239 (90.9%) 143 (87.2%) 
Diabetes    
Yes 33 (12.5%) 22 (13.4%) 
0.90 
No 230 (87.5%) 142 (86.6%) 
IHD    
Yes 82 (31.2%) 56 (34.1%) 
0.60 
No 181 (68.8%) 108 (65.9%) 
CVD    
Yes 49 (18.6%) 32 (19.5%) 
0.91 
No 214 (81.4%) 132 (80.5%) 
Smoking    
Never 88 (33.5%) 73 (44.5%) 
*0.04 
Current/Ex 174 (66.1%) 91 (55.5%) 
BMI    
>= 25 108 (41.9%) 85 (54.1%) 
*0.02 
<25 150 (58.1%) 72 (45.9%) 
 
 
 
 
 
 
 
208 
 
8.4 Extent Of Un-Diagnosed and Mis-Diagnosed PVD 
24 participants (5.6%) had diagnosis of PVD on GP record review (Table 8.7).  19.0% 
participants (n=50; 16.4% of males and 21.1% of females) who had no formal GP 
diagnosis of PVD had definite PVD on the basis of ABI assessment. Five participants 
with a diagnosis of PVD in the GP record (31.2%) had normal or low normal ABI 
(Table 8.8).  Thus, there was substantial under-diagnosis and misdiagnosis of PVD in 
our cohort. 
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Table 8.10  Undiagnosed Peripheral Vascular Disease 
 Definite PVD Borderline PVD Low Normal ABI No PVD Total 
No GP diagnosis of 
PVD 
50 (19%) 37 (14.1%) 50 (19%) 110 (41.8%) 247 (93.9%) 
GP Diagnosed PVD 8 (3%) 3 (1.1%) 3 (1.1%) 2 (0.8%) 16 (6.1%) 
 58 (22.1%) 40 (15.2%) 53 (20.2%) 112 (42.6%) 263 (100%) 
 
 
Table 8.11 Undiagnosed Peripheral Vascular Disease by Gender 
 
Men Female 
 
Definite 
PVD 
Other Total 
Definite 
PVD 
Other Total 
No GP diagnosis of 
PVD 
19 (16.4%) 
88 
(75.9%) 
107 (92.2%) 31 (21.1%) 109 (74.1%) 140 (95.2%) 
Diagnosed PVD 4 (3.4%) 5 (4.3%) 9 (7.8%) 4 (2.7%) 3 (2%) 7 (4.8%) 
Total 23 (19.8%) 
93 
(80.2%) 
116 (100%) 35 (23.8%) 112 (76.2%) 147 (100%) 
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8.5 Medications and Peripheral Vascular Disease (PVD) 
Only 10 participants (41.7%) with a GP diagnosis of PVD were on lipid lowering 
treatment and only 12 (50.0%) participants were on any antiplatelet medication 
(aspirin n=11, clopidogrel n=1) (Table 8.10). 23 participants (39.6%) diagnosed with 
definite PVD on ABI assessment were on lipid lowering treatment and only 29 
(50.0%) participants were on antiplatelet medication (aspirin n=24, clopidogrel n=3 
and dipyridamol n=2).  31 (53.4%) participants with definite PVD (ABI) were 
undiagnosed and were not on any lipid lowering treatment.  28 (48.3%) people with 
definite PVD (ABI) were undiagnosed and were not on any anti-platelets. (Table 
8.11) 
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Table 8.12 Medications and Peripheral Vascular Disease 
  PVD – GPRR (n=427) PVD – ABI (n=263) 
  PVD (n=24) No PVD (n=403) 
PVD 
(n=58) No PVD (n=205) 
Statin      
 Yes 10 (41.7%) 127 (31.5%) 23 (39.6%) 71 (34.6%) 
 No 14 (58.3%) 276 (68.5%) 35 (60.4%) 134 (65.4%) 
Aspirin      
 Yes 11 (45.8%) 123 (30.5%) 24 (41.4%) 66 (32.2%) 
 No 13 (54.2%) 280 (69.5%) 34 (58.6%) 139 (67.8%) 
Clopidogrel      
 Yes 1 (4.2%) 18 (4.5%) 3 (5.2%) 10 (4.9%) 
 No 23 (95.8%) 385 (95.5%) 55 (94.8%) 195 (95.1%) 
Dipyridamol      
 Yes 0 (0.0%) 8 (2.0% 2 (3.4%) 5 (2.4%) 
 No 24 (100%) 395 (98.0%) 56 (96.6%) 200 (97.6%) 
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Table 8.13 Undiagnosed PVD and Medications 
Statins    
  PVD (GPRR) No PVD (GPRR) 
Yes PVD - ABI 4 (6.9%) 19 (32.8%) 
  No PVD - ABI 3 (1.5%) 68 (33.2%) 
     
No PVD - ABI 4 (6.9%) 31 (53.4%) 
  No PVD - ABI 5 (2.4%) 129 (62.9%) 
     
Antiplatelet    
Yes PVD - ABI 4 (6.9%) 22 (37.9%) 
  No PVD - ABI 5 (2.4%) 71 (34.6%) 
     
No PVD - ABI 4 (6.9%) 28 (48.3%) 
  No PVD - ABI 2(1.0%) 126 (61.5%) 
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8.6 Summary 
Burden of atrial fibrillation and peripheral vascular disease is high in 85+ year old 
population. Majority of people with atrial fibrillation and peripheral vascular disease 
were undiagnosed. Majority of people with atrial fibrillation in 85+ year cohort were 
at high risk of thromboembolism or stroke and despite that very few people were on 
thromboprophylactic treatment. 
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Section 4 
Final Summary And Discussion 
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Chapter 9: Final Summary and Discussion 
 
9.1 Statement of Principal Findings      
This study provides estimates of the prevalence of both systolic and diastolic cardiac 
dysfunction, atrial fibrillation and peripheral vascular disease in a large sample of 85+ 
year old community dwelling people.  This study also provides a comprehensive 
assessment of echocardiographic characteristics including the prevalence of 
significant valvular heart disease in this age group. We also established the normative 
range of NT-proBNP in 85+ year old community dwelling ‘healthy’ cohort and its 
diagnostic performance to detect LV dysfunction in this age group. 
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9.1.1 Prevalence of Symptomatic and Asymptomatic Left Ventricular (LV) 
Dysfunction 
We found that almost a half (50%) of participants had systolic dysfunction (LVEF < 
55%), and a further 14.5% had moderate or severe diastolic dysfunction in the 
presence of preserved systolic function.  Overall 37.4% of participants had symptoms 
consistent with heart failure accompanied by significant LV systolic (29.5%) or 
diastolic dysfunction (7.9%) on echocardiography, but only 11.5% of these people 
had been diagnosed with heart failure. A pre-existing diagnosis of heart failure was 
present in only 5.8 % of our participants and in almost 25% of these we found no 
evidence of significant LV dysfunction on echocardiography. In addition, 18% of 
participants had asymptomatic LV systolic dysfunction; around 5% of participants 
had asymptomatic isolated moderate or severe diastolic dysfunction, all of which were 
undiagnosed. As previously documented by others at younger ages, we also found the 
diastolic dysfunction was more common in females and hypertensive patients. In 
contrast systolic dysfunction was commoner in males and patients with ischaemic 
heart disease.  
Valvular heart disease was not very common in 85+ years old. Moderate and severe 
aortic stenosis was present only in 1.8% and 0.3% participants respectively. Moderate 
to severe mitral stenosis was also quite rare (0.3%). Majority of the participants had 
had normal sized left ventricular. In 19.6% participants LV systolic function was 
moderate (16.8%) or severely (2.8%) impaired. However, right ventricular structure 
and systolic function was preserved in majority of the participants. 12.8% and 11.3% 
had moderate or severely dilated left atrium and right atrium respectively. 
We did not find and significant association between markers of arterial stiffness 
including arterial pulse wave velocity (PWV) and augmentation index and LV 
systolic or diastolic dysfunction. Arterial PWV was higher in patients with systolic 
and diastolic functions compared with healthy cohort but it was not statistically 
significant. Overall, participants with diastolic dysfunction had stiffer arteries as 
compared to participants without diastolic dysfunction with higher augmentation 
pressure, augmentation index and central systolic blood pressure. However, these 
differences were not statistically significant. We also noted CIMT (posterior mean) 
was significantly higher in patients with LV systolic dysfunction (p = 0.04).  
Previous community-based studies have recruited small numbers of individuals over 
the age of 85 and echocardiographic assessments were performed in hospital or clinic 
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settings. We were aware of the challenges of recruitment in this age group could be as 
people find it difficult to attend research centres and leave their homes [275, 276]. 
This potentially could create a recruitment bias towards a relatively health cohort. In 
the Newcastle 85+ pilot study around 50% of the participants said they would have 
refused to attend hospital setting for assessment. [252] We therefore, recruited 
participants regardless of cognitive impairment or place of residence, and conducted a 
domiciliary echocardiographic assessment. This strategy was superior to previous 
studies with respect to representativeness and likely to show higher estimates of 
prevalence than in previous studies including the very old.  
 
Direct comparison with previous studies is complicated mainly due to criteria used to 
define ventricular dysfunction and age group cut-offs. Overall, however, the 
prevalence of systolic dysfunction in our population was over twice that of previous 
large population-based studies in those over 75 years of age. In the Olmsted County 
study, prevalence of LVSD (LVEF of 50% or less) was 12.9 among 298 participants 
aged 75 years and above. In the Cardiovascular Health Study, among 689 people over 
80, prevalence of LVSD (LVEF 45% or less) was 6%. In the Canberra Heart Study, 
among 118 people 80-86 years old prevalence of LVSD (LVEF 50% or less) was 
14%.[277] In the UK ECHOES study, among 66 participants over 85, reported 17% 
with LVEF <= 50%. In Rotterdam study group only 29 people were aged 85 years 
and above and 10.3% showed LVSD (fractional shortening <= 25; equivalent to 
LVEF ~ 50%). In Helsinki Ageing study only 136 participants were 85 years or above 
and 11.3% among showed LVSD (fractional shortening <= 25; equivalent to LVEF ~ 
50%). Our much larger sample along with domiciliary approach of data collection 
increases the reliability of those previous estimates and provides additional 
information on the prevalence of less severe systolic dysfunction and diastolic 
dysfunction of all grades at this age. 
With respect to diastolic dysfunction, the prevalence in our study (88% for any 
diastolic dysfunction, 31% for moderated or severe dysfunction, 61% for isolated 
mild, moderate or severe dysfunction, and 14.4% for isolated moderate or severe 
dysfunction) was again substantially higher than previously described by others in 
less elderly populations and in the few studies of the very old.  For example, among 
those aged 75 and above in the Olmsted County study moderate or severe dysfunction 
was about half as common as in our sample (18%), and any diastolic dysfunction was 
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present in 71% of participants; among 80-86 year olds in the Canberra Heart Study 
moderate or severe dysfunction was present in 14% and any diastolic dysfunction in 
64%.  There are no studies to date that have reported data on diastolic function in 
substantial numbers of participants of this age group. In a recent longitudinal study 
Halley and colleagues have shown increasing mortality with worsening degree of 
diastolic dysfunction in patients with preserved systolic function.[278] Moderate and 
severe diastolic dysfunction alone were associated with increased mortality risk 
(hazard ratio, 1.58; 95% CI, 1.20-2.08; and hazard ratio, 1.84; 1.29-2.62, respectively;
 
P <.001 for each). 
We believe the higher prevalence of both systolic and diastolic dysfunction among 
our study participant is mainly to the older age of our participants and the inclusive 
nature of our study design, although other differences including the comorbid 
conditions and their optimal control like hypertension, ischaemic heart disease and 
renal impairment between our population and previous studies cannot be excluded as 
causes or contributing factors. For example, higher prevalence of hypertension and 
ischeamic heart disease in our study cohort and Jerusalem heart study (56.9% and 
71.6% respectively) might be contributing to higher systolic and diastolic dysfunction 
as compared to other studies including the Rotterdam study, the Helsinki Ageing 
study and the Olmsted county study where prevalence of hypertension is relatively 
less (36%, 37%, and 39% respectively).  
We reported prevalence of symptomatic LV dysfunction 37.4%, in which systolic 
dysfunction was 29.5% being more prevalent than isolated moderate/sever diastolic 
dysfunction (7.9%). This is considerably higher than the prevalence of heart failure 
reported from previous population-based studies including this age group which range 
between 2 and 18%.  However, caution is needed before comparing our prevalence of 
symptomatic dysfunction to that of heart failure reported by previous studies as the 
focus of our study was to identify cardiac dysfunction by echocardiography and to 
determine the proportion that was symptomatic rather than to identify cases of heart 
failure by the application of clinical criteria. 
Asymptomatic LV dysfunction (also termed as preclinical heart failure) that we have 
reported in our study is higher (23.0%) than previously reported studies of 
similar/younger age groups. In the Olmsted County study overall prevalence of 
asymptomatic LV dysfunction (LVEF<= 50% or moderate/severe diastolic 
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dysfunction) was 11.7%, however its prevalence in high risk population (aged 65+ 
and Hypertensive or coronary artery disease) is 27.4% which is similar to our finding.  
In our study more than 80% participants with symptomatic LV dysfunction were 
undiagnosed. 25% of the participants with known diagnosis of heart failure had no 
underling systolic or diastolic dysfunction. Previous reports, in younger populations, 
cite the percentage of LV systolic dysfunction which is undiagnosed as between 50 
and 80% [18, 43, 279]. In UK Poole study of heart failure prevalence in general 
population,   Morgan and colleague reported 52% of the undiagnosed validated heart 
failure in elderly cohort ( mean age 77 years). It is also important to note that Morgan 
and colleagues only assessed heart failure with underlying systolic dysfunction and 
only 20 people with age 80 years and above were included in their study, which can 
be a reason for lower prevalence and fewer undiagnosed cased of heart failure. In 
Olmsted County study Redfield and colleagues has reported almost 80% of LV 
systolic dysfunction (LVEF<= 50%) had no validated diagnosis of heart failure 
however similarly nearly half of participants with moderate-severe systolic 
dysfunction and severe diastolic dysfunction had no recognised heart failure 
diagnosis.  Mis-diagnosis of heart failure is also common with 34-75% of general 
practice cases unsubstantiated by echocardiography and/or specialist assessment.[45, 
280-282] Our mis-diagnosis rate (25%) is at the lower end of this range which may be 
due to two factors: first, our inclusion of moderate/severe diastolic dysfunction in the 
definition of significant dysfunction whereas previous studies have mainly focused on 
systolic impairment alone; and second, that our study was conducted after the 
introduction of the National Service Framework (NSF) for Coronary Heart Disease 
(CHD) and NHS Quality and Outcomes Framework in 2004 which includes an 
indicator for the proportion of patients with a diagnosis of heart failure confirmed by 
echocardiogram or specialist assessment.[283] 
The diagnosis of heart failure in very elderly patients, particularly in general practice 
remains very challenging due to the non-specific nature of its clinical findings, 
multiple comorbidities mimicking the similar symptoms including anaemia, COPD 
and renal impairment and the limited access of routine echocardiography (in the UK 
setting). Many studies have shown in the past that nearly half of the patients were 
incorrectly diagnosed with heart failure when evaluated with more subjective 
diagnostic tool like echocardiography.[284] Echocardiography remains a very 
important diagnostic tool to correctly identifying the condition. In 2004 National 
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Service Framework (NSF) for Coronary Heart Disease (CHD) & NHS Quality and 
Outcomes Framework set national standards for improving the diagnosis and 
treatment of heart failure and recommended that of patients with a diagnosis of heart 
failure should be confirmed by an echocardiogram or specialist assessment. However, 
the proportion of people undergoing echocardiogram, especially elderly with 
suspected heart failure remain below the national standards. Majeed and colleagues 
looked at the records of 26 general practices in south of England and to compare the 
management of heart failure with the standards set by NSF. They noted, older people 
with a diagnosis of heart failure made in the community were less likely to have an 
echocardiogram than younger patients. [285] This possibly explains the higher 
numbers of mis-diagnosed heart failure in this age group. It also highlights the need 
for change in our current strategies to manage heart failure especially in elderly 
population. 
Significant valvular heart disease was quite uncommon in our study cohort. Moderate 
and severe aortic stenosis was present only in 1.8% and 0.3% participants 
respectively. Moderate and severe mitral stenosis was very rare and present in 0.3% 
participants. Moderate mitral regurgitation was present in 6.6% participants. 
Previously reported study in similar age group has reported higher prevalence of 
significant valvular heart disease.[286] Thomas van Bammel and colleagues have 
reported prevalence of moderate and severe aortic stenosis 5%and 1% participants 
respectively. Moderate and severe mitral regurgitation was present in 30 and 15% 
individuals respectively. It is also important to note only 81 participants in this study 
had echocardiographic data on valvular heart disease available. That might have 
caused some uncertainty in their estimates of valvular heart disease.  
 
 No treatment has yet been shown to convincingly reduce morbidity and mortality in 
patients with HF-PSF. Unfortunately, very few large randomised controlled trials 
have looked at the patients with HF-PSF as compared with HF-RSF and hence, there 
is insufficient data on mortality benefit of medications used for patients with HF-PSF. 
[47, 70, 122, 123]  It is believed among physicians and researchers that treating co-
morbidities might help to improve survival. Therefore, mainstay of treatment remains 
on diuretics to control the symptoms and adequate control of blood pressure and 
ventricular rate. [24, 124] Two trials with target to lower blood pressure in patients 
with HF-PSF have suggested that ARBs (CHARM preserved trial) and ACE 
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inhibitors (PEP-CHF trial) may reduce the hospitalisation in patients with HF-PSF. 
[125]   Effectiveness of therapies of heart failure due to systolic dysfunction  (HF-
RSF) are well established, especially pharmacological therapies including ACE 
inhibitors/ARBs and beta blockers. However, the importance of treating AHA/ACC 
class B patients (pre-symptomatic but with evidence of LV systolic dysfunction) to 
prevent progression to overt heart failure is recognised in guideline statements. We 
have previously identified a high level of undiagnosed hypertension in this age group 
and a low level with adequate control in those with diagnosed disease. [251] Whether 
the risk of progression to HF could be ameliorated in the substantial population of 
85+ individuals with diastolic dysfunction by more aggressive management of such 
co-morbid conditions is a question of considerable interest. 
Our findings highlight the continuous nature of the increase in prevalence of cardiac 
dysfunction with age observed by others in the “younger old”, with high levels of 
both systolic and diastolic dysfunction found in community-dwelling very old people.  
We also found a substantial burden of undiagnosed and potentially treatable LV 
dysfunction.  Whilst no therapy has been proven to be effective in preventing the 
progression of preclinical diastolic dysfunction to HF-PEF, or indeed in improving 
outcomes in established HF-PEF, [287-294]  effective (and cost-effective[295]) 
therapies for HF-REF are well established.[183, 289, 292, 296-307] There is 
additionally an increasing emphasis on identifying asymptomatic LV dysfunction and 
preventing its progression to heart failure,[298, 308-311] and the importance of 
treating people with asymptomatic LV systolic dysfunction recognised in guideline 
statements.[312] Around a quarter of our participants had undiagnosed LV systolic 
dysfunction potentially amenable to therapies which can prolong survival and enhance 
quality of life through symptom control and improved functional status.  
Co-morbidities, including renal impairment, anaemia and chronic obstructive 
pulmonary disease, have been reported to influence the progression of asymptomatic 
cardiac dysfunction to heart failure and/or to act as prognostic factors in established 
heart failure.[308, 313-315] We have previously reported the high prevalence of such 
co-morbidities in this study population.[316] Whether more aggressive management 
of such co-morbid conditions in the very old could ameliorate the risk of progression 
of asymptomatic dysfunction to heart failure and improve the prognosis in those with 
established heart failure is a question of considerable interest.  
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9.1.2 Diagnostic Performance of NT-ProBNP to Detect Left Ventricular 
Dysfunction In 85+ Year Old Community Dwelling People 
 
We reported normal reference levels of NT-proBNP in ‘normal and healthy’ 85+ year 
old community dwelling individuals. Mean (SD) and median (IQR) values of NT-
proBNP in ‘normal and healthy’ 85+ year old cohort were 189±140 pg/mL and 163 
(108) pg/mL respectively. There was no significant gender difference in NT-proBNP 
levels as previously reported by others in people aged 75 years and above. [317] 
However, many studies in younger age groups have shown slightly higher NT-
proBNP levels in females. [229, 232] 
No previous studies have reported the normal values of NT-proBNP in a community 
dwelling 85+ cohorts. Two previous studies by Costello et al [230] and Abhayaratna 
et al [234] included people above 75 years and over as subgroup or exclusively and 
used NT-proBNP test. NT-proBNP levels in ‘normal patients’ were slightly higher in 
our cohort than reported by Costello-Boerrigter et al in people aged 75 years and 
above (female, median = 124pg/ml; male, median = 57pg/ml). As levels of NT-
proBNP increase with increasing age [229, 232-234, 317], we believe this slightly 
higher levels of NT-proBNP levels in our cohort are due to our more elderly cohort 
than Costello-Boerrigter et al study. In the Leiden 85+ study NT-proBNP test was 
used to detect various echocardiographic abnormalities in community dwelling 85+ 
cohort but investigators have not reported the normative range of NT-proBNP in this 
cohort. [318]  
We also reported a significant increase in plasma NT-proBNP levels with progression 
in LV systolic (p<0.00001) or diastolic dysfunction (p<0.00001) and worsening of 
NYHA functional status (p = 0.0017). However, NT-proBNP levels did not change 
significantly with increasing arterial stiffness.  
Investigators of the Framingham Heart Study have reported significant positive 
association of BNP and ANP with worsening severity of both systolic and diastolic 
dysfunction in relatively young participants (mean age = 58±10 years). [319] Tschöpe 
et al have also reported a significant rise in NT-proBNP levels with worsening 
severity of overall diastolic dysfunction in younger age group (mean age = 51±9).  
[241] Similar results were reported by Abhayaratna et al in Canberra Heart Study in 
older community based people (aged 60-86 years, mean age = 60.4 years).[234] 
Blonde et al reported a significant increase in plasma BNP levels in people (84.3 ± 7.4 
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years old, 65–102) with worsening NYHA functional status.[320] Similar correlation 
has also been reported by others in younger age group (mean age 57 years, 31-80 
years). [239, 321, 322] Frankenstein et al reported a significant rise in NT-proBNP 
levels with worsening NYHA status in both younger (<65 years, mean age = 53±8 
years) and older (>65 years, mean age = 73±6) heart failure patients and suggested 
that NT-proBNP levels equally predict the severity of heart failure symptoms in both 
younger and older patients. [323] However, we believe no study has so far reported 
this association in 85+ years old community dwelling participants. Our findings 
highlight the similar associations of NT-proBNP with systolic, diastolic and NYHA 
status in community-dwelling very old people as observed by others in the “younger 
old”. 
We found NT-proBNP test performed much more poorly to detect LV dysfunction 
(systolic /+ diastolic) in community-dwelling 85+ years old people than has been 
previously reported in younger cohorts. Moreover, the diagnostic performance of NT-
proBNP did not improve with lower EF and symptomatic patients (NYHA 2 and 
above) as suggested by others in the “younger old”. The performance of NT-proBNP 
(AUC, 95%CI) for the detection of EF <55%, <45%, <35% and moderate-severe 
diastolic dysfunction was 0.68 (0.63-0.73), 0.70 (0.65-0.74) and 0.64 (0.59-0.69) 
respectively. The performance of NT-proBNP (AUC, 95%CI) for the detection of 
symptomatic EF <55%, <45%, <35% and moderate-severe diastolic dysfunction was 
0.68 (0.60-0.75), 0.72 (0.64-0.79) and 0.68 (0.60-0.75) respectively.     
Natriuretic peptides have been shown reliably to exclude LVSD, symptomatic 
isolated diastolic dysfunction and heart failure in younger patients. [241, 324-328] 
However, in an elderly community dwelling population, its diagnostic performance 
decreases.  Redfield et al have reported BNP as a suboptimal test for screening for 
asymptomatic LV dysfunction in community dwelling 45 years and above (mean age 
= 75 years). They found the diagnostic performance of BNP was higher to detect 
asymptomatic moderate – severe LV systolic dysfunction (AUC = 0.82-0.92) than any 
systolic dysfunction (AUC = 0.51-0.74), moderate –severe diastolic dysfunction 
(AUC = 0.74-0.79) or any diastolic dysfunction (AUC = 0.52-0.68). [329] 
Investigators of the Framingham Heart Study have also reported poor performance of 
BNP to identify LVSD in a community based sample of the “younger old” with 
overall AUC less than 0.75, even in a subgroup that were at high risk. [319] 
Abhayaratna et al also found similar results in cohort aged 75-86 years (n=46). They 
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found the diagnostic performance of NT-proBNP to detect any degree of LV 
dysfunction was poor (AUC = 0.56-0.66). In contrast, the performance of NT-proBNP 
for the detection of EF ≤40% and moderate-severe diastolic dysfunction was much 
stronger with AUC levels consistently >0.90. [234] In a meta-analysis of natriuretic 
peptides in the diagnosis of heart failure and screening of LVSD in the community, 
Ewald et al have reported the age related decrease in the performance of NT-proBNP 
and BNP. At a given cut point, which would give sensitivity of 85% for BNP to detect 
underlying LVSD, the associated specificity would decrease from 90% in people  
aged  55 years  to 54% in people aged 85 years. The values for NT-proBNP decrease 
more steeply. [245] In another systemic review, Vaes et al also found limited 
evidence of diagnostic utility of natriuretic peptides to detect LVSD and heart failure 
in community dwelling elderly patients aged 75 and over.[246] Hetmanski et al also 
have reported the poor ability of BNP to identify LVSD in a large (n= 653) 
community based elderly population (median = 76 years, IQR = 70-82 years). 
However, BNP levels in people with LVEF < 40% were significantly higher than 
people with LVEF > 40%. [330].  Our findings of poor diagnostic performance of 
NT-proBNP to detect LV dysfunction in 85 years and above community dwelling 
people confirm the similar findings reported by others in “younger olds”.  
The exact cause of this poor performance of natriuretic peptides to identify LVSD and 
heart failure in community dwelling elderly population remains unclear. However, 
increased prevalence of co-morbidities in the elderly population, including renal 
impairment, ischaemic heart disease and atrial fibrillation that could influence the 
circulating levels of natriuretic peptides, may reduce the diagnostic utility of 
natriuretic peptides. [318, 324, 331] Cardiovascular medications including diuretics, 
ACE inhibitors, angiotensin receptor blockers (ARBs) and beta blockers have also 
shown to reduce the circulating levels of natriuretic peptides and probably can affect 
their diagnostic performance of to identify LVSD and heart failure. [328, 332-335] In 
our study nearly 33% people were taking diuretics, nearly 28% were taking ACE 
inhibitor or angiotensin receptor blockers (ARBs) and nearly 28% were taking beta 
blocker medications.  
Prevalence of both asymptomatic and symptomatic LV dysfunction is high in the 
rapidly growing very old population in the community and is quite difficult to 
diagnose especially in primary care settings. Therapeutic interventions in both cases 
have shown to reduce the morbidity. [336-340] In order to maintain independence and 
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better functioning in this rapidly growing fraction of the ageing population it is 
important to early detection of under LV dysfunction and initiate therapeutic 
interventions. Since the role of natriuretic peptides in the diagnostic algorithm of LV 
dysfunction and heart failure in very old still remains unclear, there is need for newer 
biomarkers and other strategies to identify LV dysfunction and heart failure in very 
old fraction of the population. Potential newer biomarkers to detect heart failure, 
including galectin-C and cystatin-C, are under investigation but this work is still in its 
early stages. [341-343] Some people have also suggested the role of handheld 
portable echocardiography to detect LV dysfunction in community. Handheld 
echocardiography systems have been shown reliably and accurately (including in this 
study) to detect LV systolic dysfunction in community.  Although cost effective, this 
technique is highly operator dependent and requires a period of training, which may 
limit its use in primary care setting. [344-348] 
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9.1.3 Burden of Peripheral Vascular Disease (PVD) and Ankle Brachial Index 
(ABI) In 85+ Years Old Community Dwelling People 
 
In this large population based study we reported the prevalence of peripheral vascular 
disease as 22.1% in the entire cohort. It means, on average every fifth person in our 
study had PVD. We did not find any significant gender difference in the prevalence of 
PVD in our cohort. (Female: male odd ratio was 1.26 [0.67 – 2.30]; p =0.45). 19.0% 
of participants (16.4% of males and 21.1% of females) who had no formal GP 
diagnosis of PVD had definite PVD on the basis of ABI assessment. A pre existing 
diagnosis of PVD was present only in 5.6% of our participants and 31% of these has 
normal ankle brachial index assessments (ABI).  Thus, there was substantial under-
diagnosis and misdiagnosis of PVD in our cohort. 39.6% participants with definite 
PVD were using lipid lowering treatment and 50% were using antiplatelet medication. 
Even people with already diagnosed PVD only 41.7% were taking lipid lowering 
treatment and only half of participants were taking antiplatelet medication. We did not 
have data on any contraindications or reasons why people were not taking these 
treatments. 
It would be difficult to compare with other studies mainly due the different methods 
used to ascertain to detect PVD and different cut-off values of ABI used to define 
PVD. Due to these factors prevalence of PVD in community varies markedly from 
each other. Also, very few studies selectively were done on people aged 85+ years 
and above to ascertain prevalence of PVD.  I am comparing our findings with those 
community based studies in ABI value <0.9 was used to define PVD and included 
people aged 75 and above. 
Our findings were almost similar to the results from the Finish study on 90 years old 
community living people. In this study Suominen et al reported prevalence of PVD as 
22% of which 85% people were asymptomatic. They also reported no significant 
gender difference in the prevalence of PVD. However, it was slightly more prevalent 
in females confirming the findings from our study. In this study a significant poor 
survival was reported in people with PVD over one year follow up. Mortality in 
people with PVD was 25% vs 7% in people with no PVD. Nearly 67% of these deaths 
were due to cardiovascular disease. [349] Criqui et also reported similar prevalence of 
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PVD (21%) in people aged 75 years and above (294  aged between 75 years and 82). 
[350] Our reported prevalence of PVD in people with 85+ year olds was much lower 
than reported by Diehm et al from the German Epidemiological Trial on Ankle 
Brachial Index (getABI Study) and by Bergiers et al from the BELFRAIL Study. 
Diehm et al randomly selected 6821 community living participants from all across the 
general practices of Germany patients aged 65 years and above to assess prevalence 
of PVD. Their sample included 150 participants who were 85 years old or above. 
Reported prevalence of PVD in community dwelling 85+ year olds was 33%.[351] 
Bergiers et al measured ABI in 80+ year old community dwelling participants (n=175, 
mean age = 85.0±3.9 years) and reported 40% participants had PVD. [352] In our 
study people who did not had ABI measurements were significantly higher prevalence 
of risk factors for PVD including hypertension, high BMI and current smokers, which 
might mean that actual prevalence of PVD in study might be higher. Furthermore, 
difference in racial demography and differences in the co-morbidities between cohorts 
may have lead to difference in the prevalence figures. In BELFRAIL Study 
prevalence of hypertension, diabetes and people with BMI ≥30 was 74.9%, 20.6% and 
40% respectively. [352] In contrast, our cohort in whom ABI measurements were 
available, prevalence of hypertension [52.9% (p<0.0001)], diabetes [12.5% (p=0.03)], 
and people with BMI ≥30 [7.8% (p<0.0001)] was significantly less. That can also 
explain the higher prevalence of PVD in BELFRAIL Study as compared to ours. 
In our study we did not collect on the data about symptoms of PVD as focus of the 
study was more on epidemiological aspects of cardiac dysfunction, atrial fibrillation 
and PVD. However, we also know that PVD is symptomatic only in small numbers of 
the patients with PVD (ABI<0.9), nearly 80%  remain asymptomatic. [353, 354] 
Diehm at al reported only 5.6% of people with age 85 years and above were 
experiencing symptoms of intermittent claudication. Moreover, symptoms of 
intermittent claudication had sensitivity of 11.0% and specificity of 98.0% in 
detecting underling PVD. [351] ABI is simple, inexpensive and non-invasive test that 
can be performed in general practice or even domiciliary (Newcastle 85+ study) 
settings with high sensitivity (79% to 95%) and a specificity (95% to 100%). [355]  
ABI value less than 0.9 is considered diagnostic of PVD as recommended in Inter-
Society Consensus for the Management of Peripheral Arterial Disease published in 
2007.[356] Although, only small fraction of PVD patients are symptomatic but 
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increased cardiovascular morbidity and mortality associated with low ABI remain 
similar in both symptomatic and asymptomatic patients. [357] Leng et al looked at a 
random sample of 1582 people aged between 55-75 from 10 General Practices in 
Edinburgh, UK and performed ABI assessment along with symptoms assessment. He 
reported increased and almost equal cardiovascular mortality in people with 
symptoms of claudication (RR: 2.67, 95% Cl: 1.34–5.29) and asymptomatic people 
with PVD (RR: 2.08, 95% CI: 1.13–3.83). Similar results were reported later in much 
larger population based studies of elderly people. [358, 359]  In a population based 
study of 6880 participants of age 65 years and above, Diehm et al reported increase in 
all cause and cardiovascular mortality in patients with symptomatic PAD and people 
with asymptomatic PAD picked up on routine screening. In this study all ABI 
measurements were done by GPs or practice nurse in the GP surgeries. [359] In a 
meta-analysis and systemic review by Doobay et al, which included 9 population 
based studies, reported an association of ABI<0.9 and adverse cardiovascular 
outcome. The specificity of low ABI for coronary heart disease, stroke, and 
cardiovascular mortality was 92.7%, 92.2%, and 87.9%, respectively.[360] In another 
meta-analysis by Ankle Brachial Index (ABI) collaboration, which included 16 
population based cohort studies, ABI<0.9 was associated with increased 
cardiovascular mortality. [361] In people with low ABI cardiovascular mortality was 
18.4% in males and 12.6% for females whereas in people with normal ABI it was 
4.4% for males and 4.1% for females. Authors of ABI collaboration also reported that 
by adding ABI to existing Framingham Risk Score for cardiovascular risk 
stratification would have reclassified the risk category and modified treatment 
strategy in nearly 19% of males and 36% of females. Until recently, screening for 
PVD was not recommended. Theses findings, especially from Diehm et al and Hooi et 
al support the idea of ABI assessment in selected patients in primary care practice to 
identify people with cardiovascular risks. Some studies have previously reported that 
at very old ages classical cardiovascular risk factors like hypertension may loose 
power to predict cardiovascular mortality. [362-364] Investigators of Leiden 85+ 
Study have reported that even Framingham risk score, which is based on the classical 
cardiac risk factors failed to predict cardiovascular mortality in a cohort of 85+ years 
olds. [365] Due to growing and strong evidence of worse cardiovascular outcomes in 
asymptomatic or symptomatic PVD patients, routine screening of people with age 70 
years and above has been recommended and some scientist are suggesting that ABI 
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might be used as a predictor of cardiovascular mortality especially in later ages. [352, 
366]  The Trans-Atlantic Inter-Society Consensus Document on Management of 
Peripheral Arterial Disease (TASC-II) was published in 2007, which is an 
international collaboration of various medical and surgical societies across Europe, 
Northern America, Asia, Africa and Australia. [356]  This consensus document 
clearly lays down the recommendation diagnosis and treatment of PVD. This 
document also recommends the routine screening of for PVD in people aged 70 years 
and above irrespective of their cardiovascular risks status (Recommendation 12) and 
also use of antiplatelet treatment in patients with PAD (Recommendation 6). 
American College of Cardiology (ACC) and American Heart Association (AHA) also 
recommend routine screening for PVD in people aged 70 years and above. [367] 
According to the recently published SIGN (Scottish Intercollegiate Guidelines 
Network)  guidelines and collaborative report from American Association of Vascular 
Surgery, Society of Vascular Medicine and Biology, Society of Interventional 
Radiology and AHA/ACC task force on practice guidelines (2010) people with 
asymptomatic PVD should be identified with examination or ABI assessment so that 
treatment should be offered to asymptomatic PVD patients to reduce the increased 
risk of MI, stroke and death in these patients. They also suggested antiplatelet therapy 
to even asymptomatic patients. Guidelines also highlighted the importance other risk 
modification including smoking cessation, optimization of blood pressure, treatment 
of dyslipidaemia and diabetic control.[356, 367-369] Risk reduction in cardiovascular 
mortality by use of lipid lowering treatment and antiplatelet therapy in symptomatic 
PAD patients has been well established.  
Due to very central role of platelets in the pathophysiology of atherosclerosis and 
thrombogenesis, antiplatelet treatments play an important role in treatment of PVD. 
Role of aspirin and other antiplatelet agents in the cardiovascular risk reduction in 
both symptomatic and asymptomatic patients of PVD is well established. 
Antithrombotic Trialists Collaboration conducted a major meta-analysis (>147 
randomised trials and >100,000 patients were included) regarding the efficacy of 
antiplatelet therapy and reported 23% odds reduction in the number of vascular events 
in PAD patients. These benefits were observed in all age groups and were unrelated to 
comorbidities including HTN and diabetes [370]  Regarding the choice of antiplatelet, 
data in a bit conflicting. Some people believe clopidogrel is superior to aspirin and 
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vice versa. Investigators of CAPRIE study (n=19,185) conducted a large multicentre 
randomised double blind trial to compare aspirin vs clopidogrel and reported, 
clopidogrel compared with aspirin significantly reduced the annual risk of vascular 
events by 23.8% (95% CI 8.9 – 36; p=0.003) in PAD. [371] Investigators from 
CHARISMA trail did not find dual therapy with aspirin and clopidogrel any better 
than aspirin alone in reducing cardiovascular mortality in PAD patients. [372]  In 
Heart Protection Study simvastatin use in patients with PVD was associated with 
significant relative risk reduction in vascular events (22%, p<0.0001). [373] Despite 
the compelling evidence of reduction in cardiovascular morbidity and mortality PVD 
patients are not aggressively treated with antiplatelet or lipid lowering therapy. In our 
study we found only 39% and 50%  people with PVD were using lipid lowering 
treatment and antiplatelet treatment respectively. Suominen et al also reported similar 
findings from the study on 90 years old community living people.  They reported only 
46% of people with PVD were taking antiplatelet medication while only 44% were on 
lipid lowering treatment. [349] Similar trends in under treatment of PVD have been 
reported by others in the past. In 2002 Hirsch et al conducted a large (>6500 people, 
aged 70 years and above) multi centred study (PARTNERS Study) on community 
based older adults and found people with CVD were less aggressively treated. In this 
study only 56% and 54% people with PVD were using lipid lowering and anti platelet 
treatment respectively. [353] similar results have been reported by Lange et al from 
‘getABI Study’ where only 53% people with PAD were using antiplatelet treatment. 
[374] Suboptimal use of antithrombotic and lipid lowering medications in PVD 
patients to lower cardiovascular risk have been reported by others as well. [375-377] 
It is difficult to comment on the low utilization of risk lowering therapy including 
antiplatelet medications in our cohort due to lack of data as this study was primarily 
designed to estimate prevalence of un-diagnose cardiovascular disease burden in this 
community dwelling population of 85 year and above people. However we can 
assume that side affect profile, multiple comorbidities, poly pharmacy and cognitive 
impairment may be playing some role in that. But these might not be the only factors 
as we have seen similar pattern of under diagnosis and poorly managed cardiovascular 
risk in relatively younger cohorts as well. Although, many studies included 
community based cohort of relatively older people (60-80 years old) but very few 
included people of age 85+ and above, highlighting the need for similar studies in 
very old cohort. 
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9.1.4 Burden of Atrial Fibrillation and Thromboprophylaxis In 85+ Years Old 
Community Dwelling People 
In this large population based study we reported the prevalence of atrial fibrillation as 
25.5% in the entire cohort. We did not find any statistically significant gender 
difference in the prevalence of AF (odds ratio [95% confidence interval] males: 
females 1.38 [0.87 to 2.20]; p=0.17). However, prevalence in males (29.3%) was 
higher than females (23.0%) as previously documented by other studies. Nearly half 
(53.2%) of these patients had had no existing GP diagnosis of AF. Majority of our 
participants with AF were in high risk category for thromboembolism or stroke 
according to NICE guidance for AF management published in 2006 and evidence 
based clinical guidelines for antithrombotic therapy in atrial fibrillation published by 
American College of Chest Physicians (ACCP) in 2008. [274, 378] 72.4% 
participants with AF had CHADS2 score 2 or greater. 87.2% participants with AF 
were CHA2DS2-VASc score 3 or above. Only 17 (15.6%) participants with AF were 
taking warfarin. 84.4% (n=92) participants with AF, who were not on warfarin, only 
42.4% participants (n=39) were either on aspirin (n=33) or clopidogrel (n=5).  
 
Direct comparison with previous studies is complicated due to different ways used to 
detect AF cases and age group cut-offs. However, prevalence of AF in our study is 
comparable with findings from the Vantaa 85+ Study and the Rotterdam Study. Both 
of these studies used similar method to detect AF like our study and age group cut-off 
at 85+ make comparison easier with these studies. The Vantaa 85+ Study was 
longitudinal prospective community based study and included 553, 85+ year old 
participants living in Finish town of Vantaa. They looked at the risk of stroke and 
dementia in this age group. They reported prevalence of AF as 22.1%. AF was 
detected by 12 lead ECG and GP medical case notes review. [379] Prevalence of 
hypertension, diabetes mellitus, ischaemic heart disease and heart failure in Vantaa 
85+ Study was 25.5%, 20.2%, 14% and 61% respectively. Whereas in our study 
prevalence of hypertension, diabetes mellitus, ischaemic heart disease and heart 
failure was 57%, 13%, 32% and 9% (37.4% symptomatic LVSD). Higher prevalence 
of hypertension and ischaemic heart disease in our study might be one of the factors 
for slightly higher prevalence of AF in our study. In Rotterdam Study 427 people 
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were 85 year and above (same number as in our study) and prevalence of AF was 
17.6%. [male = 17.9%, female = 17.5%; OR 1.03 (0.54 – 1.9)].[380] To detect cases 
with AF, all participants had 12 lead ECG along with GP medical case notes review.  
In large cross-sectional US study ATRIA prevalence of AF was reported as 10.5% 
(n= 1891) in people aged 85 year and above. They also reported that 45% of all AF 
cases were in people aged 75 years and above. AF was more prevalent in males than 
female in all age groups. In 85+ year cohort prevalence in males was 11.1% and in 
females 9.1%). [381] In ATRIA Study AF was diagnosed by searching electronic 
medical case notes, electronic ECG database and hospital discharge database. None of 
the participant was offered ECG as this survey only involved review of database. AF 
prevalence in our study was almost double than reported by ATRIA study in 85+ year 
age group. There are probably many factors that may cause the difference between 
studies. Many people with AF remain asymptomatic or unaware of the arrhythmia and 
also majority of the people with AF get treated in community with no contact with 
hospital. [382, 383] Due to the screening nature of our study every participant was 
offered an ECG even people with asymptomatic AF might have been picked. 
Furthermore, difference in racial demography and differences in the co-morbidities 
between cohorts may have lead to difference in the prevalence figures.  
Sudlow et al reported prevalence of AF in people aged 75 year and above as 10.0% in 
males and 5.6% in females. They detected AF cases by performing limb lead ECG in 
a sample of 3678 community based people aged 65 year and above registered with a 
large General Practice in southern part of Northumberland, UK. Participants were 
invited to attend a clinic for ECG. [384]  Prevalence of hypertension, diabetes 
mellitus, cerebrovascular disease and heart failure was 56%, 9.5%, 23% and 9.3% 
respectively which was almost similar to our cohort (57%, 13%, 19% and 9% 
respectively). However in our study mean age of participants was higher and 
prevalence of significant LVSD (55%) was also much higher than the cohort reported 
by the Sudlow et al (prevalence of LVSD as defined by fractional shortening <25 was 
only 3%). This may be one of the possible reasons for difference in prevalence figures 
between two studies. Another factor that might affect the prevalence figures of all 
studies is the presence of paroxysmal atrial fibrillation, which would depend on atrial 
fibrillation being present at the time of the test. The better way to detect the atrial 
fibrillation or paroxysmal atrial fibrillation would be through frequent repeated ECGs 
233 
 
or Holter monitoring. Neither of these options is feasible for such cohort of elderly 
people. 
We do not know how many of our participants with AF had contraindications for the 
use of warfarin but only 15.6% participants with AF were taking warfarin. Sudlow et 
al and others have reported that people with AF especially above 75 years age are 
under prescribed with warfarin even in the absence of any contraindication. [384, 385] 
Sudlow et al looked at the prevalence of AF in the community dwelling people aged 
75 year and above and also the proportion of people that might benefit from 
thromboprophylaxis. They assessed the risk factors for stoke and contraindication to 
warfarin in this high risk population. They reported that most common 
contraindications to warfarin in people with AF aged 75 year and above were fall, 
uncontrolled hypertension and poor compliance. 34% of the people with AF aged 75 
year and above had contraindications to warfarin. Whereas, 93% of females and 94% 
of males aged 75 year and above had one or more clinical or echocardiographic risk 
factors for stroke. Only 16.9% people with AF aged 75 year and above were taking 
warfarin. In ATRIA Study mean age of participants was 71.7 ± 11.6 years and 65% of 
the participants with AF had at least one risk factor for stroke other that increasing 
age (>65 years). Only 17% of these had contraindication to warfarin. Only 55% of 
participants with AF and no contraindication were using warfarin. Warfarin use was 
much lower in people aged 85 year and above. Only 35.4% of participants aged 85 
year and above with AF and no contraindication were taking warfarin. [386] We 
cannot compare this figure with our study as we do not know the contraindications to 
warfarin in our study participants with AF. Results from SCAF Study (Stockholm 
Cohort-study on Atrial Fibrillation) also reported people with AF and aged 80 years 
and above were under treated with warfarin even in the absence of any 
contraindication to warfarin therapy. [387]  Investigators of ATRIA study also 
reported that people aged 85+ years [OR (95% CI); 0.35 (0.31– 0.40)], previous 
history of intracranial bleed [[OR (95% CI); 0.33 (0.21– 0.52)] and gastrointestinal 
bleeding [[OR (95% CI); 0.47 (0.40–0.57)] were major factors with low likelihood for 
using warfarin. Existing studies show that high risk of bleeding, inability of patient to 
follow dosing or monitoring advice and high risk of falls are major reasons why 
clinicians consider patients unstable for warfarin. Whereas, fear of bleeding, actual 
bleeding, difficulties with monitoring and poor understanding of stroke risk/benefit of 
warfarin therapy were major reasons why patients refuse warfarin therapy.[388-390] 
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Atrial Fibrillation is associated with increased risk of stroke which increases 
significantly with increasing age. Risk of thromboembolic stroke is increased up to 
sevenfold in people with non rheumatic AF. In Framingham Heart Study annual risk 
of stroke attributed to AF increases from 1.5% in 50-59 years olds to 23.5% in 80-90 
year old.[391]  Key consideration in the management of AF in elderly is to reduce the 
risk of thromboembolic events associated with it. Several scoring tools are available 
to assess the risks of stroke associated with AF. CHADS2 is one of the commonly 
used tools (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus 
and Previous history of TIA/Stroke each attract 1 score except Stroke which attracts 2 
scores).[392] Results from the National Registry of Atrial Fibrillation reported that 
the stroke rate per 100 patient-years without warfarin therapy increased by a factor of 
1.5 (95% CI, 1.3-1.7) for each 1 score increase in the CHADS2 score. People with AF 
and CHADS2 score 2 have 5.9 fold higher risk of stroke without antithrombic therapy.  
The Euro Heart Survey on Atrial Fibrillation later refined the existing scoring system 
(CHADS2) and suggested another validated scoring tool to assess the risks of stroke 
associated with AF (CHA2DS2-VASc) which included additional risk factors 
including peripheral vascular disease and raised the weightage of increasing age as a 
stronger risk factor by attributing two points for age above 75 years. [393] It is 
suggested that people with CHADS2 score ≥2 or CHA2DS2-VASc score ≥ 2 are in 
high risk category of stroke and merit antithrombic (warfarin) therapy (providing no 
contraindication). [394, 395] Majority of our study participants 72.4% participants 
with AF had CHADS2 score 2 or greater. 87.2% participants with AF were 
CHA2DS2-VASc score 3 or above. Only 15.6% participants with AF were taking 
warfarin. 84.4% participants with AF, who were not on warfarin, only 42.4% 
participants were either on aspirin or clopidogrel.  We do not know how many of our 
participants had contraindications for the use of warfarin, but probably, at least 
partially, the low rate is related to attitudes, co-morbidity,  concerns of serious adverse 
events polypharmacy and drug interaction as mentioned in previous studies. Atrial 
fibrillation is associated with significant burden in especially in elderly due to its 
association with thromboembolic events including stroke and disability caused by 
stroke. In Framingham Study, AF was a strong independent predictor of the degree of 
functional deficit following a stroke. It was reported that ischaemic stroke due to AF 
was associated with higher mortality than non- AF stroke. [396] Investigators from 
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ATRIA study have reported a substantial risk reduction of thrombotic stroke in cohort 
aged 85 years and above with warfarin. Annual stroke rate in those aged 75-84 years 
and were no taking warfarin was 1.4% compared with 3.3% in aged 85 years and 
above who were also not taking warfarin. These people had no additional stroke risk 
factor apart from increasing age and atrial fibrillation. Annual stroke rate in those 
aged 75-84 years and were taking warfarin was 0.53% compared with 0.86% in aged 
85 years and above who were also using warfarin. [386] This indicates a substantial 
benefit of warfarin in stroke prevention in atrial fibrillation in this age group. 
Warfarin has also proven superior to aspirin in preventing stroke in people aged 75 
years and above with AF. The Birmingham Atrial Fibrillation Treatment of the Aged 
Study (BAFTA) was a randomised control trial randomly that compared the efficacy 
of warfarin verses aspirin in preventing stroke in AF patients aged 75 years and 
above. [397] 934 participants with AF were recruited from 234 general practices and 
mean age of participants was 81.5 ± 4.2 years. Primary outcome was fatal and non-
fatal disabling stroke (ischaemic and haemorrhagic) and intra-cranial haemorrhage. 
Participants were randomly assigned warfarin (target INR 2.0- 3.0) and warfarin 
(75mg OD). Both groups were almost identical in co-morbidities (both had nearly 
28% participants with CHADS2 score 3 or above). There were 10 ischaemic strokes, 6 
haemorrhagic strokes and 2 other intracranial haemorrhages in group assigned to 
warfarin compared to 32 ischaemic strokes, 5 haemorrhagic strokes and one other 
intracranial haemorrhages in group assigned to aspirin. Participants assigned to 
warfarin had annual stroke risk of 1.8% vs 3.8% in aspirin group (p=0.003). Whereas 
yearly risk of extracranial was 1.4% in warfarin group vs 1.6% in aspirin group. This 
study clearly showed that anticoagulation was significantly more effective than 
aspirin without any difference in major bleeding event. In another randomised 
prospective study of primary thromboprophylaxis for AF in elderly patients (aged 
between 80-90 years) comparing aspirin vs warfarin showed that more people 
discontinued aspirin than warfarin mainly due to gastrointestinal side affects. [398] 
Despite clearly shown benefits of warfarin in preventing stroke in atrial fibrillation in 
elderly patients issues associated with INR monitoring including repeated blood tests, 
cognitive impairment and poor mobility can make its use quite challenging in certain 
people.[399] However, newer oral anticoagulants including dabigatran can possibly 
bridge the gap created by under utilization and under prescribing of warfarin due the 
factor motioned already. In a recently publish trial (Re-LY, Dabigatran versus 
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warfarin in patients with atrial fibrillation) dabigatran showed similar efficacy at 110 
mg BD dose, for preventing stroke/systemic embolism in patients with AF (annual 
stroke rate 1.53% vs 1.69% for warfarin) and 20% less major bleeds compared to 
warfarin; the 150mg BD dose had approximately 35% superior efficacy and similar 
rates of major bleeds to warfarin. Both dabigatran dose arms had significantly less 
intracranial bleeds or haemorrhagic strokes, compared to warfarin. [400] Dabigatran 
has advantages over warfarin as it does not need monitoring or loading and has few 
interactions with diet or other drugs. Hence, it may prove particularly useful in the 
elderly. NICE guidance on use of dabigatran is currently awaited. Guidelines 
published by European Society of Cardiology guideline (2010) and from the 
American College of Cardiology/American Heart Association/Heart Rhythm Society 
(2011) have mentioned dabigatran as an alternative to warfarin in stroke prevention in 
patients with atrial fibrillation. [401, 402] However, the Canadian Cardiovascular 
Society guidelines (2011) state that dabigatran should be used in preference to 
warfarin, for stroke prevention in patients with atrial fibrillation. [403] 
Trials on some other newly available oral antithrombotic agents like Ximelagatran 
have also shown the better efficacy than warfarin in stroke prevention in AF 
(SPORTIF V Trial). [404] 
Availability of newer antithrombic agents will hopefully improve outcomes and 
contain costs associated with ischaemic stokes and disability caused by acute 
ischaemic stroke in the rapidly expanding population of the very old.  
 
 
 
 
 
 
 
 
237 
 
9.2 Strengths and Limitations 
Strengths of this study include its population-based sample, which included both 
cognitively impaired and institutionalised participants who have been excluded from 
many previous studies in this age group[405-408], and the domiciliary 
echocardiographic approach; we have previously shown that up to 50% of very old 
people would be unwilling to participate in a study requiring hospital attendance.[409] 
The Newcastle 85+ Study cohort has been shown to be socio-demographically 
representative of the local population, including the proportion in care homes.[316] 
We undertook quantitative echocardiographic assessment of both systolic and 
diastolic dysfunction using rigorous and heamodynamically validated Doppler 
criteria.  Rather than rely on self-reported diagnoses, which are known to be 
unreliable at this age, [410, 411] we carried out review of general practice records to 
ascertain disease diagnoses. In addition we repeated our analysis after removing 
participants with spirometric evidence of significant intrinsic lung disease and showed 
that this did not alter our conclusions.  Some limitations merit comment.  We did not 
assign or validate heart failure diagnoses using Framingham or other criteria and we 
cannot therefore consider our category of symptomatic LV dysfunction as entirely 
overlapping with heart failure.  Participants in this study cannot be considered a 
random sample of the very old population; they had elected to participate in the 
Newcastle 85+ study and made a subsequent additional commitment to undergo the 
cardiac assessment. It is therefore possible that study participants were in somewhat 
better health than the general population of the very old and as a result we may have 
under-estimated the true population prevalence of LV dysfunction. Our population 
was of overwhelmingly white ethnicity and although representative of the very old in 
the UK,[412] may not be typical of people of this age resident in other parts of the 
world.  Although diagnostic performance of natriuretic peptides to detect LV 
dysfunction  in elderly cohort have shown to be poor in some previous studies as well, 
but some cardiovascular medications could also affect plasma levels of theses 
peptides and can interfere with the diagnostic performance of natriuretic peptides to 
detect LV dysfunction (LVD). In our study nearly quarter of participants were on 
some cardiovascular medication, which could have also affected the diagnostic 
performance of NT-proBNP to detect LVD. We also lacked the data on 
contraindications and reasons for of thromboprophylactic medications in AF patients 
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in our cohort which could partially explain the low rates of thromboprophylactic 
medications in AF participants. 
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9.3 Conclusions 
 
LV systolic and diastolic dysfunction was very common in community-dwelling 85+ 
year olds and the majority of those affected had limiting symptoms of dyspnoea. 
Despite the NHS Quality and Outcomes Framework[283] initiative to improve the 
management of heart failure in primary care in England, the majority of very old 
people with symptomatic LV dysfunction remained undetected. Due to poor 
performance of NT-proBNP to detect symptomatic or asymptomatic LV dysfunction, 
its role in the diagnostic algorithm remains unclear in older adults.  Accurate and early 
diagnosis of LV dysfunction and heart failure, followed by the implementation of 
individually tailored therapy, is needed to improve outcomes and contain costs in the 
rapidly expanding population of the very old. Further studies are needed to determine 
the optimal approach to identifying those with, and at risk of, heart failure in this age 
group.  
Peripheral vascular disease (PVD) is also very common in community dwelling 85-89 
year olds. Majority of this remain undiagnosed. Undiagnosed PVD and associated 
other cardiovascular pathologies probably are barrier for effective primary and 
secondary prevention of atherosclerotic diseases. ABI assessment can be used in 
primary care setting to screen for PVD and can be used to predict cardiovascular 
morbidity and mortality. However, there is need for further studies to determine the 
optimal approach to screen PVD in primary care and optimise cardiovascular risk in 
older adults. 
Atrial fibrillation is very common arrhythmia in community dwelling 85+ year olds. 
As the population is ageing with rapidly expanding numbers of 85+ year olds, the 
prevalence of AF will continue to increase. AF is affecting approximately 2.3 million 
people in United States and 6 million in Europe and these figures are expected to 
double by year 2050. [381, 413, 414] In order to reduce mortality, morbidity and 
maintain independent functioning among very old is stroke prevention in patients with 
atrial fibrillation. Most effective intervention would be to develop strategies to detect 
atrial fibrillation and offer them appropriate thromboprophylaxis after risk 
stratification for stroke.  
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9.4 Further Research Directions 
Further research is needed to identify the optimal approach to detecting heart failure 
or asymptomatic cardiac dysfunction in community-dwelling very old people, 
particularly in health care systems with limited availability of echocardiography. The 
UK National Institute for Health and Clinical Excellence 2010 Chronic Heart Failure 
Guidelines advocate the use of circulating natriuretic peptides in those in whom there 
is a clinical suspicion of heart failure to either rule out the diagnosis or identify those 
requiring specialist assessment including echocardiography.[295] Population-based 
screening of high risk groups, such as the elderly, has been suggested to additionally 
identify those with asymptomatic dysfunction.[415-418] The role of natriuretic 
peptides in diagnostic algorithm in the very old remains unclear and requires further 
investigation[246] as levels rise with age[233, 419, 420] and with co-morbidities[232, 
233, 295] prevalent at this age.[316]   Should such screening approaches be widely 
adopted, our finding of the high prevalence of the target condition suggests that 
substantially increased provision of echocardiography, in accessible settings, will be 
required for the very old. In this regard, our study has demonstrated the feasibility of a 
domiciliary approach.  
Further studies are needed to determine the optimal approach in identifying those with 
atrial fibrillation (even asymptomatic AF) and at risk of cerebrovascular disease in 
this age group. In order to maintain independent functioning and prevent stroke 
related mortality and morbidity in this age group thromboprophylaxis is important. 
However, further research is needed to find safer and convenient therapeutic 
interventions to reduce thromboembolic risk associated with AF in this age group. 
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Recruitment Profile to the Newcastle 85+ Study Phase 1 
Appendix 1 
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Appendix 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment Profile to the Newcastle 85+ Study Phase 2 
 
 
 
 
 
SAMPLING FRAME  
At the end of Ph 1 
n=819 
 
RIP & withdrew                  n=103 
MAILED OUT 
n=716 
RIP                                      n=34 
CONTACT ESTABLISHED 
n=682 
Withdrew & RIP n=49 
Opt Out                                    n=2 
 
RECRUITED 
n=631 
MDA plus 
 GP record review 
n=630 
 
Multidimensional 
Health Assessment 
(MDA) only 
              n=1 
 
 
RR  n=630 
Men            n=369 
Women          n=660 
 
MDA n=631 
Men       n=323 
Women       n=529 
 
Interview 1    n=630 
Interview 2    n=627  
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Appendix 3. 
Multidimensional Health Assessments undertaken in Newcastle 85+ Study 
 
 
 
MULTIDIMENTINAL HEALTH ASSESSMENT 
Questionnaire 
Socio-demographics 
Family data 
Physical health 
 
Depression 
Disability 
Diet 
Lifestyle 
Social support 
Use of health and social care 
Gender, ethnic origin, living arrangements, socioeconomic status 
Number of siblings and children 
Self rated ‘global’ health status, self reported long standing illness, angina, shortness of breath, joint pain, 
generalized pain, fractures, falls, vision and hearing, incontinence 
 
Aids/appliances, house hold modifications 
 
Smoking, alcohol, exercise 
Clinical measurements 
& Functional tests 
Blood pressure 
Cognitive function 
Hand grip strength 
Walking test 
Anthropometrics 
12 lead ECG 
Spirometry 
Tooth count 
 
Mini mental state examination and computerised assessment of memory and attention (CDR) 
 
Timed ‘up and go test’ 
Weight, bio impedance (body composition- fat and water), demi-span, waist and hip circumference 
 
Forced expiratory volume in one second (FEV1), Forced vital capacity (FVC),  
Blood tests 
Routine haematology and 
biochemistry 
Lipid profile 
Thyroid function 
Inflammatory markers 
Nutritional markers 
Biomarkers 
Markers of immunosenescence 
Full blood count, renal function and electrolytes, liver profile, glucose and glycosylated haemoglobin 
 
Cholesterol, triglycerides, high and low density lipoproteins, apolipoproteins A1 and B 
Free T4, free T3, reverse T3, TSH and TPO antibodies 
High sensitivity CRP, rheumatoid factor, cytokines (TNF –alpha & interleukin 6) 
Vitamin B2, B6, B12, C and D, ferritin, folate and homocysteine. 
DNA repair capacity, telomere length, F2 isoprostane 
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Appendix 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
ASSESSMENTS Phase1 Phase2 Phase3 
 
Application of 7 day activity  monitor  X X 
Blood pressure: Sitting X X X 
Chair stand test  X X 
Cognition: CDR assessment X   
Demi-Span X   
Disability X X X 
ECG X X X 
Eyesight X X X 
Geriatric depression scale X X X 
Hand-grip strength   X X X 
Hearing   X X X 
Spirometry and oximetry  X X X 
Standardised mini-mental state examination 
(sMMSE)  
X  X 
Timed “up and go” test  X   
Timed up and go test (with pam)  X X 
Tooth count   X  X 
Waist and hip circumference   X   
Assessments included in each phase of Newcastle 85+ study 
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Appendix 5 
 
NEWCASTLE 85+ STUDY 
CARDIOVASCULAR PHENOTYPING- PHASE 2/3 
ABNORMAL RESULTS PROTOCOL 
 
 
 
 
ECHOCARDIOGRAMS 
 
Following abnormal findings will be reported back to GPs. 
 
 Significant impairment of LV function (ejection fraction less than 
35%) 
 Significant Valvular heart disease 
 
o Severe Aortic stenosis/regurgitation 
o Severe Mitral stenosis/regurgitation 
o Severe Tricuspid stenosis/regurgitation 
 
 Significant other findings such as Hypertrophied obstructive 
cardiomyopathy (HOCM), Atrial myxoma. 
 
In the presence of any of the above abnormalities, study will be discussed 
with Dr Antoinette Kenny or Prof Bernard Keavney before informing the 
participant’s GP. 
 
A letter will also be sent to concerning GP mentioning the abnormality 
detected along with a copy of scan report and copy of abnormal results 
protocol. 
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Appendix 6 
 
 
Newcastle 85+ Phase 2 ECG PROTOCOL 
 
Send ECG to Glasgow for URGENT report if: 
 Interview 3: GGG6 ‘Yes’ to unexplained falls or GGG28: ‘Yes’ to fits, faints, 
funny turns, blackouts  
 ECG Print out report states complete or 3rd degree heart block or A-V 
dissociation. 
 ECG Print out report states ventricular arrhythmia, ventricular tachycardia 
 ECG Print out report states something else alarming: check with Karen first. 
 
Depending on report from Glasgow, you may then need to inform the GP urgently by 
telephone and faxed letter; Glasgow will advise. 
Please complete the spreadsheet with details of all ECGs sent for urgent report 
 
For all other ECGs, transmit to Glasgow routinely. 
All the automatic print out reports are checked by Professor MacFarlane, amended as 
necessary and copies sent back to us. 
 
Wait for these CONFIRMED reports before contacting GPs with other ‘notifiable’ 
abnormalities. Send a copy of the confirmed report ECG. If there is a ‘notifiable 
abnormality’ state whether or not they have symptoms (GGG1 any falls, GGG6 
unexplained falls and GGG28 fits, faints, funny turns, blackouts).  
 
Only clinically significant arrhythmias and heart block will be notified: 
  
1. Atrial fibrillation or flutter; with or without symptoms    
   
 Inform within 1 month 
 
2. Sinus bradycardia <50; only if associated with symptoms: falls (GGG1) or fits, 
faints, funny turns, blackouts or severe dizziness (GGG28) 
Inform within 1 week 
 
3. Sinus bradycardia between 50 and 60 only if in conjunction with 1st degree heart 
block and then only if associated with symptoms (as above) 
Inform within 1 week. 
 
4. 1
st
 degree heart block ONLY if associated with symptoms (as above). 
 
5. 2nd or 3rd degree A-V block; with or without symptoms 
3
rd
 degree (complete) heart block: Inform urgently by phone and fax letter 
2
nd
 degree heart block: Inform within 1 week 
 
6. Right bundle branch block only if in conjunction with left or right axis deviation; 
only if associated with symptoms (as above). 
Inform within 1 week. 
 
248 
 
7. Left bundle branch block only if in conjunction with 1st degree heart block; only if 
associated with symptoms (as above) 
Inform within 1 week 
 
8. WPW: only if associated with symptoms (as above) 
Inform within 1 week 
 
9. Long QTc: only if associated with symptoms (as above) 
Inform within 1 week 
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Newcastle 85+ Phase 3 ECG PROTOCOL 
 
Send ECG to Glasgow for URGENT report if: 
 Interview 2: EE5 ‘Yes’ to unexplained falls or EE13: ‘Yes’ to fits, faints, 
funny turns, blackouts  
 ECG Print out report states complete or 3rd degree heart block or A-V 
dissociation. 
 ECG Print out report states ventricular arrhythmia, ventricular tachycardia 
 ECG Print out report states something else alarming: check with Karen first. 
 
Depending on report from Glasgow, you may then need to inform the GP urgently by 
telephone and faxed letter; Fahad/Glasgow will advise. 
Please complete the spreadsheet with details of all ECGs sent for urgent report 
 
For all other ECGs, transmit to Glasgow routinely. 
All the automatic print out reports are checked by Professor MacFarlane, amended as 
necessary and copies sent back to us. 
 
Wait for these CONFIRMED reports before contacting GPs with other ‘notifiable’ 
abnormalities. Send a copy of the confirmed report ECG. If there is a ‘notifiable 
abnormality’ state whether or not they have symptoms (EE1 any falls, EE5 
unexplained falls and EE13 fits, faints, funny turns, blackouts).  
 
Only clinically significant arrhythmias and heart block will be notified: 
  
1. Atrial fibrillation or flutter; with or without symptoms    
   
 Inform within 1 month 
 
2. Sinus bradycardia <40; with or without symptoms 
Inform within 1 week 
 
3. Sinus bradycardia between 40 and 50 only if associated with symptoms: falls 
(GGG1) or fits, faints, funny turns, blackouts (GGG28) 
Inform within 1 week 
 
4. Sinus bradycardia between 50 and 60 only if in conjunction with 1st degree heart 
block and then only if associated with symptoms (as above) 
Inform within 1 week. 
 
5. 1
st
 degree heart block ONLY if associated with symptoms (as above). 
 
6. 2nd or 3rd degree A-V block; with or without symptoms 
3
rd
 degree (complete) heart block: Inform urgently by phone and fax letter 
2
nd
 degree heart block: Inform within 1 week 
 
7. Right bundle branch block only if in conjunction with left or right axis deviation; 
only if associated with symptoms (as above). 
Inform within 1 week. 
250 
 
 
8. Left bundle branch block only if in conjunction with 1st degree heart block; only 
if associated with symptoms (as above) 
Inform within 1 week 
 
9. WPW: only if associated with symptoms (as above) 
Inform within 1 week 
 
10. Long QTc: only if associated with symptoms (as above) 
Inform within 1 week 
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Appendix 7 
 
MM. SHORTNESS OF BREATH (Questionnaire) 
POSSIBLE WITH AN INFORMANT 
I would now like to find out whether shortness of breath limits your day to day 
activities. I am not just asking 
whether or not you GET short of breath but whether the shortness of breath LIMITS 
you. I am interested in how 
you have been over the last 4 weeks that is since......(State date 4 weeks previously) 
1 So in the last 4 weeks, has shortness of breath limited your ability to move 
around your home (on one level)? 
DO NOT INCLUDE STAIRS 
o Yes 
o No SKIP'MM.2(8) 
o Limited for reason(s) unrelated to shortness of breath SKIP'MM.2(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
2 How much has shortness of breath limited your ability to move around your 
home (on one level)? 
o A bit 
o A lot 
o Completely unable to move around the home due to shortness of breath 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
3 In the last 4 weeks, has shortness of breath limited your ability to walk 
outdoors, on the level, at your own pace? 
o Yes 
o No SKIP'MM.4(8) 
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o Limited for reason(s) unrelated to shortness of breath SKIP'MM.4(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
4 How much has shortness of breath limited your ability to walk outdoors, on the 
level, at your own pace? 
o A bit 
o A lot 
o Completely unable to walk outdoors, on the level, at own pace due to 
shortness of breath 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
5 In the last 4 weeks, has shortness of breath limited your ability to hurry on the 
level? 
o Yes 
o No SKIP'MM.6(8) 
o Limited for reason(s) unrelated to shortness of breath SKIP'MM.6(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
6 How much has shortness of breath limited your ability to hurry on the level? 
o A bit 
o A lot 
o Completely unable to hurry on the level due to shortness of breath 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
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o  
 
7 Over the past 4 weeks, have you had any swelling in your feet, ankles or legs? 
ONLY RECORD BILATERAL SWELLING 
o Yes 
o No SKIP'MM.8(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
8 Was this swelling ever so bad that you were unable to put on your shoes? 
o Yes 
o No 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
9 Shortness of breath section answered by 
o Participant alone SKIP'MM.10(8) 
o Informant/consultee alone SKIP'MM.10(8) 
o Participant and informant/consultee 
o Not applicable 
o Item not completed 
10 If participant and informant/consultee, was this 
o Mainly participant 
o Mainly informant/consultee 
o Equal contribution 
o Not applicable 
o Item not completed 
 
11 Was this section omitted? 
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o Yes SKIP'MM.1(8) MM.2(8) MM.3(8) MM.4(8) MM.5(8) MM.6(8) 
MM.7(8) MM.8(8) MM.9(8)MM.10(8) 
o No SKIP'MM.12(98) MM.13(8) 
o Not applicable 
o Item not completed 
 
12 Why was it omitted? 
o Interviewer decision - Participant frailty/fatigue SKIP'MM.13(8) 
o Interviewer decision - Participant distress SKIP'MM.13(8) 
o Interviewer decision - Participant unwell SKIP'MM.13(8) 
o Interviewer decision - Participant too busy SKIP'MM.13(8) 
o Interviewer decision - Concern re interviewer safety SKIP'MM.13(8) 
o Interviewer error SKIP'MM.13(8) 
o Participant refused 
o Relative/carer refused 
o Other reason (specify) SKIP'MM.13(8) 
o Not applicable 
o Item not completed 
 
13 Why did they refuse? 
o No reason given 
o Distress/anxiety 
o Unwell 
o Fatigue 
o Other reason (specify) 
o Not applicable 
o Item not completed 
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NN. CHEST PAIN (Questionnaire) 
NOT POSSIBLE WITH AN INFORMANT 
Now I would like to ask you some questions about chest pain, again I am interested in 
what has happened over 
the last 4 weeks that is since (STATE DATE 4 WEEKS PREVIOUSLY) 
1 In the last 4 weeks, have you had any pain or discomfort in your chest? 
o Yes SKIP'NN.2(8) 
o No 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
2 In the last 4 weeks, have you had any pressure, heaviness or tightness in your 
chest? 
o Yes 
o No SKIP'NN.3(8) NN.4(8) NN.5(8) NN.6(8) NN.7(8) NN.8(8) NN.9(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
3 Did the 'symptom' come on when you exerted yourself? 
o Yes 
o No SKIP'NN.4(8) NN.5(8) NN.6(8) NN.7(8) NN.8(8) NN.9(8) 
o Completely unable to exert self for reason unrelated to 'symptom' 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
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4 Did the 'symptom' limit your ability to move around your home (on one level)? 
DO NOT INCLUDE STAIRS 
o Yes 
o No SKIP'NN.5(8) 
o Limited for reason(s) unrelated to 'symptom' SKIP'NN.5(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
5 How much did the 'symptom' limit your ability to move around your home (on 
one level)? 
o A bit 
o A lot 
o Completely unable to move around home due to 'symptom' 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
6 Did the 'symptom' limit your ability to walk outdoors, on the level, at your own 
pace? 
o Yes 
o No SKIP'NN.7(8) 
o Limited for reason(s) unrelated to 'symptom' SKIP'NN.7(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
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7 How much did the 'symptom' limit your ability to walk outdoors, on the level, at 
your own pace? 
o A bit 
o A lot 
o Completely unable to walk outdoors, on level, at own pace due to 'symptom' 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
8 Did the 'symptom' limit your ability to hurry on the level? 
o Yes 
o No SKIP'NN.9(8) 
o Limited for reason(s) unrelated to 'symptom' SKIP'NN.9(8) 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
9 How much did the 'symptom' limit your ability to hurry on the level? 
o A bit 
o A lot 
o Completely unable to hurry on the level due to 'symptom' 
o Don't know 
o Not applicable 
o Refused to answer 
o Not asked 
 
10 Was this section omitted? 
o Yes SKIP'NN.1(8) NN.2(8) NN.3(8) NN.4(8) NN.5(8) NN.6(8) NN.7(8) 
NN.8(8) NN.9(8) 
o No SKIP'NN.11(98) NN.12(8) 
o Not applicable 
o Item not completed 
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11 Why was it omitted? 
o Interviewer decision - Participant frailty/fatigue SKIP'NN.12(8) 
o Interviewer decision - Participant distress SKIP'NN.12(8) 
o Interviewer decision - Participant unwell SKIP'NN.12(8) 
o Interviewer decision - Participant too busy 
o Interviewer decision - Informant/consultee ONLY answering - section not 
possible with 
o informant SKIP'NN.12(8) 
o Interviewer decision - Concern re interviewer safety SKIP'NN.12(8) 
o Interviewer error SKIP'NN.12(8) 
o Participant refused 
o Relative/carer refused 
o Other reason (specify) SKIP'NN.12(8) 
o Not applicable 
o Item not completed 
 
12 Why did they refuse? 
o No reason given 
o Distress/anxiety 
o Unwell 
o Fatigue 
o Other reason (specify) 
o Not applicable 
o Item not completed 
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Appendix 8 
 
Standard Operational Procedure For The Cardiac Examination 
(Echocardiography) Using Vivid-I   Within The Newcastle 85+ Study 
 
Document Number: 0003/IAH/85+ 
Title: SOP for cardiac examination (Echocardiography) 
Version: Final Draft 
Author: Fahad Yousaf 
 
 
Responsibilities: 
 
Research investigators trained in the method are responsible for: 
 Accurate measurement and recording of cardiac examination                             
(echocardiography) by using Vivid-I from participants 
 Clear explanation of the procedure to participants and  
 Ensuring that equipment is in optimal working order. 
 
Equipment: 
 
 Vivid I (BT06 system) 
 3S-RS phased array cardiac USG probes with lead 
 ECG leads (3: red, green & black) 
 Wedge foam Pillow (help position the participant) 
 
General Precautions: 
 
 Make sure all the connections are secure. 
 Make sure all equipment is fully charged before going to participant’s house. 
 Make sure to put paper towel on the bed on to avoid 
smearing of participant’s clothe or bedding with gel. 
 Try to be very gentle while performing the scan and 
provide paper towels to participant to wipe off the gel from the 
chest 
 Do follow the manufacturer’s instruction for 
maintenance and specific cleaning and disinfection for probe. 
 For cleaning of probe always disconnect it from the 
unit. 
 
260 
 
Instructions for using the Vivid-I (Cardiac BT06 package) 
 
The investigator must read the accompanying instruction manual carefully, and then 
familiarise themselves with the equipment. Step-by-step instructions for day-to day use 
will be kept with each device.  
Creating a new Participant’s record 
 Press PATIENT 
The patient handling screen will come up 
 Press CREAT NEW PATIENT 
An operator log window will appear. Press log on. The search/create Patient window will 
come up. 
 Enter participant’s details (last name, first name, date of birth and ID). We ll 
use PID number instead of last and first name due to confidentiality issues. 
 Than press ‘Create Patient’ to store participant details. 
Participant’s positioning 
 Ask participant to lye down on the 
bed, ideally in steep left lateral decubitus 
position. Consistent with their comfort. A sofa 
would be an acceptable alternative if participant 
prefers. If participant is too immobile to 
achieve an appropriate position for study, this 
should be noted but the data should, as far as is 
possible, still be recorded. 
 Participant has to undress down to 
waist/ umbilicus level. 
 Put 3 ECG stickers on participant 
body, (Red-Right shoulder; Yellow-Left shoulder; Black- Right flank) and connect these 
with respective ECG leads. 
Selecting the cardiac probe 
 Ensure a cardiac probe 3S-RS is connected and selected for cardiac scan 
(Echocardiogram) 
Capturing participant’s data 
 All standard views (parasternal long axis, parasternal short axis, apical 4 
chamber, apical 5 chamber, apical 2 chamber, apical 3 chamber and epigastric views w 
ill be obtained in above mentioned position. 
 All standard view images will be stored as cine loop for min 5 cardiac cycles, by 
pressing the Store button twice. 
 All still images will be stored by (Press Freeze button initially to get a still 
frame) pressing Store button once. 
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  Still images will be taken by freezing the frames for all M-mode, CW Doppler, 
and PW Doppler measurements. ( these functions can be activated by moving the 
Cursor and Pressing the respective buttons (MM, CW and PW) 
Parasternal view: Long Axis 
 Store a cine loop 
 M-mode the LV and Ao/LA-  and store 
still frames 
 Put colour on MV and AV and record 
as cine loop. 
Parasternal view: Short Axis 
 At AV level- Store a cine loop with 
and with out colour on each valve (AV, TV, 
PV) 
 Obtain CW Doppler frames through 
TV and PV but moving the cursers, and store 
still frames.  
 At MV level- Store a cine loop with 
and with out colour. 
 At papillary muscle level- Store a cine 
loop. 
Apical 4 chamber view: 
 Store a cine loop 
 Press TVI button and store a TVI loop as well (analysed later in FRH on vivid 
7) 
 Press TDI button and move he cursor on lateral and medial MV annulus 
respectively, to get E’ recording. Store as a still frame. 
 Put colour on MV and store as a cine loop. 
 Get PW Doppler on MW to record E & A waves, store as still frame. 
 Get PW Doppler on Pulmonary veins, if visible. 
 Put colour on TV, store cine loop. 
 Get CW Doppler on TV to record TR Vmax, store as a still frame. 
 Put M-mode cursor on TV lateral annulus to record TAPSE. Store as a still 
frame. 
Apical 5 chamber view 
 Store a cine loop. 
 Put colour on AV, store a cine loop. 
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 Put cursor thought AV and record PW and CW for AV. Store as a still frame. 
Apical 2 chamber view 
 Store a cine loop. 
 Put colour on MV, store cine loop. 
Apical 3 chamber view 
 Store a cine loop. 
 Put colour on MV and AV, store cine loop. 
Epigastric view 
 Store a cine loop. 
 Put colour on IAS, store a cine loop. 
 M-mode the IVC, store cine loop and still frame as well. 
 If IVC appears dilated, get an image with sneezing manoeuvre as well. 
 Give paper towel to participant to wipe off the gel from his/her chest. 
 Remove the ECG stickers from participant’s chest. 
 Press Review button and End exam button to end and store the examination. 
 Clean the probe & ECG leads, remove from the machine and pack them away. 
 Examination will be analysed offline in 85+study’s office according to our study 
protocol. 
Archiving and exporting the data in to database 
 Insert a removable media in the drive (CD-R) 
 Press PATIENT on the front panel, and then select Patient List. 
 Select the source archive in Dataflow field: Local Archive-Int.HD 
 Press Export, then select CD/DVD Archive as a destination 
 Press OK, a window‘ll appear saying: Current media is not formatted. Do you 
wish to format it? Select Yes. 
 Select the examination from Patient List that you want to export. 
 Press Copy and then press Ok to resume export. And finally press Done in the 
Export patient widow to complete the process. 
 Press Alt + E to eject the CD.  
 Make another copy of the same exam by using the same procedure.  
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To export data in excel and pdf format, insert the Encrypted USB memory disk 
(Kingston-8GB) in USB slot on the back of Vivid I.  Repeat the above procedure but 
select excel file and pdf file respectively, when you‘ll press Export. And also select 
Removable memory disk as a destination. 
Data will than be stored on 85+ study’s shared hard drive on university’s network. 
 
Approval and sign off  
Author: 
Name: Dr Fahad Yousaf  
Position: Clinical Research Associate 
Signature: Date: 31/10/2008 
Approved by: 
Name: Prof Bernard Keavney 
Position: Consultant Cardiologist 
Signature: Date: 
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Standard Operational Procedure For The Recording Of Carotid Intima-
Media Thickness (CIMT) Measurements Within The Newcastle 85+ Study 
 
Document Number: 0003/IAH/85+ 
Title: SOP for recording CIMT measurements 
Version: Final Draft 
Author: Fahad Yousaf 
 
Responsibilities: 
 
Research investigators trained in the method are responsible for: 
 Accurate measurement and recording of carotid 
intima-media thickness (CIMT) by using Vivid I from 
participants 
 Clear explanation of the procedure to participants and  
 Ensuring that equipment is in optimal working order. 
 
Equipment: 
 
 Vivid I 
 12L-RS linear USG probes with lead 
 
General Precautions: 
 
 Make sure all the connections are secure. 
 Make sure all equipment is fully charged before going to participant’s house. 
 Make sure to put paper towel on the collar to avoid searing of participant’s 
clothe with gel. 
 Try to be very gentle while performing the scan and provide paper towels to 
participant to wipe off the gel from neck. 
 Do follow the manufacturer’s instruction for maintenance and specific 
cleaning and disinfection for probe. 
 For cleaning of probe always disconnect it from the unit. 
 
Instructions for using the Vivid-I (CIMT package) 
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The investigator must read the accompanying instruction manual carefully, and then 
familiarise themselves with the equipment. Step-by-step instructions for day-to day use 
will be kept with each device.  
 
Creating a new Participant’s record 
 
 Press PATIENT 
The patient handling screen will come up 
 Press CREAT NEW PATIENT 
An operator log window will appear. Press log on. The search/create Patient window will 
come up. 
 Enter participant’s details (last name, first name, date of birth and ID). We ll 
use PID number instead of last and first name due to confidentiality issues. 
 Than press ‘Create Patient’ to store participant details. 
 
Participant’s positioning 
 
 Ask participant to lye down on the bed as flat as is consistent with their 
comfort. A sofa would be an acceptable alternative if participant prefers. If participant is 
too immobile to achieve an appropriate position for study, this should be noted but the 
data should, as far as is possible, still be recorded. 
 Ideally participants are placed in supine position with head rotated by 45° to 
the left/right, with their arm rested at their sides. 
 
Selecting the vascular probe 
 
 Ensure a vascular probe 12L-RS is connected and selected for carotid scan to 
measure CIMT. 
 
 
Capturing participant’s data 
 
 A longitudinal image of carotid artery 
will be obtained as mentioned in CIMT 
imaging protocol. 
 Optimize the image by using depth 
and focus settings. 
 Press freeze 
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 Scroll to end-diastolic frame where the intima layer is clearly visible  
 Press measure 
 Select the appropriate IMT measurement. If measuring the IMT of posterior 
wall of the right common carotid select Rt and CCA IMT Post. 
 Place the cursor in the artery closer to 
the posterior wall and press SET to anchor the 
start of search region. 
 Move the cursor parallel to the artery 
to define the end point of the search region. 
Make sure the intima and media layer are with 
in the search region. Press SET to anchor the 
point. Automated software will automatically 
detect the IMT and will do the calculations. 
The measurements are displayed in the 
Measurement result table on top left hand side of the screen.  
 Images will be stored by using STORE button.  
 Finish the exam by clicking END EXAM button. 
 Clean the probe, remove from the machine and pack it away. 
 Give paper towel to participant to wipe off the gel from the neck. 
 
 
 
Exporting that data in to database 
 
By selecting the given participant measurement will be exported in to an excel format to 
an encrypted USB memory disk (Kingston-8Gb). Data will than be stored on 85+ study’s 
shared hard drive on university’s network. 
 
 
 
Approval and sign off  
 
 
Author: 
Name: Dr Fahad Yousaf  
Position: Clinical Research Associate 
Signature: Date: 30/09/2008 
Approved by: 
Name: Prof Bernard Keavney 
Position: 
Signature: Date: 
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Standard Operational Procedure For The Recording Of Pulse Wave 
Velocity (PWV) And Ankle Brachial Index (ABI) Measurements Within 
The Newcastle 85+ Study 
 
Document Number: 0002/IAH/85+ 
Title: SOP for recording PWV and ABI measurements 
Version: Final Draft 
Author: Fahad Yousaf 
 
 
Responsibilities: 
 
Research investigators trained in the method are responsible for: 
 Accurate measurement and recording of pulse wave velocity (PWV) and ankle 
brachial index (ABI) measurements by using Vicorder from participants, 
 Clear explanation of the procedure to participants and  
 Ensuring that equipment is in optimal working order. 
 
Equipment: 
 
Vicorder Instrument 
USB Lead x 1 
Pressure Cuffs (limbs) x 5 
Pressure Cuffs (neck) x 1 
Pressure Hoses x 2 
PPG Sensors x 2 (Photoplethysmography) 
5 MHz and 8 MHz Doppler probes with lead 
Laptop (Toshiba – Satellite Pro) 
 
General Precautions: 
 
 Make sure all the connections are secure 
 Make sure all equipment is fully charged before going to participant’s house 
 When using neck cuff or any other cuffs the participant should be advised that a mild 
constriction will be felt when they inflate. 
 Cuffs should automatically deflate but if for some reason they fail to deflate, unplug 
the pneumatic cuff connectors. 
 Cleaning the Vicorder, its components and leads should only be undertaken by wiping 
with a soft cloth moistened with mild soap or antiseptic solution. 
 Vicorder will require periodic calibration of its pressure channels to maintain its 
accuracy. 
 
Instructions for using the ‘Vicorder’ 
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The investigator must read the accompanying instruction manual carefully, and then 
familiarize him with the equipment. Step-by-step instructions for day-to -day use will be 
kept with each device.  
 
Entering participant’s details 
 
 Click ‘File’ → ‘New Patient’. (New patient’s window will appear). 
 Enter participant’s details (last name, first name, date of birth and ID). We shall use 
PID number instead of last and first name due to confidentiality issues. 
 Then click ‘Finish’ to store participant details. 
 
Participant’s positioning 
 
 Participant will be in a supine position with the head and shoulders raised by 
approximately 30 degrees; this will prevent venous contamination of arterial signals. 
 We will use a pillow or a neck wedge for this purpose. 
 
System setup 
 
 Connect the Vicorder instrument with the laptop using USB cable. 
 Connect the 2 coloured pneumatic hoses to ‘PRESS 1’ & ‘PRESS 2’ on the front 
panel of the Vicorder. 
 Connect the 2 coloured PPG connectors to ‘PPG 1’ & ‘PPG 2’ on the front panel of 
the Vicorder. 
 Start the Vicorder software by double clicking the icon on computer’s screen. 
 
Capturing participant’s data 
 
 Select the PWA ABI protocol 
 
 Apply cuffs, as shown in the pictures below: 
 
o neck cuff 
(The neck cuff is placed around participant’s neck with 
pressure pad over right carotid area – just below the cricoid 
cartilage) 
 
o arm cuffs on each side 
(Place just above cubital fossa) 
 
o thigh cuff on right side 
(Placed over upper part of the thigh, as high as possible) 
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o ankle cuffs on each side 
(Place just above the ankles joints) 
 
Step 1- Arm Pressures 
 
 Now attach the Red Hose to the Right Arm and Blue Hose 
to Left Arm. 
 
 Apply PPG sensors to the largest finger on the left and 
right hands. (Red PPG to right hand and Blue PPG to left 
hand) 
 
 
 The Right Arm Pressure button starts the ABI measurements. 
 
 
 Note: if software only displays a single channel/trace than  
 press the F4 Multi-Chan button and it will show 2 traces, one for each limb. 
 
 
 Press ‘Space Bar’ to inflate the cuffs. 
 
 
 Once you get a decent trace, press ‘Save’ key to store the 
results. 
 
 
Step 2 – Leg Pressures 
 
 
Now attach the Red Hose to Right Ankle and Blue Hose to Left Ankle. 
 
 
Apply PPG sensors to the big toe of each foot. (Red PPG to 
right hand and Blue PPG to left hand) 
 
 
The Right Ankle Pressure button starts the ABI 
measurements. 
 
Press Space Bar to inflate the cuffs. 
 
Once you get a decent trace, press ‘Save’ key to store the results. 
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Step 3 – Aortic Pulse Wave Velocity 
 
Now attach Red Hose to neck cuff and Blue Hose to right thigh cuff. 
 
Click on the large white area in ‘Right Arm Box’ as shown to 
enter the PWV Mode. 
 
Measure the distance between Supra-sternal notch and the 
top of Thigh cuff in centimetres. (L) 
 
*(The distance between carotid and femoral sampling sites 
will be measured above the body surface with a metal tape 
measure to avoid over-estimation) 
 
Click on F8 button to enter the data (L) in ‘length’ box. 
 
Now press the Space Bar to inflate the cuffs (do remember to 
mention to the patient that you are about to inflate the cuffs). 
 
Once stable wave forms are obtained, press space bar again.  It 
will give us PWV and TT (transient time) measurements.  
 
Press Return/Save to finish the measurement and save the 
reading. 
 
Remove the cuffs and pack all the equipment properly.  
 
 
 
 
 
 
 
Exporting that data in to database 
 
In the end result be stored in Vicorder database, which should be backed up in University 
network database. Database should be backed up after every visit. 
 
Approval and sign off  
 
Author: 
Name: Dr Fahad Yousaf  
Position: Clinical Research Associate 
Signature: Date: 09/09/2008 
 
Approved by: 
Name: Prof Bernard Keavney 
Position: 
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Standard Operational Procedure For The Recording Of Pulse Wave 
Analysis (PWA) Measurements Within The Newcastle 85+ Study 
 
Document Number: 0001/IAH/85+ 
Title: SOP for recording PWA measurements 
Version: 1st Draft 
Author: Fahad Yousaf 
 
Responsibilities: 
 
Research investigators trained in the method are responsible for: 
Accurate measurement and recording of pulse wave analysis measurements (PWA) by 
using SphygmoCor ® Px from participants, 
Clear explanation of the procedure to participants and  
Ensuring that equipment is in optimal working order. 
 
Equipment: 
 
SphygmoCor Electronics Module – Px 
AtCor Tonometer (In module Tray) 
Serial Cable 
Power Cable 
Carry Bag 
Laptop (Dell) 
Omron 705IT Blood pressure apparatus 
 
General Precautions: 
 
Make sure all the connections are secure 
Make sure all equipment is fully charged before going to participants house 
When tonometer is not in use, protect it by putting the plastic dome cover over it. 
Tonometer should be routinely cleaned every month with mixture of warm water and mild 
detergent. 
 
Instructions for using the SphygmoCor ® Px. 
 
The investigator must read the accompanying instruction manual carefully, and then 
familiarise themselves with the equipment. Step-by-step instructions for day-to day use 
will be kept with each device.  
 
System setup 
 
Connect the SphygmoCor Module with the laptop using serial cable. 
Plug the electronic module power cable into the main power. 
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Turn the Module ‘on’ by switching the on/off button. 
Connect the tonometer’s socket to its matching connector located in the module’s tray.  
 
 
 
 
Entering participant details 
 
Open the ‘Patient’ screen by clicking on the Patient Button, select the ‘Create New’ button 
and enter the participant details. Enter PID number, Date of Birth and Sex. Click on the 
‘Update’ button to add the details of the participant to the database. (Name, sex and DOB 
are mandatory in the software, but we ll use PID number in Name field because of 
confidentiality issues.) 
 
 
 
 
Capturing participant’s data 
 
Open the study screen by clicking on ‘study icon. 
Following screen will appear 
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Make sure radial box is ticked 
Enter systolic and diastolic BP readings ( BP should be taken by Omron 705IT as per 85+ 
study protocol ) 
 
Performing the Data capture 
 
Now we are ready to take the capture data. To go on data capture screen press enter from 
laptop keyboard or click on icon ‘Capture Data’ 
 
 
 
Participant will be in supine position, with shoulders and neck elevated by around 30 
degrees. 
Feel for the location of the strongest pulse at radial artery of the participant’s wrist and 
place the tonometer on the skin at this point. 
Gently press the tonometer into the skin until a waveform signal appears on the screen. 
(Tonometer should be perpendicular to the wrist) 
Once achieved a consistent waveform, hold it steady for 12 seconds and press ‘space bar’ 
that will capture the data. 
After that report screen will automatically displayed with all the required measurements. 
(Aortic systolic pressure, aortic pulse pressure, augmentation pressure, augmentation index 
@ HR 75, ejection duration and SEVR ). 
 
 
Examine the report for Quality control 
 
Operator Index is an indicator of overall quality of captured data. Anything more than 80 is 
acceptable. It is calculated by assigning a weighting to Quality Control Indices (as 
mentioned below) 
 
 
Minimum average pulse height: 100 units 
Maximum pulse height variation: 5% 
Maximum diastolic variation: 5% 
Minimum quality index: minimum 80 
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Augmentation index: <50% 
If any of above criteria is not met study should be repeated. 
 
 
 
 
Exporting that data in to database 
 
In the end result be stored in SphygmoCor database, which should be backed up in 
University network database. 
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Standard Operational Procedure For The Recording Of Electrocardiograph Within The 
Newcastle 85+ Study 
 
Responsibilities: 
 
Research investigators trained in the method are responsible for accurate measurement and 
recording of echocardiographs from volunteers. Clear explanation of the procedure to volunteers. 
Ensuring that equipment is in optimal working order. 
 
Equipment: 
 
 Atria 6100 ECG machine 
 Power cable and adaptor 
 Leads with clips attached 
 Electrodes 
 Moist Wipes to clean skin (if necessary) 
 Recording paper 
 
Instructions for using the ATRIA 6100 
Before use 
 The investigator must read the accompanying instruction manual carefully, and then 
familiarise themselves with the equipment and correct electrode / lead placement by using 
the device on one or more volunteers. Step-by-step instructions for day-to day use will be 
kept with each device.  
 
Set the Date and Time 
 
 Press On/Stby 
 Press Setup then select System option in the menu 
 Select Date (DD.MM.YYYY) option 
 Enter date in required format (using number keys and delete key to correct errors) 
 When date correct press Enter to review time 
 Enter or change time using number keys and delete key to correct errors (time is entered 
in 24 hour format) 
 Press Home to return to main display 
 
Setting Required fields 
 
 Press Setup 
 Scroll down to Patient and press Select 
 Ensure the following fields are tagged as ON (Patient ID is automatically selected as 
ON).  
  Last Name 
  Date of Birth 
  Gender 
  Technician 
  Comment 
All other fields should be turned off. 
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Changing the status of a field 
 Scroll to required field and press Select 
 Scroll to required status (ON or OFF) and press Select 
 Continue to work through each field as required or press Back at any stage to skip to 
another field 
 
Adding Participant Demographics 
 Press Patient then select Enter New Patient 
 Enter ID number, must include letters NE and all numbers, then press Select  
 In Last Name field re-enter ID as before and press Select 
 Enter date of birth in required format and press Select 
 Choose gender and press Select 
 Enter nurse ID number as 2 digit number and press Select 
 Enter any comment if necessary eg. if ECG obtained with participant in sitting position 
(maximum of 25 characters allowed), then press Select 
 
Acquiring an ECG 
 Ensure that the individual is as relaxed as possible. Prepare volunteer and place electrodes 
and corresponding leads according to the diagram on Quick Steps page. 
 Press ECG then scroll to Acquire ECG, current patient data and press Select 
 ECG will now be acquired and printed 
 ECG will automatically be saved in memory 
 If print out not suitable then readjust leads, stickers etc until satisfied then highlight 
Acquire new ECG on same patient and press Select.  Do not press ECG button as this 
records ECG with no demographics. 
 
Retrieving Participant Details 
 Press Patient Directory 
 Select View Patient Directory 
 Scroll to required ID number and press Select 
 
Replacing Paper 
 Remove the paper tray cover (on left side of machine) by squeezing lever until it clicks 
and pulling out tray 
 Place the new stack of paper into the compartment so that: 
 The black queue mark on the lower left hand corner of paper is visible 
 The writing is on bottom of document 
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 The red line that appears at the bottom of the paper is on last few sheets of 
 paper (not first few) as this is a reminder that paper is about to run out 
 Lift the top sheet up and replace the tray cover by laying it flat and sliding it back into 
machine.  Push in until tray clicks into place.  Do not insert tray at an angle 
 To advance the paper to the start of the next sheet, ready for use, press the Form Feed 
button.    
Transmitting ECG to Glasgow 
 Press Send/Rec  button 
 Select Select Records to Send 
 Highlight each record and either select hold or send 
 When all required records have been selected to send (and all non-required records have 
been checked as hold) press Back button 
 Ensure modem is switched on and connected to phone line 
 Connect modem to ECG machine via 9 pin adaptor 
 Highlight  Send All New or Selected ECGs and press Select 
 Machine should then connect to modem and transmit data 
 Once transmission is complete a confirmation message will be displayed 
 Print a copy of report to confirm ECG has been sent 
 
General information 
 The device should be calibrated according to the instruction manual chapter 2 p2-3. 
 Do not clean the monitor with detergents; if dirty, wipe with a damp cloth 
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Standard Operational Procedure For The Measurement Of Blood Pressure Within 
The Newcastle 85+ Study 
 
Responsibilities: 
Research investigators trained in the method are responsible for: 
 Ensuring equipment is in optimal working order 
 Clearly explain procedure to participant 
 Accurately measure and document blood pressure 
 The safety of the participant throughout the procedure 
 
  
Equipment: 
 Digital blood pressure monitor (Omron HEM 705-IT) 
 Blood pressure cuffs (1 regular 1 large) 
 Tape measure 
 AA batteries x4 
 
Instructions for using the OMRON HEM 705-IT 
 
Before use: 
 Read the instruction manual carefully, insert batteries and then familiarise yourself 
by using the device on a few volunteers.  
 Set the time and date. 
 Keep step-by-step instructions for day to day use with each device.  
 
General information: 
 The device should be calibrated biannually (refer to instruction manual p20). 
 Batteries should be replaced when the symbol indicating low battery power is 
shown. (Batteries should provide 500 measurements). 
 The monitor automatically stores up to 28 readings, when this total is reached the 
oldest readings will be deleted and new reading stored. 
 Do not clean the monitor with detergents; if dirty, wipe with a damp cloth. 
 
Preparation of participant: 
 Ideally participants should have an empty bladder, have not smoked and not 
consumed alcohol in the 30 minutes before blood pressure measurement. 
 Ensure that the individual is as relaxed as possible. Ask the participant to sit with 
both feet parallel and flat on the floor. 
 Participants should rest for five minutes in the sitting position before 
measurement. 
 Participants should be asked not to talk during blood pressure measurement. 
 
Choosing the correct cuff: 
 Arm circumference (AC) should be measured midway between the shoulder tip and 
the olecranon process. 
 If AC <32cm use regular cuff; if AC >32 use large cuff. If AC <22cm use small 
cuff. 
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ARM CIRCUMFERENCE CUFF TO BE USED 
17 – 22 cm SMALL 
22-32 cm REGULAR 
32-42 cm LARGE 
 
 
Positioning the cuff: 
 See OMRON manual (pg 7,8) for correct placement of cuff. 
 The cuffs are designed for blood pressure measurement on the left arm. If the cuff 
cannot be applied on the left arm, the right can be used – but be certain that the 
green strip on the lower boundary of the cuff is always on the brachial artery. 
THE SAME ARM SHOULD BE USED THROUGHOUT THE STUDY. 
 The cuff can be placed over a thin shirt or blouse sleeve. 
 Ensure the arm is supported on a cushion or table top, so the cuff position is in 
line with the level of participant’s heart (see manual illustration p8). 
 Instruct participant to relax and to take 3-4 deep breaths prior to commencing the 
procedure. This aids in stabilising their blood pressure. 
 
Preparing the equipment and taking the blood pressure: 
 Insert the air inflation tubing from the cuff into the air jack of the monitor. Switch 
on the device by pressing the 0/I button, and wait until the display shows a ‘0’ and 
the heart symbol appears on the display. 
 Press the START (inflation) button and immediately release it. Instruct the 
participant to remain still. A noise will be heard as cuff automatically inflates. The 
monitor automatically determines ideal inflation level. The monitor also 
automatically detects pulse even during inflation the display screen will flash a 
heart symbol during the process. 
 Inflation stops automatically. As the cuff slowly deflates, decreasing numbers 
appear on the display. Once the recording has taken place. The cuff then 
completely deflates and the blood pressure and pulse will be displayed in the 
screen. 
 In rare circumstances a higher inflation level may be necessary. In this case, the 
monitor re-inflates the cuff up to 30 mmHg higher than initial inflation.  
 If it becomes necessary to stop the recording during inflation press the 0/I button 
again. The monitor will stop inflation and commence rapid deflation and then the 
monitor will turn off. 
 If any error codes – ‘E’ – are displayed, refer to page 17 of the instruction manual. 
 
Take 2 measurements in succession, with a 2 minute gap between each 
measurement. 
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Appendix 9 
 
Newcastle 85+ Study: Cardiovascular Phenotyping 
DETAILED SCRIPT – VERBATIM FOR CARDIAC STUDIES 
 
 
 
Overview Of Researcher Responsibilities  
 
 Visit preparation 
1. Ensure all equipment is in good working order and batteries are fully 
charged. 
2. Ensure all required equipment is packed up correctly before each visit. 
 
Start of each visit 
1. Always be on time for each visit. 
2. Register visit details and duration with Guardian 24. 
3. Ensure mobile telephone is on silent/vibrate alert – do not turn off your 
mobile. 
 
During each visit 
1. Reconfirm verbally that consent is enduring 
2. Always show respect towards the participants and their significant 
others. 
3. Explain all procedures step by step using clear, ‘non jargon’ language. 
4. Be prepared to speak loudly.  
5. Be prepared to repeat the instructions and go over things as many times 
as the participant or significant other requires. 
6. Continuously encourage the participant during the visit “you are doing 
very well” 
7. Communicate your actions to the participant throughout the visit and 
particularly during the test e.g. “I just need to move this monitor 
slightly”, “I just need to enter this information onto the computer”. 
8. Respect participants’ dignity at every stage of the study visit. 
9. Be aware of using too much pressure to gain carotid and/or cardiac scan. 
10. Be prepared to stop tests at any time if the participant is uncomfortable.  
11. Be prepared to stop tests if requested to do so by the participant or 
significant other. 
12. Be prepared to stop tests at any time if you feel it is appropriate to do so. 
13. Be prepared to go back again and finish the visit another day if 
participant gets exhausted or tired and wants you to stop 
 
 
Detailed Researcher Instructions 
 
 On arrival introduce yourself to the participant (show ID). 
“Good morning/afternoon my name is Dr Yousaf and I am the heart doctor with the 
85+ Study.” 
 
 Ask preferred name of participant. 
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“I have your name as Mr/Mrs………… is this what you prefer to be called?” 
 
 
 Check participants’/ significant others understanding of the visit  
“Did the nurse making the appointment explain to you why I was coming today?” (Wait 
for their response and then provide confirmation or clarification) 
 
(Note: for those participants/ significant others who have not had the most up to date 
cardiac information this should be provided and explained) 
 
“I am here to do some tests which will tell us something about the health of your heart 
and circulation. This will include scans of your heart and neck.  
 
 
 Check consent is enduring  
I will explain each test and step as I go along.  If you have any questions please don’t 
hesitate to ask me.  You can stop me at any stage if you don’t feel comfortable. 
 
Is this ok with you? 
 
Ok then let’s start. 
 
Ask participant if it is ok to do the test in their bedroom as this the best place for you 
and probably the most comfortable for them.  Only think of alternative if they really 
don’t want to use the bedroom.  Offer them assistance to get there if necessary.  When 
you get there explain to them that they need to take off their shoes and socks at this 
point and lie down flat. Make the participant is comfortable and supported. 
 
 
 Blood Pressure 
“OK first I would like to check your Blood Pressure.  I will need to put this cuff on the 
top of your arm and the monitor blows up the cuff to tighten. I will tell you before the 
cuff starts to tighten.” (Be prepared to deflate cuff and discontinue measurement if the 
participant indicates to do so) 
 
“Ready to begin – you will now feel the cuff tightening on your arm.” record 
measurement 
 
(Note: If the participant asks about their blood pressure reading always be aware about 
causing anxiety. The safest response wherever appropriate is to say “Its fine” If the 
participant is extremely hypertensive explain that the measurement is “up a little bit but 
blood pressure changes all of the time and the reason for it being high today is 
probably because they are having these tests done” If very concerned check with nurse 
team when return to the 85+ study office). 
 
Whilst discussing above pack away omron and set up for PWA (SphygmorCor) 
 
 
 PWA - SphygmorCor 
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“Ok now I would like to measure your pulse and the softness of your arteries because 
we know these can stiffen up as we get older. To do this I will put this small monitor on 
your wrist where your pulse is. Ready to start?” 
 
Perform radial tonometery. 
If you need to do the test again, or it is taking some time explain  that “sometimes its 
difficult to pick up the pulse” – need to think about how many times to re try something 
as may sicken people early on, consider trying again at end of assessments.  
 
(Note: Let the participant know if they need to be quiet – sometimes best as if talking 
often move around.) 
 
Once PWA data is obtained pack the SphygmorCor equipment away and set up the 
Vicorder equipment explaining about the test while you are doing so. 
 
 
 Vicorder 
“Now I would like to measure the speed of your pulse going through your body. To do 
this I am going to put these cuffs (show cuffs) on your arms, ankles and thigh (top of 
leg).  Like the BP cuff these will tighten, but again I will let you know before this 
happens. 
I am also going to put another cuff on your neck, but don’t worry this one doesn’t 
inflate much, its only about as tight as a shirt collar for just a few seconds, but let me 
know if it is uncomfortable for you and I will stop”. (Support participants head to put 
the neck cuff behind participant neck- do not fasten this cuff until time to take the 
measurement) 
 
Perform ABI part of (ABI0PWV) protocol first. (Inform at each stage which cuff will 
inflate) 
 
Then Perform PWV part of (ABI-PWV) protocol.  (Fasten neck cuff now and inform 
when cuff will inflate). 
 
I just need to measure between the neck cuff and the thigh cuff.  That will help me to 
work out the speed of your pulse. 
 
Obtain measurement of the ‘L’ distance between neck and thigh cuffs. 
 
Input all  Vicorder data then pack away equipment and set up to perform the CIMT 
measurements explaining test as you are doing so. 
 
 
 CIMT 
“Sometimes as we age our blood vessels thicken up a little so I would like to take a 
picture of the main blood vessels/arteries in you neck with this scan (show scanner) to 
measure how healthy they are”.  
 
(Note: may be good here to explain that need to put gel on side of neck to get a good 
contact and therefore may prefer to take top clothing off – also need to do this anyway 
for heart scan – so will be prepared. If this is the case then cover participant through 
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CIMT measurement and ensure does not get cold. Only offer explanation of how 
scanner works if asked response along lines of : “Its similar to when pregnant ladies 
have scans on their stomach to check the baby is ok”.) 
 
 Position participant always providing clear instruction e.g. “Can I ask you to slightly 
turn your head to the left/right?” Place protective cover at side of participant’s neck to 
protect bed clothes from gel. Explain that need to put gel on side of neck to get a good 
contact and warn that gel may feel slightly cold. Be very gentle on participant’s neck, 
don’t press too hard!  
 
Note: Keep checking that the participant is comfortable and be prepared to discontinue 
measurement if participant indicates to do so. 
 
Record the CIMT data and then make separate folder for cardiac scan. 
 
 
 Cardiac scan. 
 
“Ok, you have done very well so far.  We have now reached the measurement where I 
would like to take pictures of your heart using the same scanner” (again show scanner)    
For this test you have to undress to your waist (if not done so already) and lie on your 
left hand side with your hand at the side of your head (Demonstrate arm position). The 
test will take 20-30 mins and again I will put some gel on different parts of your chest to 
take pictures of your heart from different angles.  
 
Prepare room i.e. protective cover on bed clothes, lights down, curtains closed – 
explaining to participant reason for doing this and asking their permission to do so. 
 
Prepare participant assist with positioning explain if need to remain quiet, If support 
wedge or pillows are needed then explain each action to participant “I am just going to 
place this support behind you back to make you more comfortable” OK are you ready 
to start? 
 
It is essential that you keep talking to the participant during the scan explaining each 
action along the way. This will help keep participants relaxed and focussed.  
 
Explanations should always include “You might feel some pressure on your ribs as I 
need to look through your ribs to get a good picture, but please tell me if it feels 
uncomfortable”. Explain just before it happens – “during this test the machine will 
make some whooshing noises, this is normal, it is the blood flowing through your 
heart”. 
 
 
 Withdraw from visit 
Ensure all gel is removed from participant.  
Don’t forget to remove ECG stickers. 
Ensure participant is appropriately dressed again, offering assistance where appropriate.  
Pack up the equipment and make sure that you don’t leave anything behind! 
 
Thank the participant for their valuable contribution to the study. 
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Explain that need to take the pictures and all of the measurement back to the hospital to 
analyse them. Advise that if there is an abnormal result according to our study protocol, 
their GP will be notified and the GP would get in touch with them so they don’t need to 
do anything.  (This is also a good standard response if you are asked any questions 
about how the scan looks etc etc during the actual procedure)  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
285 
 
Appendix 10 
Letter of introduction 
 
 
 
 
To Whom It May Concern: 
Dr Fahad Yousaf is employed on the Newcastle 85+ Study, a research study into 
health and ageing in older people which is being conducted by the Institute for Ageing 
and Health at Newcastle University.  He will be carrying out visits to older people in 
their own homes to perform cardiac assessments (heart scan and blood vessel scan). All 
appointments will have been made in advance by the 85+ Study research nurses. He will 
be carrying a photo identity badge from Newcastle University. If you have any queries 
about this study, please telephone the Newcastle 85+ study office on 0191 2481116; if 
no one is available to take your call please leave a message and someone will get back 
to you. 
 
Thank you. 
Karen Davies 
Research Nurse Manager 
 
 
 
 
    The Newcastle 85+ Study 
    Institute for Ageing and Health, 
Biogerontology Building 
    Newcastle University, Campus for Ageing 
and Vitality  
    Newcastle Upon Tyne, NE4 5PL 
    Telephone: 0191 248 1116    Fax: 0191 248 
1110 
    Email: Karen.davies@ncl.ac.uk 
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Appendix 11 
     
The Institute for Ageing and Health 
Newcastle University 
 
 
The Newcastle 
 
Study 
 
 
Stage Two 
Participant Consent Form 
 
We are inviting you to take part in stage two of the Newcastle 85+ study. 
 
Please ensure you have read the accompanying information booklet which 
explains why we are doing this research and what we are asking you to do 
in this stage.  If you find reading or understanding the information difficult, 
please ask a family member or a carer to help you. 
 
Please ask the research team any questions. 
 
Remember: 
 
 That participation in this study is entirely voluntary and you may 
withdraw from the whole or any part of the study at any time without 
affecting your usual medical care. 
 
 It is unlikely that taking part will have any direct benefit for you.   
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I (name of participant)..…………………………………………………… 
 
of (address)……………………………………………………………… 
 
…………………………………………….……………………………… 
 
agree to take part in stage two of The Newcastle 85+Study.   
 
I understand the information that has been given to me about the study and 
this particular stage. I have been given time to think about the information 
and the opportunity to ask questions. I know that my consent is voluntary, 
and I can withdraw from the whole or any part of the study at any time. I 
understand that declining to participate will not affect my usual care. 
 
I understand that during the course of this study it may become necessary 
for the research team to contact someone to represent my best interests 
(known as a consultee). In my opinion I would nominate,: 
Name:……………………..……………………………………………… 
Relationship to participant:……………………………………………….. 
(Interviewer instruction: This individual would normally be a ‘personal 
consultee’ i.e. next of kin, closes relative or friend. If the nominated 
individual is NOT a ‘personal consultee’ but ‘nominated consultee’ i.e. a 
paid carer please provide information where possible to explain choice.) 
………………………………………………………………………………
…………………………………………………………………………. 
Address:……………………………………………………………………
……………………………………………………………………………. 
Contact number:…………………………………………………………..   
as the person best able to do this. 
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I understand that, in the event that something goes wrong and I am harmed 
during the research study, there are no special compensation arrangements.  
If I am harmed and this is due to someone’s negligence then I may have 
grounds for a legal action for compensation against Newcastle University.  
 
 
 
 
The nature and demands of the study and this particular stage have been 
explained to me; I fully understand and accept them.  
 
Signed:……………………………………….Date……………………… 
 
Investigator Statement: 
I confirm that I have explained the nature of the study and given every 
opportunity for …………………………………..to receive and consider 
the information about the study and stage two. 
 
Name…………….…………………………Signed…..………………… 
Designation…………………………………Date….…………………… 
 
Copied for participant ( (Tick when completed)  
 
Consultee approval also obtained        (yes)      (N/A) 
   
 
 
 
Please initial box Consent  Decline 
I agree to participate in stage two of the Newcastle 
85+ study 
  
I agree that blood samples can be taken from me   
I agree that samples of my blood can be stored for 
future analysis of genetic and other factors 
involved in health in old age, ageing and life-span.  
 
  
I agree to allow my doctor to be contacted with   
the results of medical tests that are important for 
my health. 
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The Newcastle 85+ Study 
The Institute for Ageing and Health 
Biogerontology Research Building 
Newcastle University 
Campus for Ageing and Vitality 
Newcastle upon Tyne 
NE4 5PL 
Telephone: 0191 2481116 
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